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Bioactivity of a biomaterial plays an integral role for bone regeneration. 
During this process, optimal healing of the defect region is heavily reliant 
upon the prevention of bacterial infection after implant placement. 
Hydroxyapatite (HA) is commonly used as a bone replacement material, but 
has slow osseointegration rate and tends to represent a site of weakness for the 
host defence, making it susceptible to implant-related infections. The rate of 
osseointegration in HA can be enhanced by the substitution of silicon whilst 
antibacterial property can be created by the substitution of silver. Given the 
beneficial properties of both elements, it is thus desirable to incorporate both 
silver and silicon ions into HA to achieve antibacterial and enhanced 
osseointegration properties, respectively. Current literature reported on the use 
of silver-substituted HA and silicon-substituted HA. However, the co-
substitution of these two elements into HA has not been explored yet. 
Therefore, this motivates the development of silver, silicon co-substituted 
hydroxyapatite (Ag,Si-HA). In this study, Ag,Si-HA is a novel bi-functional 
bone graft material that possesses antibacterial and enhanced biological 
properties, to facilitate bone healing. A phase-pure Ag,Si-HA with a bone-
mimicking morphology (60 nm x 10 nm) was successfully synthesised using 
an aqueous precipitation technique. Phosphate, hydroxyl and silicate 
functional groups were observed in the FTIR spectra. Silver and silicon ions 
were structurally incorporated in the HA structure as reflected by the 
increment of the lattice parameters and unit cell volume. A silver content of 
0.5 wt.% was demonstrated to produce the optimum antibacterial effect with a 
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7-log reduction in the growth of adherent Staphylococcus aureus (S. aureus) 
and Escherichia coli (E. coli) over a period of 7 days. Subsequently, the 
antibacterial action and biological properties of Ag,Si-HA containing 
optimised content of 0.5 wt.% of silver and 0.7 wt.% silicon were investigated. 
Silver ions of Ag,Si-HA was first reported to diffuse towards the crystal 
surface, damaging the cell wall and thereby inducing potassium ions leakage 
from the adherent S. aureus. Furthermore, the substitution of silicon promoted 
the proliferation of human adipose-derived mesenchymal stem cells on Ag,Si-
HA, which in turn, permitted greater bone differentiation (alkaline 
phosphatase, type I collagen and osteocalcin) as compared to HA and AgHA. 
On the whole, this study shows that Ag,Si-HA functions by firstly allowing 
the incorporated silver in Ag,Si-HA to exert its antibacterial action against 
adherent bacteria and subsequently, the incorporated silicon promotes the bone 
differentiation process. All these results demonstrated that the approach of co-
substituting silver and silicon could complement their functions in the apatite 
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1.1 Background   
Bone is a dynamic and complex tissue that provides structural support, and 
withstands load bearing for the body. In addition, bone also serves as a 
reservoir for minerals, supports muscular contraction for mechanical 
movement, and protects the internal organs [1]. Bone undergoes remodelling, 
and has the innate capacity to regenerate and repair itself upon damage. 
However, when huge amount of bone is lost in circumstances such as trauma, 
diseases or old age, the function of bone is adversely affected. In these 
circumstances, bone function can only be restored by surgical reconstruction. 
Approximately 1 million bone grafting procedures take place annually [2], 
with around 860,000 joint replacement surgeries performed in the United 
States, England and Wales [2]. It has been forecasted that by 2015, the US 
market for bone grafts can reach as much as US$3.18 billion. Since 2000, the 
ageing population has been rising steadily at a rate of 2-3 % [3], accounting 
for the 'boom in reconstructive surgery’. Furthermore, young people are now 
engaging in more active lifestyles, resulting in an increase in sports-related 
injuries and joint damage. With the improvement of the quality of life, people 
are more inclined to get new bone replacements to restore their bone function. 
Hence, all these factors give rise to the increased demand for bone grafts.   




Bone grafting is a procedure of replacing the defect part with material from 
either the patient’s own body (autografting) or that of a donor (allografting) [4, 
5]. Autografts contain living bone cells and growth factors that offer 
osteogenesis and stimulate induction, hence providing bone ingrowths. Even 
though autograft is considered the “gold standard”, only a limited amount of 
bone can be harvested safely for the use in bone grafting. Unfortunately, the 
supply of a viable alternative-allografts is unable to meet the high demand for 
it. Furthermore, both autografting and allografting involve multiple surgeries, 
and are often associated with the risk of a series of complications such as 
infection, hematoma, cosmetic disadvantages, postoperative pain, and chronic 
pain at the donor site [6, 7]. Thus, autografts and allografts will not always 
provide the best solution for bone grafting, consequently all these factors 
greatly drive the market for synthetic bone alternatives.  
 
 
Hydroxyapatite (HA) is an ideal synthetic bone alternative, which possesses a 
chemical similarity to the bone mineral. It can be easily prepared by 
conventional ceramic processing techniques, which eliminate the site 
morbidity problems occurred in the use autografts and allografts. Since HA is 
biocompatible when implanted in-vivo, it exhibits bioactive behaviour by 
forming a close physicochemical bond between the implants and bones 
(osseointegration). However, the rate of this process is relatively slow as 
compared to other bioceramics such as bioglass [8, 9]. To improve its 
bioactivity, the chemical composition can be adjusted close to that of the bone 
mineral. Natural bone mineral is described as a multi-substituted calcium-




phosphate apatite, in which trace amount of ionic elements play a significant 
role in the biochemistry of bone. It has been shown that the presence of silicon 
can stimulate specific families of genes for osteoblastic proliferation, and the 
production of bone extracellular matrix [10]. For example, an unsupplemented 
silicon diet on chicks in Carlisle’s experiment showed that silicon is essential 
for growth and skeletal development [11, 12]. A retarded skeletal development, 
reduced growth, and diminished feather development were evidenced in the 
abnormally-shaped skull and reduced thickness of leg bones in chicks. Hence, 
silicon plays an important role in connective tissue metabolism, particularly 
for bone and cartilage. To mimic the mineral component of bone better, 
silicon-substituted HA (SiHA) has been extensively investigated by many 
researchers [13-26]. The incorporation of silicon into HA has been shown to 
have the potential to increase the rate of bone apposition on HA implants 
significantly [19, 21, 27, 28]. Therefore, SiHA is considered as state-of-the-art 
in term of its improved bioactivity.  
 
 
Although an improvement in the bioactivity of the material can facilitate the 
healing process of the patients, patients are still encountering complications 
during orthopaedic surgeries. Since SiHA is biocompatible, proteins, amino 
acids, and other organic substances can easily adhere to SiHA, thus allowing 
the replication of bacteria in SiHA. Furthermore, with the lack of protection 
from body immune system, the implanted SiHA will become infected when 
bacteria adhere to the surface of SiHA. The adherent bacteria can colonise and 
form a biofilm, which shield the bacteria from phagocytosis and antibiotics, 




condemning the immune system in our body, and clinical treatment to 
annihilate it [29]. Therefore, the risk of infection is increased by the presence 
of implant. Each year, implant-related infections affect about 2.6 million 
American patients, and cause about 90,000 deaths during orthopaedic 
surgeries [30]. Untreated infection can spread to other healthy tissues, and 
complicate the bone healing process. At worst, it can result in more medical 
procedures such as the removal of prosthetic or even a second operation, 
which incur costs on patients at the expense of their comfort [31]. As such, 
implanted-related infections are highlighted to be one of the most significant 
rising complications that cause high mortality and morbidity rates in 
orthopaedic surgeries. Hence, the development of biomaterial with 
antibacterial property is necessary to protect against the initial bacterial 
invasion during implantation.  
 
 
The use of silver has recently become one of the preferred antibacterial agents 
to confer microbial resiliency. Well known for its broad antibacterial effect, 
silver is frequently used in wound healing [32, 33] or biomedical applications 
[34, 35]. Silver can be incorporated in HA via ion-exchange (AgHA), and has 
been demonstrated to exhibit excellent antibacterial activity in-vitro against 
the following pathogens: Staphylococcus aureus (S. aureus), Escherichia coli 
(E. coli), Streptococcus mutans (S. mutans), and Candida albicans (C. 
albicans) [36-39]. The released silver ions from AgHA were generally 
proposed as the source to generate the antibacterial action [36, 40, 41]. 
However, sustainability of the antibacterial effect was compromised with 




premature release of silver ions [42]. Chen et al. [37] and Oh et al.[42] 
reported that more than 50 % of the loaded silver was abruptly released within 
the first 24 h. These ions can produce undesirable consequences such as local 
toxicity and short-term antibacterial property. Thus, the sustainability of the 
antibacterial effect in AgHA has not been fully achieved. Recently, Stanic et 
al. [36] observed a reduction of the bacterial growth in the AgHA samples, 
with no detectable released silver ions in the dissolution test. This AgHA was 
different as silver ions were incorporated during the nucleation of apatite. This 
phenomenon suggested that the antibacterial action of this AgHA against 
bacteria may not be entirely attributed to the released silver ions. However, 
there was no explanation on the observed phenomenon. Hence, the mechanism 
of antibacterial action in AgHA, particularly the surface feature of AgHA 
remains to be elucidated.  
 
 
Although studies concerning substituted apatites are conventionally performed 
by the addition of single cation or anion, co-substitution has been considered 
in recent years [43-48], and is certainly becoming a considerable field of 
research for apatites. Co-substitution combines the functions of various ions 
into a single apatite compound, which can eliminate problems encountered in 
the composite system. Furthermore, the fact that natural bone mineral is a 
multi-substituted calcium phosphate apatite implies that performing co-
substitution in apatite is achievable with considerations. Indeed, the greatest 
motivation to apply substituted apatites is that they can emulate the chemistry 
of the native tissue more accurately to facilitate bone regeneration. Past co-




substitution studies reported on the improvement of biological responses in 
apatites in-vitro [43-45], but few have studied on producing co-substituted 
apatites with added functional properties. On the whole, it is evident that 
incorporating the apatite with antibacterial property and enhancing its 
osseointegration process are crucial factors for the success of bone repair. 
Therefore, it will be beneficial to co-substitute both silver and silicon into 
apatite to create bi-functional properties of antibacterial property and 
enhanced osseointegration in facilitating bone regeneration.  
 
 
In accordance to facilitate the bone regeneration by possessing antibacterial 
and enhanced osseointegration properties, this project aims to co-substitute 
silver and silicon into HA, and investigates the synergistic effects in term of 
antibacterial action and biological behaviour in Ag,Si-HA. In addressing the 
challenges faced by the current AgHA for prolonged antibacterial property as 
well as minimum cytoxicity, it is important to understand the antibacterial 
action of AgHA. Due to the lack of clear data demonstrating evidence of 
antibacterial action by the surface silver ions of AgHA, it is also the intention 
of this project to investigate the surface silver ions of Ag,Si-HA in relation to 
their contributions towards the antibacterial action.   
 
 
1.2 Objectives  
This project aims to develop an effective bone substitute material with bi-
functional properties by co-substituting silver and silicon into hydroxyapatite 




(Ag,Si-HA). Furthermore, the biocompatibility and antibacterial action of 
Ag,Si-HA will be explored. 
  The specific objectives of this research project are as follows: 
 To determine the feasibility of co-substituting silver and silicon into 
hydroxyapatite to form Ag,Si-HA via a wet precipitation method,  and 
characterise its physicochemical properties, 
 To optimise the silver content in hydroxyapatite for effective 
antibacterial properties,  
 To determine the mechanism of the antibacterial action in Ag,Si-HA, 
and to evaluate the effect of the damages in the bacteria, particularly 
the permeability and cell wall of the bacteria caused by Ag,Si-HA; and  
 To investigate the effects of silver and silicon on the biological 
properties of Ag,Si-HA. 
 
1.3 Scope 
Chapter 1 established the background, illustrating the need for synthetic bone 
substitute materials. Particularly, HA and improvements to its property were 
discussed. The co-substitution of silver and silicon was also proposed to 
incorporate antibacterial property in conjunction with enhanced bone 
formation in HA. Subsequently, relevant literature review including bone, 
various bone repair treatments and fracture healing, calcium phosphate 
materials in particularly, HA and substituted apatites are covered in Chapter 2. 
In addition, the synthesis, characterisation, and biological testing of AgHA, 




SiHA, and various types of co-substituted HA will be reviewed. Detailed 
study on the synthesis and characterisation of the physiochemical properties of 
Ag,Si-HA are presented in Chapter 3. Chapter 4 investigates the optimization 
of the silver content in AgHA for effective antibacterial properties. 
Furthermore, Chapter 5 evaluates the in-vitro antibacterial property, and 
describes the mechanism of antibacterial action of Ag,Si-HA. The in-vitro 
biocompatibility of Ag,Si-HA is evaluated in Chapter 6. Lastly, Chapter 7 
summaries the overall conclusion of the present work, and Chapter 8 explores 














Literature Review  
 
2.1 Bone Physiology 
On an elementary level, the framework of bone may be explored by three main 
components: bone marrow, bone cells, and bone matrix. Bone marrow is 
responsible for the production of new cells, and acts as a source of stem cells 
and nutrients. The various bone cells are responsible for maintaining the 
structure of the matrix, regulating its oxygen and nutrient supply, and storing 
or releasing minerals as required whilst the bone matrix provides mechanical 
strength, and acts as the body’s mineral store. The following sections will 
cover the introduction of bone, which includes its structure, cells, and matrix. 
In addition, various bone repair treatments will be discussed, particularly in 
the use of synthetic bone graft.  
 
 
2.1.1 Structure of Bone  
Bone is assembled from various hierarchical structural units, from nano to 
macro scales in order to offer multiple functions [49]. At the nanostructural 
level, bone mainly comprises of collagen fibers and nanocrystals of bone 
minerals, in particularly hydroxyapatite (HA). Collagen fibrillar bundles to 
form lamellae whilst the plate-like apatite crystals occur within the discrete 
spaces within the collagen fibrils, and grow with specific crystalline 




orientation along the c-axes, which is parallel to the long axes of collagen 
fibrils [50]. The nanocomposite is being constructed into layers of lamellae, 
osteons or trabeculae, and haversian systems at the microstructural level. Each 
bone lamellae consists of alternating thin and thick layers of aligned 
mineralised collagen fibrils [51]. The haversian system or secondary osteon is 
make up of concentric layers of bone lamellae surrounding a central canal [52]. 
These microstructural units thus form the architecture of bone. The 
hierarchical structure of the bone is illustrated in Figure 2.1.  Although bone is 
made up of hierarchical structure, the small size (nanoscale) is a very 
important factor related to the solubility of biological apatite, which in turn 
affects its biological interaction. 
 
 
Figure 2.1 Hierarchical structure of the bone: the ultra-to molecular level 
composed of apatite mineral crystal embedded between collagen firbrils, the 
micro-to ultra level is the arrangement of these fibrils into lamellae with 
preferred orientation, and maro-level is the arrangement of the lamellae into 
cylindrical osteons, which form the basic structure of cortical or cancellous 
bone  [53]  




There are two types of architectural forms: cortical (80 % of the total skeleton) 
and trabecular (around 20 % of the total skeleton) (Figure 2.2). Cortical bone, 
which is also known as compact bone, is built from repeating units of osteons 
or haversian system. It is almost solid, containing only about 10 % porosity. 
Compact bone contains pores ranging from 10-20 µm in diameter, and mostly 
separated by intervals of 200-300 µm. It is observed in the shafts of long 
bones and on the exterior surrounding cancellous bone, protecting the 
trabeculea. In contrast, trabecular bone makes up of interconnecting 
framework of plate-like trabeculae, often referred to as cancellous or spongy 
bone. It is sponge-like and is surrounded by cortical bone. Trabecular bone is 
lighter and less dense than compact bone. It has higher porosity, thus results in 
higher concentration of blood vessels compared to the compact bone. The 
diameter of the pores may range from few micrometers to millimetres. It is 




Figure 2.2 Sectioned human formal featuring architectural forms of bone [1] 
 




2.1.2 Bone Cells 
Bone is always in a dynamic state, which is controlled by five essential bone 
tissues namely osteoprogenitor cells, osteoblasts, osteocytes, bone-lining cells, 
and osteoclasts [54]. The bone tissues are responsible for activating, and 
controlling the bone metabolism. Bone is derived from mesenchymal stem 
cells. These cells are able to divide and differentiate into bone-precursor cells, 
which are also known as osteoprogenitor cells. Osteoblasts are the bone 
forming cells and responsible for the production of bone. The osteoblasts 
attach, proliferate, and differentiate, leading to production of matrix proteins 
that include collagen (mostly type I), osteopontin, bone sialoprotein, 
osteonectin, osteocalcin, fibronectin, and bone morphogenetic proteins before 
mineral deposition [55-57]. Minerals such as calcium and phosphate from the 
bloodstream are being coated onto the collagen that is secreted by osteoblasts, 
thus giving rise to the formation of new bone. Osteoblasts continue to grow 
and mature to become osteocytes, which eventually help to maintain the bone 
cells by transporting the minerals between bone and blood. Inactive or 
“resting" osteoblasts have been described as bone lining cells, and are 
commonly observed in mature bone as a single layer of cell adjacent to the 
mineral surface. On the other hand, osteoclast is a multi-nucleated cell that 
dissolves the minerals and collagen, which will be transported further by the 
bone-lining cells to different parts of the body. Hence, osteoclast is 
responsible for bone resorption. These cellular components work 
simultaneously to build, maintain, and remodel the hierarchical bone structure. 




All these processes must be in equilibrium to ensure the development of a 
healthy bone.  
 
2.1.3 Bone Matrix 
The bone matrix is composed of two major phases namely the organic phase 
(~ 30-40 wt.% protein) and the inorganic phase (~ 50-60 wt.% minerals), with 
the remaining making up of biological compounds [58].  
 
Collagen is the most abundant protein found in the human body, which 
comprises approximately 95 % of the non-mineralised component of bone 
matrix. Osteoblasts synthesise collagen in the form of long procollagen 
molecules. Procollagen molecules consist of 3 pro-α chains, which undergo 
processing to α-chains, and subsequently assemble to form collagen fibrils 
(tropocollagen), which are coiled to form a helical structure. Each 
tropocollagen molecule is longitudinally displaced by approximately one 
quarter of its length relative to its nearest neighbour when they are aggregated 
together. This staggering effect of tropocollagen molecules gives rise to the 
characteristic “D” spacing observed in collagen fibrils when examined under 
an electron microscope [59]. This arrangement of tropocollagen fibres leaves a 
void “gap zone” between the end of one triple helix and the beginning of the 
next, which may act as nucleation sites for apatite formation [59].   
 





Figure 2.3 A schematic diagram illustrating the organisation of collagen fibrils 




During the early stage of development, type I collagen provides the base 
attachment structure for cells within many tissues. As development progresses, 
other proteins and biomolecules are absorbed either from the serum or 
secreted from the cells. Subsequently, they combine further with type I 
collagen to form various native extracellular matrix (ECM) of differentiating 
tissues. The mature ECM then mediates cellular attachment, migration, 
proliferation, and differentiation.  
 
Observations of bone mineral crystal size and morphology obtained by 
electron microscopy and X-ray diffraction studies tend to differ as the sub-
microscopic structure of the fused apatite crystals make it difficult to examine 
the exact structure of bone mineral [61-63].  The morphology of bone minerals 




are initially reported to be needle-like with dimensions of 3-6 nm in width and 
40-100 nm in length [64]. On the other hand, Fernnandez-moran and 
Engstrom [65] observed shorter bone minerals of less than 30 nm in length. 
Recently, bone minerals are described as discrete, plate-like in morphology 
with dimensions of 50 nm in length, 25 nm in width and 2-3 nm in thickness 
when viewed under transmission electron microscope. As the morphology and 
dimensions of apatite crystals vary with age, species and health, reported 
dimensions of bone minerals can become inconsistent [66]. Despite 
discrepancies in the reported dimensions, bone is generally defined as plate-
like HA nanocrystals (4 by 50 by 50 nm) embedded in fibrous collagen bone 
protein (100-2000 nm) that is further built into unique structure and 
composition, giving rise to an amazing nanocomposite.  
 
Electron microscopy and X-ray diffraction studies revealed that an amorphous 
phase is presented in bone mineral and appeared to precede the calcination 
front [67-69]. Glimercher [70] observed that non-stoichiometric apatite 
increased in crystallinity and approached stoichiometry with time. Subsequent 
study further suggested the possibility of a mixture of amorphous and 
crystalline calcium phosphate phases in bone mineral [71]. Therefore, bone 
mineral is heterogeneous, consisting of crystalline and amorphous calcium 
phosphates phases.    
               




Bone mineral is a calcium deficient apatite. The bone mineral crystal 
approaches close to the stoichiometric hydroxyapatite formula of 
Ca10(PO4)6(OH)2 as bone ages [72]. The principle chemical constituents of 
bone mineral are calcium, phosphate, and carbonate, with trace amounts of 
other ionic elements [73]. Various ions such as sodium, magnesium, strontium, 
barium, and fluoride can be readily substituted for the calcium, phosphate or 
hydroxyl sites in the apatite crystals. Divalent cations such as magnesium and 
strontium can substitute for the calcium sites whilst the monovalent cation 
such as sodium requires a protonation of an adjacent group during the 
substitution at calcium site. On the other hand, anions such as fluoride can 
substitute for the hydroxyl group in the apatite crystals. Carbonate ions occupy 




The substitution of these ions in bone mineral thus increases the reactivity of 
the mineral, causing bone to undergo chemical and structural changes in order 
to obtain a stable apatite structure. It was reported that bone mineral is 
metabolically active as a result of the crystalline imperfection created by the 
substitution of ions for the calcium, hydroxyl, and phosphate ions [72]. Study 
has shown that there was a stimulation effect of carbonate ions on the release 
of osteoclasts [75]. Magnesium and zinc are essential for activating a large 
number of enzymes such as alkaline phosphatase and pyrophosphates [76]. 
Many other trace ions such as sodium, potassium, rubidium, cesium, cadmium, 
chromium, and copper ions have been observed in bone mineral, playing a 




significant role in the different enzyme systems involved in the function of 
bone cells [1]. Furthermore, silicon is also recognised as an essential trace 
element in bone development, which will be further discussed in detail in 
Section 2.5.1. However, due to difficulties encountered in monitoring and 
quantifying the ion contents in bone mineral, which varies in composition 
upon dietary, physiological and pathological factors, the role of many of these 
ionic species is an area not easily explored [77]. Nevertheless, these different 
ions indeed play a major role in the biochemistry of bone.     
 
 
2.2 Bone Repair 
A bone fracture results in the discontinuity of the bone matrix along with soft 
tissue damage, torn blood vessels and bruised muscles. The most common 
cause of single or multiple bone fractures are direct trauma from physical 
injury. Contrastingly, indirect trauma usually results in a single fracture at the 
"weak link" within the bone [78]. Apart from these causes, bone fracture can 
also occur from pathological conditions including bone tumours, osteoporotic 
bone, osteomyelitis, and osteomalacia [78]. The infected bone system or 
underlying bone then becomes abnormal, and more susceptible to fracture.  
Broken bones need to be aligned and immobilised at the start to achieve 
effective fracture healing. Different types of orthopaedic devices will be 
applied for treatment of fractures depending on the severity and nature of 
fracture. These include: (1) closed treatment such as casing, traction or braces, 
(2) rigid fixation with internal plate, and screws or external fixators, and (3) 




fixation using intramedullary nailing and dynamic external fixation [79]. 
However, the use of fixation devices may not be sufficient for adequate 
healing and hence, surgeon may require the use of bone grafts to repair 
damaged or missing bone.    
 
2.2.1  Bone Graft  
The functions of bone grafts are to fill voids, provide support, and most 
importantly, promote biological repair of bone fractures by guiding bone 
growth into the graft. This bone ingrowths acts as a bridge between the 
existing bone and graft material, thereby strengthening the grafted area. 
Ideally, the bone graft should interact with the host tissue, recruit, and even 
promote differentiation of oseogenic stem cells, to allow the newly-formed 
bone to replace much of the graft [1].  
 
 
In general, the bioactivity, structural, and mechanical properties of the bone 
graft are critical factors in determining its success or failure. The essential 
criteria for the selection of a bone graft material are tabulated in Table 2.1.  In 
terms of biological response, an ideal bone graft is required to be osteogenic, 
osteoinductive, and osteoconductive. Currently, autograft is the only bone 
graft materials that exhibit all these biological responses [80]. Its use, 
however, is severely limited by complications including prolonged 
hospitalization, donor site morbidity, and increased risk of deep infection [1]. 
Complications have been reported to occur in about 10-35 % of patients with 




varying degrees of severity [81]. In relation, a dominant alternative in skeletal 
reconstructive surgery has been the use of donated allogenic bone. Similarly, 
allografting carries a finite risk of transferring contaminants, diseases, toxins 
or infection from the donor site [82]. Moreover, the processing (freezing or 
demineralisaion) of the allografts adversely affects the structural integrity of 
the material, and its osteoinductive and/or osteogenic activity [80]. Failure of 
union as a result of fatigue fracture over several years have been reported for 
the use of allografts [83, 84]. In addition, ample supply of the allograft is not 
always available at the time of surgery [85]. Therefore, transplantation of 
organ, and/or tissue replacement will not always yield a satisfactory result. 







Table  2.1 Summary of the essential basic functions and requirements of a bone graft material [80]  
Factor Function Requirements of bone 
graft material 
Correct chemistry to support 
or simulate an appropriate 
host response 
    No toxic response Biocompatible material 
 
Encourage bone migration into the scaffold  Osteoconductive 
Support and promote osteogenic differentiation in the non-
osseous, synthetic scaffold 
Osteoinduction 
Enhance cellular activity toward scaffold-host tissue 
integration 
Osseointegration 
Recruitment and stimulation of immature cells to develop 
into preosteoblasts that are essential for bone remodelling 
Osteogenesis 
Degrade in a controlled manner and produce non-toxic 
degradation products (12-18 months) 
Bioresorbable  material 
Provide temporary mechanical support (1-3 months) and 
withstand mechanical loading / stimulation throughout the 
implantation period  
Strength: 130-180 MPa 








2.2.2 Synthetic Bone Graft  
The design of synthetic bone graft will try to fulfil most of the criteria (Table 
2.1) as it will have an impact on the interaction between the cells and bone 
graft. Since the properties of the material will determine, to a great extent, the 
properties of the bone graft, the selection of the most appropriate material to 
produce a bone graft for biomedical applications is a crucial step towards the 
construction of a bone graft.  
 
 
Many materials have been proposed for bone replacement, ranging from 
metals, polymers, ceramics, and composites. Metal is the pioneer biomaterial 
used for implantation. Metallic implants such as stainless steels, cobalt-
chromium alloys, titanium alloys are mainly used in two areas: (1) permanent 
prostheses such as hip prosthesis, dental implants, and (2) fixation tools for 
bone fractures such as plates, pins, screws, and rods. Metallic implants provide 
mechanical support in load bearing applications, but do not confer 
osteoconductive, osteoinductive or osteogenic properties and as such, these 
implants are usually not integrated into the bone tissue. There are also 
concerns regarding the undesirable tissue response caused by the released ions 
from these metallic implants [86]. The high mechanical stiffness of metallic 
implants often results in stress shielding and bone resorption due to the 
mismatch of elastic modulus between metals and bone [87]. As a 
consequence, it often leads to the need for a second operation to remove the 
failed metallic implants. Improvement of implant integration in bone can 




either be accomplished by cement fixation, use of a porous bead implant 




Polymer is another group of biomaterial that is used widely as implants, for 
applications like vascular prostheses, sutures, and many others. However, due 
to their weak mechanical properties, only limited number of polymers has 
been used for bone replacements. This can be overcame by either the 
modification of the structure of the polymer or the strengthening of the 
polymer with fibre and/or filler. Polymer can be designed to be biodegradable 
by introducing ester bonds, amino bonds to the polymer structure, which is 
beneficial for drug release applications and tissue-engineered scaffold. Yet, it 
is tough to obtain a biodegradable polymer that is mechanically strong as 
compared to the cortical bone. Poly(lactide) and poly(glycolic) acid are 
regarded as the strongest biodegradable polymers available for medical 
applications since they have a tensile strength and young’s modulus up to 72 
MPa and 4 GPa  for poly(lactide) acid; and 57 MPa and 6.5 GPa for 
poly(glycolic) acid, respectively [87]. Nevertheless, these polymers are still 
weak, and reinforcement is still required in order to compete with the 
mechanical strength of the cortical bone. 
 
 
During the last 40 years, bioceramics have received significant attention for 
bone grafting due to its ability to interact with human biological system. A 




wide array of ceramic materials have been used, ranging from chemically-pure 
oxides such as alumina and zirconia to various calcium phosphate-based 
ceramic [88], glass [89], glass ceramic [90], and the chemically and 
microstructurally complex ceramic-matrix composites [91]. Moreover, they 
can be fabricated in a variety of forms to serve various different functions in 
body repair (Figure 2.4).  Bioceramics are commonly classified according to 
their tissue response in-vivo namely bioinert, biodegradable, and bioactive 




Figure 2.4  Clinical uses of bioceramics [90] 
  
 
   Table 2.2 Implant-tissue responses to bioceramics [92] 
Implant-tissue response Consequence Examples 
Bioinert 
 
A material that elicits comparatively little response from the 
body, either beneficial or deleterious. Typically, the host-







A material that can be degraded by cells. The host-tissue 
degrades and replaces the implant 
 





Materials designed to elicit a specific biological host response 











Bioinert ceramic materials such as alumina and zirconia do not elicit adverse 
response or cause damage to the host tissue. However, the body regards the 
presence of bioinert material as foreign, triggering fibroblasts to form a fibrous 
capsule around the implant. The formation of a protective fibrous layer tends 
to isolate the implant from the host tissue, creating a separation between the 
implant and host [93]. Biodegradable ceramic materials such as 45S5 bioglass 
and tricalcium phosphates are able to degrade during the implantation period. 
The degradation rate is an important factor for biodegradable ceramic 
materials as the formation of new bone should match the rate of degradation in 
order to provide adequate mechanical support. Bone can form directly an 
interfacial "bond" with the surface of bioactive bioceramic. An example of this 
is synthetic HA. Studies have reported that the interfacial strength between 
bone and bioactive surfaces, as determined by mechanical push-out tests, is 
significantly greater than the interfacial strength between bone and bioinert 
surface [94]. Unlike the failure occurred at the interface between bioinert 
implant and host bone [94], failure of the bioactive implant has been reported 
to occur either in the implant or the bone [95]. Thus, the degree of bioactivity 
in bioceramic plays a vital role in the success of implantation. The underlying 
mechanism of "bone bonding" ability of HA ceramics will be discussed in 
more detail in Section 2.3.  
 
 
Clearly, no individual material can fulfil all the requirements of the bone. As 
such, composite material system would be the best option. Composite is a 
mixture of two or more materials that combine and produce the desirable 




properties. It is much favoured as the different materials are able to 
complement each other in producing the desirable set of properties. Over the 
years, there has been increasing interest in the development of 
organic/inorganic composites particularly in nanoscale dimension. 
Nanocomposites can combine the flexibility, toughness, and bioresorbability 
of a polymer with the stiffness, strength, and osteoconductivity of a 
nanoceramic. Hence, reconstruction of bone tissue using nanocomposite 
material, which mimics the natural bone, is a goal to be pursued [96-99]. 
However, due to the complexity of bone, there has been relatively little 
success in fabricating a nanocomposite material system for clinical 




2.2.3 Factors Affecting Bone Healing and Implant-Related 
Infections  
Despite much efforts have been made to fulfil the essential criteria of a bone 
graft, the healing process of bone fracture can also be affected by other factors. 
As bone fracture healing is a cellular process, it can be modified by 
endogenous or exogenous factors that influence the metabolic function of cells. 
Pentinen [100] reported several factors that can retard bone healing, which are 
summarised as follows:  
 




 Degree of local trauma  
The healing of the fracture requires the surrounding soft tissue to provide 
mesenchymal cell for bone regeneration. Fractures associated with severe soft 
tissue damage will thus heal slower.   
 Type of bone involved 
Cancellous bone tends to heal faster than cortical bone due to a greater surface 
area and blood supply. 
 Degree of immobilisation  
The fracture site must be immobilised for vascular ingrowths and bone healing 
to occur. Inadequate immoblisation leads to delayed union.  
 Avascular necrosis 
Inadequate blood supply impairs healing.  
 Infection 
If infection is superimposed upon a fracture, the local defences are mobilised 
to eliminate the infection and therefore, healing is retarded. Among these 
factors, infection was identified as one of the serious factors that hindered and 
complicated the healing process of bone fracture. 
 
 




Similar to other medical intervention approaches, the insertion of medical 
prostheses including bone graft represents a site of weakness for host 
defences, leading itself and surrounding tissues susceptible to both immediate 
and delayed infection. Despite use of perioperative antimicrobial prophylaxis 
and laminar flow operating rooms, implant-related infections are frequent and 
serious [101]. According to the U.S. national centres for disease control and 
prevention (CDC), the risk of acquiring a serious infection during the medical 
treatment has risen over 35 % in the last 20 years [102]. In 1990s, implant-
related infections accounted for about half of all hospital-acquired infections 
[103]. Today, with the increasing use of implant, the cases of implant-related 
infections are expected to increase, particularly in sub-populations comprising 
of immune-compromised, chronically ill, and elderly patients. Besides pain 
and suffering, implant-related infections often incur huge medical costs [31]. 
For example, an estimated average total direct cost associated with an infected 
case ranges between US $15 000 and US $30 000 (approximately 3 times of 
the initial intervention) was reported [30] (Table 2.3). Although the rate of 
infection was reported to be only 5 % for primary cases, it could greatly 
increased to 43 % for previously infected cases [104]. Thus, implant-related 
infections is still a major problem affecting the service life of medical implants 
[105, 106]. As such, it is equally important to reduce the intrinsic vulnerability 














A very large proportion of implant-related infections is caused by 
staphylococci, particularly Staphylococcus aureus and Staphylococcus 
epidermidis. They represent the main causative agents in orthopaedic surgeries. 
Other pathogenic species, which also contribute to implant-related infections 
in orthopaedic surgeries are represented in Figure 2.5. Upon implantation, a 
competition exists between integration of the material into the surrounding 
tissue and adhesion of bacteria to the implant surface [107]. For a successful 
implantation, tissue integration must occur prior to appreciable bacterial 
adhesion, as host defences are often not capable of preventing further 
colonization if bacterial adhesion occurs before tissue integration. Implant-
related infections are caused by the consequence of bacterial adhesion and 
subsequent biofilm formation at the implantation site. Biofilm formation 
proceeds as a four-step process: (1) initial attachment of bacterial cells; (2) 
accumulation in multiple cell layers; (3) biofilm maturation; and (4) 
detachment of cells from the biofilm into a planktonic state to initiate a new 




cycle of biofilm formation elsewhere [108]. Bacteria living in a biofilm are 
highly resistant to antibacterial agents, and biofilm shields them from the 
influence of the host’s defence [109]. Thus, even antibiotic therapies remain 




Figure 2.5 Percentage of the main pathogenic species among orthopaedic 




Previous works on loading biomaterials with antibiotics for orthopaedic 
applications have been carried out using bone-filler materials and bone 
cements [111-113]. However, the removal of pathogen in the open fracture 
injury and periapical lesions of jaws (dental) is not easily resolved by 
systematic antibiotics. Moreover, bacteria tend to develop resistance against 
antibiotic over time. In some worst cases, when biomaterial responds poorly to 




the antibiotic therapy, removal of the infected implant is necessary to cure it 
[114]. Nevertheless, effective results of antibacterial activities of implant 
materials designated with antibacterial properties have been reported in recent 
commercially available silver-impregnated dressing and catheters [115-117]. 
Hence, this shows the potential of incorporating antibacterial properties to the 
implant material and, which will become the upcoming strategies to treat 
implant-related infections.  
 
2.3 Calcium Phosphate: Hydroxyapatite (HA) 
Calcium phosphates are one of the most extensively studied bioceramics. They 
are first considered for clinical application as filler for bone defects in the 
1920s, and first incorporated in dentistry and orthopaedics in the 1980s [118]. 
Various types of calcium phosphates materials includes HA, β-tricalcium 
phosphate, α-tricalcium phosphate, tetra calcium phosphate, and many other 
more, which differ from each other in term of the Ca/P molar ratio. Table 2.4 
lists several calcium phosphates according to their Ca/P molar ratio. Ca/P 
molar ratio is an important parameter that determines the acidity and solubility 
of calcium phosphates. The lower the Ca/P molar ratio, the more acidic and 
water-soluble the calcium phosphates become. For example, monocalcium 
phosphate monohydrate exhibits very high solubility, while tetracalcium 
phosphate is unstable in aqueous conditions. HA, tricalcium phosphate, 
hydrated dicalcium phosphate, and anhydrous calcium phosphate are all 
soluble in-vivo [63, 119]. While a range of calcium phosphates compositions 
have been considered, HA, with a Ca/P molar ratio of 1.67 [120] received the 




most attention [121]. The reason is because HA has a comparable chemical 
composition and structure as the natural bone mineral [122]. However, HA 
lacks sufficient tensile strength and is too brittle to be used in most load 
bearing applications [123]. Hence, clinical usage of HA has been limited to 
applications, where HA is used to confer bioactivity on nearly inert implant, 
such as coating on a metal core [124, 125], or in situations where considerable 
mechanical strength is not required such as bone cements for the repair of 
craniofacial defects [126, 127], and maxillary sinus floor augmentation [128]. 
In load bearing situations, HA has to be incorporated into polymers to form 
composites [129-131] in order to provide good strength with adequate 
ductility. This section will discuss on HA, its synthesis, biological properties 
and crystal structure.  
  
 
Table  2.4 Various calcium phosphates with their respective Ca/P molar ratios [99] 
 
Ca/P Name Formula Acronym 
0.5 Calcium metaphosphate (α,β,γ) Ca(PO3)2 CMP 
0.5 Monocalcium phosphate 
monohydrate 
Ca(H2PO4)2.H2O MCPM 
0.67 Tetracalcium dihydrogen phosphate Ca4H2P6O20 TDHP 
0.7 Heptacalcium phosphate Ca7(P5O16)2 HCP 
1.0 Calcium pyrophosphate dehydrate Ca2P2O7.2H2O CPPD 
1.0 Calcium pyrophosphate (α,β,γ) Ca2P2O7 CPP 
1.0 Dicalcium phosphate CaHPO4 DCPA 
1.0 Dicalcium phosphate dehydrate CaHPO4. 2H2O DCPD 
1.33 Octacalcium phosphate Ca8H2(PO4)6.5H2O OCP 
1.5 Tricalcium phosphate (α,β,γ) Ca3(PO4)2 TCP 
1.67 Hydroxyapatite Ca10(PO4)6(OH)2 HA or OHA 
 Amorphous calcium phosphate Ca10-xH2x(PO4)6(OH)2 ACP 
2.0 Tetra calcium phosphate Ca4O(PO4)2 TTCP or TeCP 
3
3 




2.3.1 Synthesis of HA 
Depending on the physical requirements (crystallinity, particle size, specific 
surface area, and morphology) of the resulting HA powder, different methods 
can be employed to synthesise HA. In general, there are two methods of 
synthesising HA: low temperature (aqueous precipitation) or high temperature 
(hydrothermal or solid state). Aqueous precipitation is the most commonly 
reported method of preparing HA.  
 
 
Aqueous methods are categorised into two groups namely precipitation or 
hydrolysis methods. Precipitation method involves mixing reactants together 
in the presence of water at a controlled temperature, atmosphere, and pH, and 
allowing the resulting precipitate to age under conditions of continuous 
stirring up to 12 h. Once aged, the precipitate is thoroughly washed, filtered, 
and dried. HA powders produced by precipitation methods can result in 
powder with deviations from stoichiometry (i.e. Ca/P ≠ 1.67), along with 
additional secondary phase such tricalcium phosphate or calcium oxide. To 
avoid the formation of secondary phases during aqueous precipitation, it is 
essential to carefully control the experimental parameters such as the 
concentration of reactants, reaction temperature, reaction atmosphere, and the 
reaction pH. Rathjue [132] is the first to describe a method of synthesising HA 
by a precipitation method that comprised of the drop-wise addition of 
phosphoric acid to a suspension of calcium carbonate in water (Equation 2.1). 
 




10CaCO3 (aq) + 6H3PO4 (aq) →  
Ca10(PO4)6(OH)2 (aq)  + 10CO2 ↑ (g)  + 8H2O (l) 
        (Equation 2.1) 
 
Several different combinations of calcium- and phosphate-containing 
compounds have also been engaged to synthesise HA [Equations 2.2-2.3] [88, 
122, 133-135]  
 
 
10Ca(NO3)2 (aq) + 6(NH4)2HPO4 (aq)  + 8NH4OH (aq) → 
Ca10(PO4)6(OH)2 (aq) + 6H2O (l)  + 20NH4NO3 (aq)    
        (Equation 2.2) 
 




Ammonia solution is used to control the pH of the reaction to overcome the 
formation of octacalcium phosphate, which will readily convert to β-
tricalcium phosphate upon sintering (Equation 2.2) [133]. Equation 2.3 
involves the mixing of calcium hydroxide and phosphoric acid at 24 °C with 
the pH level maintained at 10. This method of synthesis has been popularly 
employed to prepare stoichiometric HA and various substituted hydroxyapatite 
[21, 24, 47, 136, 137].  




On the other hand, hydrolysis methods of preparing HA involve the hydrolysis 
of acid calcium phosphates (dicalcium phosphate dihydrate) in carbonate, 
fluoride, chloride, ammonium, sodium or potassium hydroxide solutions 
depending on the desired composition of the apatite. For instance, calcium 
carbonate can be hydrolyzed to apatite ammonium in sodium phosphate 
solutions, or to fluorapatite in fluoride solutions [63]. In addition, α- or β- 
tricalcium phosphate and tetra calcium phosphate can also hydrolyze to 
calcium deficient apatites [138-140].  
 
 
High temperature and pressures are applied to the aqueous solutions of 
calcium- and phosphate-containing compounds in a platinum-lined 
hydrothermal bomb for hydrothermal methods [141, 142]. Calcium carbonate 
in the presence of the appropriate amounts of calcium hydrogen phosphate or 
ammonium hydrogen phosphate can also be transformed to HA by 
hydrothermal methods [92]. 
 
 
HA can also be synthesised by stoichiometric mixing of reactants at high 
temperatures through solid state diffusion of the calcium, phosphate, and 
hydroxyl ions. For instance, the formation of HA can be achieved through a 
solid-state reaction between tri- and tetracalcium phosphates or alternatively 
of tricalcium phosphate and calcium oxide; dicalcium phosphate and calcium 
carbonate, and fluorapatite with steam [143]. 
 




For the synthesis of HA, aqueous precipitation is more economical and 
quicker method than hydrothermal and solid state methods. Moreover, 
aqueous precipitation methods simulate the biological mineralization as 
precipitation is carried out at around physiological temperatures, yielding 
small crystals of low crystallinity.  
 
2.3.2 Crystal Structure of HA 
The structure of HA is based on the structure of naturally occurring 
fluorapatite. Fluorapatite [Ca10(PO4)6F2] and its isomorphs is reported to 
crystallise in hexagonal symmetry with space group P63/m ( a = b ≠ c, α = β = 
90 °, λ = 120 °) using X-ray diffraction techniques [144, 145]. X-ray 
diffraction study by Psoner et al. [146] further demonstrated the definitive 
structure for HA, and calculated the unit cell dimensions of a = b = 0.943 nm, 
and c = 0.688 nm. These findings were further substantiated by neutron 
diffraction studies [147], suggesting that the structure of HA consists of the 
hexagonal arrangement of calcium and phosphate assembly crossed by parallel 
columns of hydroxyl ions (Figure 2.6).  
 





Figure 2.6 Crystal structure of hydroxyapatite [147, 148] 
 
 
Calcium ions are allocated at 2 different sites: Ca(I) and Ca(II). Ca(I) ions 
coordinated by 9 oxygen atoms form a polyhedron, are located in columns 
parallel to the hydroxyl channels. Ca(II) ions coordinated by 5 oxygen atoms 
and 1 hydroxyl group form an octahedron, are arranged in staggered triangular 
arrays on the screw axis to form the channel walls [149] (Figure 2.6). Ca(I) 
ions are fixed and aligned in columns, and any small change in the metal–
oxygen interactions will affect the entire lattice. On the other hand, the Ca(II) 
ions are staggered in consecutive layers, which can be displaced without 
compromising the whole structure. As illustrated in Figure 2.7, the phosphate 
tetrahedral groups are located in a similar manner to the Ca(II) atoms. Both 
phosphate tetrahedral and Ca(II) atoms are arranged in equilateral triangles 




around hydroxyl groups. Centre hydroxyl group is in columns parallel to the c-
axis, passing through the centres of Ca triangles [147]. Thus, when the 
structure of HA is viewed along crystallographic c-axis (along the line of the 
hydroxyl groups), the Ca(II) ions appeared in the shape of hexagon centred on 
the hydroxyl groups. In the unit cell of HA, hydroxyl ions lie on the corners of 
the plane at equal intervals along columns perpendicular to the plane and are 
surrounded by 6 Ca(II) in a hexagonal arrangement [147, 150]. The oxygen 





Figure 2.7 Atomic assembly of HA in a unit cell [151] 
 
 
2.3.3 Substituted Apatite 




6)(BO4)X2, the crystal structure of HA is 
susceptible to substitutions by other ions. The high stability and flexibility of 
the apatite structure accounts for a variety of possible cationic and anionic 
substitutions [152]. For instance, site A can be accommodated by monvalent, 
divalent or trivalent ions such as silver, sodium, calcium, magnesium, 




strontium, lead, barium, aluminium ions whereas site B can be occupied by 
carbonates, phosphates, sulphate, vanadates, arsenate or silicates, and site X 
can host fluoride or hydroxyl [153]. Substitutions can take place 
independently or simultaneously, and are generally governed by ionic 
charge/valance and radius of the ionic substituent(s). In general, ionic 
substitutions can affect the lattice parameters, crystal morphology, crystallinity, 
solubility, and thermal stability (Table 2.5). These in turn, all influence the 
biological properties. 




Table 2.5 Qualitative effects of ionic substitutions in HA [154] 
Site Substituting ions 
Ionic radii 
(nm) 
a-axis c-axis Crystallinity 
A Calcium, Ca
2+
 0.099    
Stronium, Sr
2+
 0.112 (+) (+) nc 
Barium, Ba
2+
 0.134 (+) (+) (-) 
Lead, Pb
2+
 0.120 (+) (+) (-) 
Silver, Ag
+
 0.126 (+) (+) (-) 
Potassium, K
+
 0.133 nc nc nc 
Sodium, Na
+
 0.097 nc nc nc 
Lithium, Li
+





0.066 (-) (-) (-) 
Cadmium, Cd
2+
 0.097 (-) (-) (-) 
Manganese, Mn
2+
 0.08 (-) (-) (-) 
Zinc, Zn
2+
 0.074 (+) (+) (-) 
Aluminium, Al
3+
 0.051 (+) (+) (-) 
B Phosphate, PO4
3-
 0.154    
Carbonate, CO3
2-
 0.131 (-) (+) (-) 
Silicate, SiO4
4-
 0.161 (+) (-) (-) 
X Hydroxyl, OH
−
 0.097    
Fluoride, F
- 
0.136 (-) nc (+) 
Chloride, Cl
-
 0.181 (+) (-) nc 
[Note: (+) = increase, (-) = decrease, and nc = no change] 




Cationic substitution can occur either in the Ca(I) or Ca(II). Due to a shorter 
distance among Ca(I) sites than Ca(II) sites, larger cations usually occupied 
the Ca(II) sites, and the smaller cations preferred to reside at the Ca(I) sites 
[155].  Substitution can take place readily and occurred for the whole range of 
composition for cations including strontium and cadmium
 
ions, which possess 
similar charge [151]. Despite having similar charge, the substitution of cations 
with smaller ionic radius such as magnesium and manganese ions resulted in a 
contraction of the a- and c-axes. On the other hand, the substitution of cations 
with larger ionic radius such as lead and barium ions caused an expansion of 
the a- and c-axes. Cationic substitution of a different ionic radius required 
more elastic energy, which will result in larger lattice relaxations of the 
surrounding oxygen [156]. However, cations with different charge can only 
occur to a limited extent as they can cause disorder within the crystal structure. 
In order to maintain charge balance between the valency differences of the 
substituting cation and calcium
 
ion, a reduction in the anionic charge will be 
required. This is achieved by the formation of vacancies on the hydroxyl sites 
[157]. The formation of vacancies may affect both the short- and long-range 
order of the crystal [63].   
 
 
Ionic substitution of HA is not only induced by the addition of cations, but 
also by the addition of anions. Through the examination of the a- and c-axes 
lattice parameters, anionic substitution of carbonates in site B or X can be 
identified [158, 159]. Similarly, charge compensation is generally proposed 
for the vacancies formation at the hydroxyl sites when the anionic substitution 




involves a valency difference (i.e. when silicates substitute for phosphates). 
However, the determination for anionic substitution is more complex as 
structural analysis carried out by X-ray diffraction is not able to distinguish 
isoelectronic ions (e.g. phosphorous and silicon), and determine the presence 
of hydrogen atoms. Therefore, more appropriate approaches are suggested by 
the study of displacement of crystallographic positions, distortion, and 
interatomic distances in the phosphate tetradron, and chemical states of the
 
anions [20, 147, 160-162].  
 
2.3.4 Biological Properties of HA 
Having a composition and structure similar to the mineral phase of bone [52], 
HA is biocompatible and bioactive [163, 164]. Therefore, when HA is 
resorbed in the body, it will cause minimum or negligible immune system 
response and systemic toxicity. Being hydrophilic, HA has also a high affinity 
for adhesion proteins and growth factors. Thus, HA can be an appropriate 
carrier for growth factors and stem cells without the need to modify its 
chemical surface [165]. Study has demonstrated that HA with growth factors 
have superior stability and in-vivo osteogenic properties as compared with 
autologous bone grafts in critical-sized bone defects [166]. The dissolution of 
HA is accompanied with the re-precipitation of a carbonated apatite, which 
has a more similar composition and chemical structure as the mineral phase in 
bone [167]. As a result, it permits the direct bonding of HA to the host bone. 
Therefore, the degradation products of HA are conducive to bone formation 
and consequently, gives rise to the bioactivity behaviour.  




Although HA has the ability to allow new bone to form along its surface, it has 
a relatively slower rate of osseointegration as compared to bioactive glasses 
and glass-ceramics [8, 9].  The release of calcium and phosphate ions from 
HA to interact with the body fluid is too slow, resulting in the slow bone 
apposition and integration with HA [168, 169]. Schepers et al. [168] observed 
that bone tissue did not grow further than 1 mm into the defect after 12 weeks, 
and multinucleated giant cells as indicated by the moth eaten appearance were 
continuously observed from that time onwards (Figure 2.8). The experiment 
showed that stoichiometric HA is osteoconductive in-vivo, but displays a 
limited bone bioactivity. Consequently, the slow bone apposition and 























Figure 2.8 Histological section of stoichiometric HA (a) after three months, (b) 
after six months, the particle surfaces have a moth eaten appearance caused by 
multinucleated cell resorption as indicated by arrows [168] 
 
A recent approach of improving the osseointegration rate of HA has been to 
incorporate biological entities such as growth factors, proteins, and cells onto 
the surface of the HA implant [170]. However, storage and sterilisation 
processes have been reported to reduce or completely removed the beneficial 
effects of these biological entities [171, 172]. Another approach to improving 
the biological properties of HA is to adjust its chemical composition to more 
closely approximate that of the bone mineral. Synthetic HA may resemble the 
(a) 
(b) 




mineral phase of bone, but, it still differs from one another in several aspects 
such as stoichiometrical composition, crystal dimensions, and degree of 
crystallinity (i.e. low degree of structural order) as illustrated in Table 2.6. As 
discussed in Section 2.1.3, bone minerals are carbonated apatites containing a 
multitude of ions, which either incorporated in the apatite crystal lattice or just 
adsorbed on the crystal surface. The substitution of these ions induce complex 
structures at the unit-cell level, and play a significant role in the dissolution 
rate of apatites, thus favouring osseointegration [169]. Low degree of 
crystallinity and small crystal sizes [52] are important factors related to the 
relatively high solubility of bone mineral with respect to stoichiometric HA. 
Thus, a potential method of improving the biological response of HA may be 





















Table  2.6 Comparison of natural bone mineral and HA [58] 
Composition, wt.% Bone HA 
Calcium 34.8 39.6 
Phosphate 15.2 18.5 
Ca/P (molar ratio) 1.71 1.67 
Sodium 0.9 - 
Magnesium 0.72 - 
Potassium 0.03 - 
Silicon 1 - 
Carbonate (CO3
2-
) 7.4 - 
Fluoride 0.03 - 
Chloride 0.13 - 
Pyrophosphate (as P2O7
4-
) 0.07 1 
Total inorganic 65 100 
Total organic 25 - 
Lattice parameters a-axis, å 9.41 9.430 




Typical crystal sizes (nm) 50 x 25 x 4 200-600 
Elastic module (GPa) 0.34-13.8 54-79 
Tensile strength (MPa) 150 100 
 




2.4 Silver-Substituted Hydroxyapatite (AgHA) 
As mentioned in Section 2.2.3, hydroxyapatite-based bone graft is a synthetic 
material and tends to represent a site of weakness for the host defence, 
subjecting itself and the surrounding tissues susceptible to infection. Implant-
related infections complicate the bone healing, and can also lead to the failure 
of orthopaedic surgery. Therefore, bacterial infection remains as a major 
problem affecting the service life of medical implants [105, 106]. To 
overcome the infection issues encountered in hydroxyapatite-based bone graft, 
substitution of functional ion such as silver has emerged as a preventative 
alternative. This section will discuss on AgHA, its synthesis, chemical and 
physical characterisation, antibacterial and biological properties.  
 
 
Chemical characterisation involves the assessment of crystal structure, phase 
purity and chemical content of ionic substitution present within AgHA. The 
methods commonly used to characterise AgHA include X-ray diffraction 
(XRD), X-ray fluorescence (XRF), inductively couple plasma spectroscopy 
(ICP), fourier transform infrared spectroscopy (FTIR). Physical 
characterisation will be concentrating on the dissolution of silver ions from 
AgHA, which has been reported to influence the antibacterial properties [36, 
40, 41, 173]. The biological assessment of AgHA comprises of in-vitro and  
in-vivo testing. In-vitro testing is performed using the components of an 
organism that is isolated from their usual biological surrounding, which can 
provide fundamental information on cellular interaction with the biomaterial, 




without stimulating the complexities of the host-implant interface in-vivo. In-
vivo testing is conducted with living organism in their normal intact state, 
which can evaluate the bioactivity of the implant under physical condition.          
 
 
2.4.1 Silver as an Antibacterial Agent 
One common and accepted strategy to prevent implant-related infections is to 
create antibacterial properties for the implant. Implants with antibacterial 
properties allow direct effect, which in turn reduce the treatment duration 
[174], and decrease the side-effects of systemic treatments [175], thereby 
improving its efficacy. Inorganic antibacterial agents generally have a low 
resistance against bacteria, and are comparatively stable than organic ones, 
thus they become an ideal choice for local antibacterial treatment. Among the 
inorganic antibacterial agents, silver and its ions show oligodynamic effect 
with a broad spectrum of antibacterial activities against bacteria, viruses, algae, 
and fungi [176, 177]. Both metallic and ionic silver have been widely 
incorporated into biomaterials and medical devices such as bone cements, 
catheter, orthopaedic fixation pins, dental implants, cardiac prostheses, and 
burn wound treatments [39, 178, 179]. Although the antibacterial activity of 
AgHA has been demonstrated in several works [36, 40, 41, 180-182], the 
exact mechanism of antibacterial action, which AgHA exert this antibacterial 
activity is not fully known and understood. Possible mechanisms of 
antibacterial action of silver ions have been suggested according to the 
morphological and structural changes found in the bacterial cells. The 




common proposed mechanism in the literature suggested that silver ions can 
interact with bacterial cells in several ways:  
 Silver ions inhibited the uptake of phosphate and caused the efflux of 
intracellular phosphate [183].  
 Darouiche et al. [101] noted that silver ions bind to sulfhydryl groups of 
the many important metabolic enzymes of the bacterial electron transport 
and respiratory chains such as NADH dehydrogenase, which suppressed 
the cell respiration [184]. For example, silver ions bind to the thiol groups 
(sulphydryl, S-H) present in the cysteine residues of the transport proteins 
[185-187], which induced a massive proton leakage through the bacterial 
membrane, resulting in complete deenergization, and ultimately leading to 
cell death [188].  
  With use of transmission electron microscopy, Feng et al. [189] 
demonstrated that silver ions enter into the bacterial cells by penetrating 
through the cell wall, and turned the DNA into condensed form, as a result, 
DNA lost its replication ability and lead to cell death.  
 Yamanaka et al. [190] reported that silver ions bind to microbial DNA by 
interacting with nucleic acids, and changed DNA structure, which 
consequently prevented bacterial replication.  
 Silver ions was also observed to increase the DNA mutation frequencies 
during polymerase chain reactions [191].  
 It was also reported that silver ions generated reactive oxygen species 
(ROS) [192, 193], and damaged the cell membrane [194, 195] 




 On the whole, bacterial cells suffered from morphological changes such as 
cytoplasm shrinkage and detachment of cell wall membrane, which 




In a nutshell, silver ions interfered with the integrity of the bacterial cell, and 
bind to the enzymes and proteins within the bacteria, which severely damaged 
the cell and its major functions, such as permeability, regulation of enzymatic 
signaling activity, cellular oxidation and respiratory processes.    
 
2.4.2 Synthesis of AgHA 
A number of studies have considered the synthesis of AgHA through a 
precipitation route [36, 38, 40, 41] whist few engaged various spraying 
methods [173, 184, 197-199], and sol-gel method [200, 201] to synthesise 
AgHA. The incorporation of silver ions into apatite is based on ion-exchange 
ability of the apatite structure, whereby silver ions are absorbed from solution 
during the nucleation of HA or from solution with the synthesised HA 
(Equation 2.14). 




+ (2−y)OH− (aq) →  
Ca10-y Agy(PO4)6(OH)2−y (aq)    
        (Equation. 2.14) 
 
 




Silver precursor was added into the calcium precursor as silver would 
substitute at the calcium site of apatite structure. During precipitation method, 
phosphate precursor was added drop-wise into the calcium precursor 
containing silver precursor, and stirred for several hours for the reaction to 
occur before undergoing ageing. Although precipitation method is the 
common route to synthesise AgHA, a variety of different combinations of 
precursors is engaged for the synthesis of AgHA. Oh et al. [38] used silver 
nitrate, calcium nitrate and ammonium phosphates for the synthesis of AgHA 
whilst Kim et al. [41] used silver nitrate, calcium hydroxide and 
orthophosphoric acid, and Rameshbabu et al. [40] used silver nitrate, calcium 
hydroxide and diammonium hydroygen phosphate. As ammonia could react 
readily with silver ions in basic condition to form a stable complex ion, 
diamminosilver(I) ion that can affect the amount of silver to be incorporated 
into apatite structure [38, 202], Stanic et al. [36] used silver oxide, calcium 
hydroxide and orthophosphoric acid for the synthesis instead. 
 
Silver ions could also undergo ion-exchange when HA was formed, but this 
method was more commonly used when AgHA was being produced in a form 
of coating. Laser beam was focused on HA and silver targets to undergo 
sputtering under inert atmosphere [184, 197]. Alternatively, others added the 
silver precursor such as silver oxide or silver powder into HA to form a silver-
containing HA suspension, and was thermally [173, 198] or plasma sprayed 
[199] onto the titanium substrate.        




Sol gel is another method employed to synthesise AgHA. Calcium precursor 
was prepared by reacting calcium nitrate tetrahydrate with methyl alcohol 
whilst phosphorus precursor was prepared by reacting triethyl phosphite in 
acetic acid. Silver nitrate and the two precursors were mixed together, and a 
drying control chemical additive was added to the mixture. All reactions were 
carried out in argon atmosphere. The mixed solution was then aged, filter, and 
further aged for a longer period. Finally, the prepared silver-doped HA sol was 
then spin-coated onto a substrate [201]. Alternatively, silver nitrate, calcium 
nitrate tetrahydrate and triethyl phosphate were mixed in anhydrous ethanol. 
Subsequently, the precursors mixture was aged at 80 °C for 16 h, followed by 
gelation for 24 h and dried at 80 °C [203, 204]. 
 
2.4.3 Chemical and Physical Characterisation of AgHA 
Obtaining a phase-pure AgHA is desired for biocompatibility, but has met 
with much difficulties. Kim et al. [41] detected the production of apatite along 
with nitrate-apatite in AgHA incorporated with 1 wt.% of silver. Rameshbabu 
et al. [40] managed to produce a single-phase apatite at a low silver content  
(< 1.63 wt.% of silver) heated below 700 °C. The phase stability of AgHA was 
not maintained, with the increase of silver content since silver phosphate 
began to form, and β-tricalcium phosphate was further produced when heated 
above 700 °C. Presence of metallic silver was even observed when heated to 
800 °C. Similarly, Singh et al. [205] also demonstrated a phase-pure apatite at 
silver content up to 2 wt.%. However, α-tricalcium phosphate was produced 
when silver content was increased to 3 and 5 wt.%. The lack of phase stability 




in AgHA at high temperature may be explained by the production of vacancy 
at the hydroxyl site, which was formed to compensate for the charge 
imbalance when silver partially substituted for calcium. On the other hand, 
phase-pure apatite has not been achieved for AgHA that are synthesised using 
sol gel route. Either one or more of the secondary phases such as silver, silver 
oxide, silver phosphate, calcium oxide or tricalcium phosphate are observed to 
be accompanied with the production of apatite at all silver content of AgHA 
[184, 198-200, 203, 204, 206, 207]. 
 
Presence of silver in AgHA was revealed when the lattice parameters namely 
a- and c- axes increased with increasing amount of incorporated silver ions in 
the XRD refinement analysis [40, 208]. Changes in lattice parameters implied 
that silver substituted for calcium in the HA lattice since silver ion (0.128 nm) 
is larger than calcium ion (0.099 nm), thus corresponding to an increase in the 
lattice parameters. In addition, Vukomanovic et al. [209] reported that the 
existence of silver in the AgHA according to the changes in the Ca/P molar 
ratio. It was also noted that there was a significant loss in the amount of the 
incorporated silver in AgHA when silver was substituted during the nucleation 
process of apatite [38]. Due the size factor, silver ions have the difficulty in 
occupying the calcium site. With the formation of diamminosilver(I) ion and 
the physical effect of washing during the synthesis process, the amount of 
silver that could be incorporated into the apatite structure was further reduced. 
Oh et al. [38] attempted to minimise the loss of incorporated silver in AgHA 
by synthesising AgHA with higher Ca/P molar ratio (e.g. 2.0) whilst Stanic et 




al. [36]  avoided the use of ammonia and nitrate precursors for the synthesis of 
AgHA.  
 
Introducing silver into the apatite structure after HA was formed tends to yield 
silver ion-rich surface. In such an environment, premature release of silver 
ions was anticipated, which greatly compromised the sustainability of 
antibacterial effect [42]. These AgHA was reported to release more than 50 % 
of the loaded silver ions within the first 24 h [37, 42]. Furthermore, Wu et al. 
[210] demonstrated increasing release of silver ions with time and silver 
content from the AgHA scaffold synthesised with the silver ions being 
incorporated after HA was formed. Increasing release of silver ions with 
immersion time can produce undesirable consequences such as local toxicity 
and short-term antibacterial property. 
 
  
Chen et al. [37] compared the release of silver ions from silver-containing HA 
coatings that were produced by 2 different methods (T1 and T2) in simulated 
body fluid and buffering fluid. T1 coating was formed when silver ions were 
incorporated during nucleation of apatite, and T2 was formed with silver ions 
being incorporated after HA was formed. For the first 50 h, the release of 
silver ions from T1 coating was greater than T2 coating in both stimulated 
body fluid and body fluid mediums. However, the release of silver ions from 
T2 coating greatly increased and exceeded the amount of silver ions released 
from T1 coating after 50 h in both stimulated body fluid and body fluid 




mediums. Approximately 0.4 and 1.4 ppm of silver ions was released from T1 
coating into the stimulated body fluid and body medium, respectively, and this 
amount of released silver ions was maintained till 336 h. The sustained release 
of silver ions suggested that the silver ions that was incorporated during the 
nucleation of apatite was more homogenously distributed within the apatite 
structure. High risks of implant-related infections often occur in the early 
period of the surgery [211]. Thus, the large release of silver ions in the initial 
stage is considered helpful for preventing implant-related infections. However, 
at the later stage, a minute and steady release behaviour is the key to provide 
long-term antibacterial property for implantation. 
 
 
2.4.4 Antibacterial Properties of AgHA  
Several antibacterial studies demonstrated that AgHA exhibit excellent 
antibacterial activity in-vitro, with a reduction of more than 99 % against the 
following pathogens: S. aureus, E. coli, S. mutans, and C. albicans [36, 40-42, 
173, 184, 199, 205, 212]. The antibacterial effect against the bacteria in the 
medium was suggested to be dependent on the release of silver ions [36, 40, 
41, 173], but the exact mechanism of antibacterial action of AgHA remained 
elusive. Zone of inhibition [36] and reduction in the number of bacteria in the 
growth medium were demonstrated in the spread plate method as represented 
in Figures 2.9 and 2.10. On the other hand, reduction of the adherent bacteria 
[205] were mostly observed using the scanning electron microscopy (Figure 
2.11), as an indicative of antibacterial effect. 










Figure 2.10 Antibacterial effect of the treated (a) HA and (b) AgHA coatings 












Figure 2.11 Scanning electron microscope images of adherent E. coli treated 




Oh et al. [42] compared the durability in the antibacterial effect between 
AgHA that was synthesised when silver ions were incorporated during 
nucleation of apatite (AgHA-CP), and AgHA that was synthesised when silver 
ions were incorporated after HA was formed (AgHA-IE). Despite rapid 
reduction of E. coli for the first 10 minutes, proliferation of E. coli was noticed 
after 100 h for AgHA-IE samples. In contrast, AgHA-CP could effectively 
suppressed the proliferation of E. coli until 1000 h. The difference in the 
durability in the antibacterial effect was explained by the amount of silver ions 
released during the initial 10 minutes [42]. Furthermore, Oh et al. [42] also 
demonstrated that AgHA-CP containing 0.53 wt.% of silver had a more 
(a) 
(b) 




durable antibacterial effect than 1.5 wt.% of silver content in AgHA-IE, 
despite a lower silver content. Regardless of the low amount of released silver 
ions in AgHA-CP, it was able to achieve excellent antibacterial property. This 
might imply that AgHA-CP exerted its antibacterial activity by the released 
silver ions to a certain extent, and might not only rely on the release of silver 
ions from AgHA.   
 
 
Most quantitative antibacterial tests were conducted on AgHA to display its 
antibacterial properties whilst studies demonstrating the effect of AgHA 
inflicted upon the treated bacteria were seldom performed. Recently, AgHA 
was shown to cause considerable morphological changes of the bacteria in an 
atomic force microscopy study (Figure 2.12). Two assembled cells of S. 
aureus treated by HA particles retained their coccal morphology whilst S. 
aureu treated by AgHA became elongated with visible damages that looked 
















2.4.5 Biological Characterisation of AgHA  
Despite obvious antibacterial benefit, few studies have reported on the 
biological properties of AgHA. The formation of bone-apatite observed on the 
AgHA coating during the immersion in stimulated body fluid suggested 
favourable biological response of AgHA [37, 198]. The presence of silver ions 
did not affect the interaction of the ions in the stimulated body fluid to form 
bone-apatite onto AgHA. Human osteoblast cell attachment was noticed on 
AgHA samples containing 0.5, 1.0, and 1.5 wt.% silver [40], and mouse 
fibroblast cell was also seen attached on AgHA samples with up 5 wt.% silver 
content [205]. Although, presence of apatite facilitated the adhesion of cells, 
adhesion of cells was demonstrated to decrease with the increase of silver 
content in AgHA (Figure 2.13). In addition, Oh et al. [180],  Chen et al. [199] 
and Stanic et al. [36] studied the cytotoxicity of AgHA. Hemolysis ratios of 
AgHA with the silver content less than 5 wt.% showed good blood 
(a) (b) 




compatibility. Similarly, the cytotoxicity of AgHA also increased with 





Figure 2.13 SEM photographs of osteoblast cell attachment on (a) tissue 
culture plate and AgHA with (b) 0.5 wt.%, (c) 1.0 wt.%, and (d) 1.5 wt.% [40] 
 
 
There was only one in-vivo experiment carried out at the periapical area of 
both mandibular 1
st
 molar of rats [214]. The wound implanted with AgHA 
healed in 1 week, and showed minimum signs of inflammation in-vivo after 3 
weeks. AgHA containing 4.3 wt.% of silver showed mild delayed in the 
organisation of fibrinoid materials in the centre of defects with mild 
inflammatory reaction at the early healing phase as compared to AgHA 
containing 0.15 and 1.5 wt.% of silver. Although the first in-vivo results are 




promising, further in-vivo results are necessary to conclude clinical relevance. 
All these results indicated that the presence of silver ions to a certain amount 
( >10 mg/L ) in the human body could be cytotoxic as it could affect the basic 
metabolic cellular functions of the mammalian cells [215]. Silver ions were 
reported to deplete the intracellular adenosine-5'-triphosphate (ATP) content, 
which could compromise the cell energy charge and precede to cell death 
[216]. As far as the toxicity concern, toxicity from silver was observed in the 
form of argyia, which only occurred when large amount of silver ions were 
used for dressing a large open wound. So far, there are no regular reports of 
silver allergy [217]. Nevertheless, it is important to always consider the 
amount of released silver ions for a long period, as it may lead to the 
accumulation of silver in the organs. Therefore, it is prudent to incorporate 
optimum amount of silver in HA to adequately reduce bacterial adhesion with 
minimum silver release for tissue cytotoxicity.       
 
 
2.5 Silicon-Substituted Hydroxyapatite (SiHA) 
As mentioned in Section 2.3.4, HA has a limited ability to form an interface 
with, and to stimulate the development of new bone tissue. Bone minerals are 
carbonated apatites containing a multitude of ions, and silicon is found to be 
one of the essential trace elements in biological processes in eliciting specific 
metabolic role connected to bone growth [11, 12]. Therefore, SiHA has 
attracted the interest of many scientists as the incorporation of silicon is 
considered to be a promising way to improve the biological response of HA 
[17, 19, 21, 23, 24, 26-28, 160-162, 218-223]. This section will discuss on 








Similarly, chemical characterisation will include the crystal structure, phase 
purity and chemical content present within SiHA. The assessment of the 
physical property will be concentrated on the microstructure, surface 
chemistry and nanoscale characteristics of SiHA as all these features have 
been reported to affect the solubility of SiHA, which in turn, influence the 
biological response of SiHA [151]. The biological characterisation will 
include the in-vitro and in-vivo testing of SiHA.  
 
 
2.5.1 Silicon as Bone Promoter 
The interest in the substitution of silicon into the HA lattice has largely 
stemmed from studies describing the beneficial role of silicon in bone 
metabolism, and calcification [11, 12, 224, 225]. The early indication of a 
physiological role for silicon in bone calcification was reported by Carlisle 
[12], where silicon levels of up to ~ 0.5 wt.% were reported to be localised in 
the active growth areas in the young mice and rat bone. Further studies by 
Carlisle [11] and Schwarz, and Milne [225] reported that the silicon deficiency 
in a chick and a rat model, respectively, resulted in retarded bone growth, 
abnormally shaped bone, and defective cartilaginous tissue. In addition, 
studies have also demonstrated a relationship between the level of dietary 
silicon and bone mineralisation as evidenced from the accelerated bone 




mineralisation with increasing silicon content [11]. From X-ray microanalysis 
studies, Carlisle [226] reported that silicon was involved at the cellular level 
and appeared to be significantly higher in metabolically active osteoblasts. 
Recently, the effect of silicon on bone and bone-like cells were investigated in 
in-vitro studies [224, 227, 228]. Reffitt et al. [224] reported that silicon ions in 
the form of orthosilicic acid stimulated type I collagen synthesis in the 
osteoblast-like cells (MG63 cell), and also enhanced osteoblastic cell 
differentiation. Arumugam et al. [228] also demonstrated that orthosilicic acid 
stimulated the production of type I collagen and mRNA at levels up to 50 µM 
with human osteoblasts. Furthermore, Jugdaohsingh et al. [227] observed an 
inhibition of growth plate closure and an increase longitudinal growth as a 
result of silicon deficiency in rats. Hidebrant et al. [229, 230] noticed that 
certain genes were activated by hydrated silicon. Hydrated soluble silicon 
would enhance the proliferation of osteoblasts and active cellular production 
of transforming growth factors [229]. All these observations implied that 
silicon plays an important role in connective tissue metabolism, especially in 
bone and cartilage. 
 
 
The role of silicon in bone was also demonstrated in silicon-rich materials 
such as bioactive glasses, and glass-ceramics [231-233]. In-vitro, and in-vivo 
studies have proposed that the bioactivity of these silicon dioxide-rich glass 
formulations was related to the role of silicon dioxide (or silicon) on their 
surface reactions [234-236]. It was proposed that Si-O-Si bonds were broken 
and formed silanols (Si-OH bonds), and subsequently silicon dioxide-rich 




layer were condensed and re-polymerised on the surface of the glass [231, 
236]. These surface reactions allowed the subsequent crystallisation of apatite 
crystal, which in turn, led to the direct apposition of the host tissue to the 
bioactive glass or glass-ceramic in-vivo  [234, 235]. Therefore, all these 
positive results motivated the potential benefits of silicon substitution in HA 
on enhancing the biological properties of HA.  
 
 
2.5.2  Synthesis of SiHA 
Different synthesis routes including sol gel procedure, hydrothermal synthesis, 
solid-state reactions, and precipitation methods were proposed to synthesise 
SiHA. Sol gel procedure involved the addition of tetraethyl orthosilicate to an 
ethanol/HA suspension. The ethanol/HA/tetraethyl orthosilicate mixture was 
stirred for 10 minutes, and water was added to the mixture to hydrolyse the 
ethyl silicate, under continuous stirring. Finally, the excess ethanol was 
removed by evaporation [26]. On the other hand, hydrothermal method 
engaged sodium hydrogen phosphate and tetraethyl orthosilicate to undergo 
hydrolysis for 24 h, after which calcium oxide was added into the mixture, and 
heated at 145 °C under a nitrogen atmosphere for 4 days [237]. A similar 
study was also conducted by Sugiyama et al. [238], which placed the starting 
materials in a stainless steel autoclave under saturated pressure at 150 °C for 
96 h instead. Boyer et al. [239] prepared SiHA via solid-state reaction with the 
addition of a secondary ion such as lanthanum or sulphate. Lanthanum oxide, 
calcium pyrophosphate, calcium carbonate and silicon dioxide were mixed 
together and pre-fired at 900 °C for several hours. The pre-fired powders were 




milled and fired at 1100 °C for longer period. Gibson et al. [24, 240] described 
the synthesis of SiHA using aqueous precipitation, which involved reactions 
between calcium hydroxide, orthophosphoric acid, and silicon tetra-acetate 
solutions. Equation 2.15 describes the reaction mechanism reported by Gibson 
et al. [24]. In order to compensate for the extra negative charge of silicate 
groups, some of the hydroxyl groups are lost to retain charge balance. In 
recent years, a new method of producing SiHA thin film has been developed 
using magnetron sputtering, by having HA and silicon as the targets [16].  
 
 
Ca10(PO4)6(OH)2 (aq)  + x SiO4
4- 
(aq) 
 →    
Ca10(PO4)6-x(SiO4)x (aq) + x PO4
3- (aq)  + x OH− (aq)   
        (Equation 2.15) 
 
2.5.3  Chemical and Physical Characterisation of SiHA 
Majority of these studies have resulted in silicon-containing apatites with 
undesirable secondary phases. Ruys et al. [26] obtained a mixture of HA, 
calcium silicophosphate, β- and α-tricalcium phosphates using sol gel method 
when it was sintered at high temperature. SiHA with 0.9 wt.% of silicon 
content, which was prepared by a solid state reaction decomposed to calcium 
pyrophosphate, calcium carbonate and silicon dioxide when sintered to 
1100 °C [162]. By far, a monophasic material at a low content of silicon (< 2.5 
wt.%) after sintering at 1200 °C were only achieved only by hydrothermal 
[237] and precipitation methods [24, 25]. SiHA coating produced by 




magnetron sputtering could produce a phase-pure apatite, up to 4.9 wt.% of 
silicon content being incorporated [16].  
 
 
Pietak et al. [219] highlighted that the production of phase-pure SiHA could 
be affected by the following factors: Ca/P molar ratio of the system, level of 
silicon addition, source of silicon precursor, synthesis method and sintering 
temperature. For instance, SiHA decomposed to HA and α-tricalcium 
phosphate at higher silicon content when tetraethyl orthosilicate was used as 
the silicon source [241]. Phase stability was only maintained with silicon 
content up to 0.8 wt.% when tetraethyl orthosilicate was used as the silicon 
precursor. On the other hand, a phase-pure apatite up to 1.6 wt.% of silicon 
content in SiHA could be obtained at 1200 °C when silicon acetate was used 
as the silicon precursor [137]. In addition, the use of different starting 
materials also affected the phase stability of SiHA. A single-phase apatite was 
obtained after sintering to 950 °C when calcium nitrate, diammonium 
phosphate and silicon acetate were used whilst a mixture of HA and β-
tricalcium phosphate were obtained when calcium hydroxide, orthophosphoric 
acid and silicon acetate were used [28]. SiHA that were obtained by high 
temperature synthesis resulted in well crystallised materials, with grain sizes 
of several hundreds of microns [20]. On the other hand, SiHA prepared by the 
aqueous precipitation method was mostly nanocrystalline or semi-crystalline, 
with needle shaped crystallites. In addition, the mean value of crystal 
decreased with increasing number mol of tetraethyl orthosilicate per mol of 
HA used [220].  




The substitution of silicon in the HA lattice resulted in a small decrease in the 
a-axis and an increase in the c-axis of the lattice parameters [24]. As a result, 
the unit cell volume increased by ~0.09 % due to a 0.1 % expansion of the c-
lattice constant. In order to compensate for the charge deficient, silicon 
substitution also resulted in a decrease of the hydroxyl groups in the unit cell. 
8-13 % reduction of the hydroxyl site occupancy was identified when the 
silicate substituted for phosphate [20, 24]. Though the substitution has no 
significant effect on the interatomic distances in the phosphate tetrahedron, 
distortion of the phosphate tetrahedron was observed. The angle distortion 
index was increased by 0.2 % when 0.4 wt.% of silicon atoms substituted for 
phosphorus atoms in the HA lattice [20]. From the point of view of crystalline 
structure, the distortion of tetrahedral and disorder at the hydroxyl site in 
SiHA could decrease the stability of the apatite structure and, therefore, 
increased the reactivity for its favourable bioactivity. 
 
 
SiHA presented strong similarities and exhibited intense vibrational bands 
characteristic of HA. They corresponded to the four vibrational modes of 
phosphate groups (v1, v2, v3, and v4), and the stretching (vS) and vibrational (vL) 





 (vS), increased as the amount of silicon content increased. 
Gibson et al. [24] reported the following infrared vibrations at 692, 840, 890, 
and 945 cm
-1
 corresponded to silicon in SiHA. Recently, Maarchat et al. [218] 
suggested the following infrared vibrations at 985, 947, and 930 cm
-1
 
corresponded to the Si-OH bond at SiHA surface, and infrared vibrations at 




893, 528, 504, and 750 cm
-1
 corresponded to silicon in SiHA. Botelho et al. 
[22] employed X-ray photoelectron spectroscopy (XPS) to validate if silicon 
was incorporated as silicate through the substitution of phosphate. The binding 
energy of silicon at 101 eV corresponded to Si-O bonding. The values of 
binding energy were very close to those reported for orthosilicates [243] and 
could therefore be assigned to silicon atoms belonging to isolated silicate
 
anions. Balas et al. [28] also reported the polymerisation of the silicate at the 
surface for SiHA that contained silicon content higher than 1.6 wt.%. 
 
 
The main structural evidences for the substitution of silicon into HA reported 
so far are the modification in the a- and c-axes lattice parameters, absence of 
secondary phases and small phosphate tetrahedron distortion changes. 
Recently, the use of neutron diffraction and solid-state nuclear magnetic 
resonance spectroscopy were employed to localise the silicate moieties to 
investigate their environment [160-162, 218]. It was noted that X-ray 
diffraction studies were insufficient to resolve the minute difference between 
phosphate and silicate as they were almost isoelectronic, and the presence of 
hydrogen atoms could not be determined by this technique as well. Neutron 
diffraction study was further engaged for the structural study of SiHA to give 
better insight into silicon and hydrogen positions [20]. Neutron diffraction 
study revealed the formation of hydroxyl vacancy at the 4e Wyckoff position 
as well as detected a difference in the hydroxylation degree in SiHA compared 
to HA [162]. By using a specific editing sequence, solid-state nuclear 
magnetic resonance spectroscopy detected an increase in the distribution of P–




H bond distances, which implied a local disorder was produced around those 
phosphate groups where silicate was incorporated in the HA structure [218]. In 
addition, a modification of the O–H bond distances was also noticed due to 





with increasing silicon content further confirmed the incorporation of silicon 
atoms into the apatite lattice [244]. The combination of solid-state nuclear 
magnetic resonance and infrared spectroscopy demonstrated that silicon 
substitution for phosphorus created hydroxyl vacancies along the channels. 
However, the solid-state nuclear magnetic resonance analysis noticed that only 
a fraction of the silicon atoms was incorporated into the HA lattice in the form 
of silicate ion, while a large amount of silicate units are located outside the 
HA structure, corresponding to silica gel units [245]. 
 
 
Beside characterising the structure of SiHA, most authors have also observed 
and reported on the effect induced by the silicon substitution on the physical 
and microstructure behaviours of HA  [14, 19, 27, 137, 221-223, 241, 246]. 
Gibson et al. [137] reported on effect of silicon substitution on the sintering 
behaviour and microstructure on HA. Densification of SiHA with 0 to 1.6 
wt.% of silicon content was inhibited at temperatures between 1000 and 
1150 °C. The inhibition of density was further reflected in a lower hardness 
and young's modulus value of SiHA compared to HA. This effect was more 
significant as the level of silicon was increased. Furthermore, it was also 
noticed that grain growth was inhibited in SiHA at high sintering temperature 




e.g., 1300 °C, which gave rise to greater hardness value in SiHA as compared 
to HA.  
 
 
Substituted silicon induced a decrease in the net surface charge and isoelectric 
point of HA as determined by the zeta potential measurements. At 
physiological pH of 7.4, the surface charge of SiHA (i.e. -70 eV) was 
significantly lowered compared to HA (i.e. -50 eV). It was known that the 
phosphate groups are preferably located at HA surface [247], and thus 
substitution of these ions for silicate groups would result in a decrease in 
surface charge. The surface of Si-O was suggested to provide a preferential 
site for the nucleation of an amorphous calcium phosphate apatite layer than 
the HA surface due to its greater electronegativity. Therefore, it was suggested 
that the adsorption of calcium ions onto the electronegative surface brought 
about an increase in surface charge, which consequently attracted the 
phosphate groups and resulted in a faster in-vitro apatite formation on SiHA in 
the stimulated body fluid testing.  
 
 
Porter et al. [19, 221, 222] compared the structure of HA and SiHA, and 
observed that defects, in particular at the grain boundaries where triple-
junctions was the starting point of dissolution in-vivo (Figure 2.14). The 
dissolution of SiHA was found to increase with greater silicon content (i.e. 1.5 
wt.% SiHA > 0.8 wt.% SiHA > pure HA). For SiHA, loss of material from 
grain boundaries and surfaces was the predominant mechanism by which 




dissolution occurred. However, grain boundary dissolution was not observed 
for HA, and was suggested to occur at the voids in the grains of HA (Figure 
2.15). The calcium, phosphate, and silicate diffused through the ceramic grains 
to the bone–HA interface, driven by a concentration gradient. The increased 
concentration of calcium, phosphate, and silicate at the apatite–SiHA interface 
accelerated the precipitation of biological apatite and induced bone apposition 
at the surface of the SiHA. Therefore, it was suggested that the substitution of 
silicon into the HA increased the number of defect structures, consequently 




Figure 2.14 TEM micrograph of a sintered SiHA powder, arrow indicated a 
triple-junction grain boundary [222] 




   
 
    
Figure 2.15 TEM micrograph of the interface between (a) pure HA and bone, 
(b) between 1.5 wt.% SiHA and bone 12 weeks in-vivo [19]. Extensive 
dissolution within the implant observed in SiHA 
 
 
It was reported that grain size could affect the dissolution rate, with the 
smallest grain size having the fastest dissolution rate [248]. The incorporation 
of silicon into HA was reported to limit the growth of grain and crystallinity 
[223, 241]. Thus, this was suggested as another potential mechanism by which 
silicon increased the in-vivo bioactivity of HA. Recently, Vandiver et al. [246] 
have shown that the incorporation of silicon into HA lattice resulted in 
(a) 
(b) 




increased nanoscale attractive van der waals interactions and also increased 
the negative charge surface charge density as compared to HA. As a result, 
SiHA was found to have increased surface adhesion less dependent on spatial 
position than HA. 
 
 
On the whole, the mechanism of the silicon action can be attributed to a 
number different factors, which act synergistically to give rise to the enhanced 
in-vitro apatite formation in SBF [22, 23, 28], increased in-vivo bone 
ingrowths [21] and remodelling [221] of SiHA over HA. The improved 
bioactivity in SiHA can be better understood after considering the various 
levels of defects (i.e. crystalline structure, surface chemistry, microstructure, 
and nanoscale characteristics), which were created as a result of the 
substitution of silicon.  
 
2.5.4  Biological Characterisation of SiHA  
SiHA has been observed in-vitro and in-vivo to increase its dissolution and 
produced an enhanced rate and quality of bone tissue repair as compared to 
HA [17, 19, 21, 23, 27, 28, 221, 222, 249]. Gibson et al. [23] showed that 
SiHA is non-cytotoxic to human osteosarcoma cells (HOC), and the 
mitochondrial activity of these cultured cells was similar to HA. Moreover, the 
metabolic activity of HOC for SiHA was higher than HA. Coatings of SiHA 
produced by plasma spraying [13] or electrospraying [250] showed enhanced 
cell proliferation and early formation of mineral nodules (Figure 2.16).  




        
 
Figure 2.16  Morphology of osteoblasts cultured on (a) HA and (b) SiHA by 
day 8. Early formation of mineral nodules indicated biomineralisation is 
occurring on SiHA [250]   
 
 
In addition, the expression of proteins namely alkaline phosphatase, type I 
collage and osteocalcin (Figure 2.17) were statistically high throughout the 
culture period, indicating the efficacy of SiHA in driving osteoblast cells 
towards the differentiation stage [250]. Furthermore, a carbonate-containing 
apatite layer, which was essential for bonding at the bone/implant interface, 
was observed to form on the SiHA coating surfaces after immersion in 
stimulated body fluid between 4 and 7 days, and by day 14, a homogeneous 
(a) 
(b) 




porous lamellar-like layer was obtained forming onto SiHA coating (Figure 
2.18) [249]. 
 
Figure 2.17 Quantitative measurement of (a) alkaline phosphatase activity, (b) 
type 1 collagen production and (c) osteocalcin expression on HA and SiHA 
samples. **, Significant difference ( p < 0.05) compared to HA. For OC level, 










Figure 2.18 SEM morphology of as-sputtered SiHA coating (a) prior to 
immersion and (b) after immersion in stimulated body fluid for 14 days [249]  
 
 
The amount of silicon, which can be incorporated into HA seemed to be 
limited to a maximum of 5 wt.% [25, 137], but 0.5-1 wt.% of silicon was 
sufficient to elicit important bioactive improvements. Nevertheless, a 
composition of 0.8 wt.% was shown to produce the optimal response for both 
bone forming and bone resorbing cells in a small animal model studied by 
Hing et al. [17]. Porous HA and SiHA scaffolds of various silicon content 
with no significant variation in porosity were compared directly. After 1 week 
of implantation, cellular infiltration and organisation, neovascularization, and 








0.8 wt.% of SiHA than all other SiHA with different silicon contents [17]. 
Patel et al. [21] implanted HA and SiHA granules into the fermoral condyle of 
New Zealand white rabbits for a period of 23 days. The results showed that 
SiHA granules were well accepted by the host tissue, in addition new bone 
formation was observed directly on the surfaces and in the spaces between 
SiHA implant (Figure 2.19). The quantitative histomorphometry, mineral 
apposition rates and the bone/implant coverage results were significantly 
higher for SiHA than HA (Figure 2.20). These findings indicated that the early 
in-vivo bioactivity of HA was significantly improved with the incorporation of 
silicon into the HA, making SiHA an attractive alternative to conventional HA 




Figure 2.19 Histological appearance of (a) bone ingrowths within SiHA and (b) 












Figure 2.20 Percentage of (a) bone ingrowths within, (b) bone coverage on the 




The safety of the presence of silicon in an implanted bone graft was confirmed 
by Lai et al. [251]. The secretion of silicon from a resorbable silicon-
containing glass was measured by tracing silicon in the blood and urine for 7 
months after implantation. Silicon was found to be extracted from the body 








is used in bone substitute applications, and is manufactured commercially by 





2.6 Co-Substituted Hydroxyapatite   
Many studies focused on single ionic substitution in the HA structure, which 
was proven to be feasible in terms of synthesis and structural characterisation. 
However, ionic substitution of HA is not limited to the addition of a single 
cation or anion. In fact, attempts have been made to perform co-substitution 
into the HA lattice [46-48, 253-255]. Co-substituting two different ions 
requires the balancing of the contrasting ionic radii and/or valence could offer 
the possibility of substituting ions such as magnesium ion, which is difficult to 
substitute alone [47]. As co-substitution of a second ion could create some 
structural change that prevent the destabilisation of the apatite structure and 
subsequent phase decomposition, which could occurred in single ionic 
substituted HA [47]. In addition, co-substitution of HA could also combine 
different types of ions such as carbonate and silicate in a single phase material 
to give rise to favourable biological responses [43]. This could in turn 
eliminate issues such as non-uniformity within the material, and interfacial 
problems, which are commonly encountered in a composite system. Therefore, 
the aim of performing co-substitution in HA is to ensure overall charge 
balance [253, 254] or stabilise the phase formation [154] in order to achieve 
enhanced bioactivity. This section will discuss on co-substituted 




hydroxyapatite, its synthesis, chemical characterisation, and biological 
properties.  
 
2.6.1 Various Types of Co-Substituted Hydroxyapatite 
Existing co-substitution combinations of HA include sodium with carbonate, 
magnesium with carbonate,  magnesium with fluoride,  magnesium with 
silicon,  silicon with carbonate, stronium with carbonate,  and magnesium with 
stronium have been reported [46-48, 253-255]. The co-substitution of 
carbonate with silicon, strontium or magnesium was shown to ensure 
controlled release and improved biological response in-vitro [43-45, 47]. Co-
substitutions were also carried out in order to counteract the structural changes 
that occurred during substitution to prevent destabilisation of the structure and 
subsequent decomposition during heat treatment. These include the co-
substitution of carbonate [45] with magnesium or yttrium with silicon in HA 
[256]. However, co-substitution of HA for functional properties such as 
antibacterial and enhanced biological properties has not yet been reported.  
 
 
2.6.2 Synthesis of Co-Substituted Hydroxyapatite 
Generally, most co-substituted HA were synthesised by wet precipitation 
method, consisting of similar procedure and starting materials as the single 
ionic substitution in HA [45-47, 257, 258]. Starting materials of calcium- and 
phosphate-precursors consisted of calcium hydroxide or calcium nitrate and 
orthophosphoric acid. The respective substituent precursors such as 




magnesium nitrate, magnesium hydroxide, tetraethyl orthosilicate, strontium 
nitrate and sodium hydrogen carbonate were added to either calcium precursor 
or phosphate precursor, depending on the site, where it would occupy in the 
structure of HA. For instance, tetrahydrate di-sodium hydrogen phosphate was 
added to calcium nitrate whilst di-sodium carbonate was added to 
orthophosphoric acid, before reacting them to produce sodium, carbonated co-
substituted HA [258]. The orthophosphoric acid mixture was then added drop-
wise to calcium hydroxide mixture under continuous stirring. All the 
precipitation reactions were carried out at 24 °C and the pH was maintained at 
10.5 by the addition of ammonium hydroxide solution. After complete mixing 
of the reactants, the suspension was aged overnight. The resulting precipitate 
was filtered, dried at 80 °C overnight and then ground to fine powder.  
 
2.6.3 Chemical Characterisation of Co-Substituted Hydroxyapatite 
Majority of the co-substituted HA were reported to achieve phase purity by 
compromising the composition of the substituting content. A series of 
magnesium, carbonate co-substituted HA, containing between 0 to 0.35 wt.% 
magnesium and approximately 0.9 wt.% carbonate were prepared. Gibson et 
al. [47] was able obtained a stable and phase-pure magnesium, carbonate co-
substituted HA, having sintered up to 1200 °C for all compositions in a carbon 
dioxide/water atmosphere. Measurement of the lattice parameters of heat-
treated samples showed that magnesium, carbonate co-substitution resulted in 
a uniform increase in the a-axis from 0.9427-0.9429 nm whilst the lattice 
parameter in the c-axis (0.6787 nm) remained unchanged. Kim et al. [46] 




synthesised magnesium, silicon co-substituted HA with the intention to 
improve biocompatibility in HA. A phase-pure apatite containing 1 wt.% of 
magnesium and 1 wt.% of silicon could be obtained for magnesium, silicon 
co-substituted HA. However, it was observed that ionic substitutions by a 
higher amount would lead to the destabilisation of the structure of HA and 
produced tricalcium phosphate and calcium phosphate silicate phases when 
samples were sintered at 1100 °C or higher. The co-substitution of magnesium 
tended to limit the amount of silicon to be substituted in HA. Similarly, 
modification of the a- and c-axes lattice parameters could be observed in 
magnesium, silicon co-substituted HA due to the structural incorporation of 
magnesium and silicon. The co-substitution of strontium and carbonate 
containing approximately 8.3 wt.% of strontium and 7.1 wt.% carbonate 
achieved a phase-pure apatite in its as-synthesised form [45]. However, phase 
purity at high temperature was not reported.  
 
 
The competition between carbonate and silicate ions substituting at the 
phosphate site was evidenced when a higher silicon content (0, 0.55 to 0.88 
wt.%) was achieved with a lower carbonate content (2.75, 2.25 to 1.75 wt.%) 
for silicon, carbonate co-substituted HA [43]. Although they tended to 
compete for the occupation of the phosphate site, at low concentration (0.4 
wt.% silicon and approximately 4.0 wt.% carbonate), carbonate ions could 
compensate for the deficit induced by silicate ions [44]. Sprio et al. [44] went 
further and attempted to co-substitute magnesium to silicon, carbonate co-
substituted HA. Despite multi-substitutions in HA, the results demonstrated a 




phase-pure apatite with 1 wt.% magnesium, 0.7 wt.% silicon and 2.6 wt.% 
carbonate obtained at the as-synthesised form of magnesium, silicon, 
carbonate multi-substituted HA. On the other hand, the co-substitution of 
magnesium and strontium has met with more difficulties. Magnesium, 
strontium co-substituted HA gave rise to the formation of apatite and β-
tricalcium phosphate phases at all level of magnesium and strontium contents 
[257]. Even though magnesium, strontium co-substituted HA tended to 
decompose to secondary phases, the co-substitution of strontium in 
magnesium substituted HA was observed to reduce the percentage of β-
tricalcium phosphate. Hence, it suggested that the co-substitution of strontium 
appeared to aid in stabilising the apatite phase. 
 
 
Fourier transform infrared spectroscopy results mainly demonstrated the 
characteristics of apatite in the various co-substituted HA through phosphate 
and hydroxyl vibrations. It is useful for the determination of the occupant of 
carbonate in the phosphate (B-type carbonate) or hydroxyl (A-type carbonate) 
[44, 45, 47, 258]. The progress on the research of co-substituted is still at the 
characterising stage in determining the occupant of the co-substituent. There is 
still a general lack of detailed studies that investigate the co-substitution in the 
HA structure. Nevertheless, these results demonstrated the potential and 
feasibility of performing co-substitution in HA.    




2.6.4 Biological Characterisation of Co-Substituted 
Hydroxyapatite 
Co-substitution in HA is performed to stabilise the formation of apatite as well 
as to utilise the beneficial effect of ions, which in turn enhanced the biological 
properties of HA. Currently, only a few in-vitro preliminary studies reported 
on the biological properties of co-substituted HA [43, 45, 46]. Simultaneous 
incorporation of silicon together with magnesium or carbonate has been 
proposed in order to obtain materials, mimicking the biological-like apatites. 
Preliminary results reported gradual cell proliferation on magnesium, silicon 
co-substituted HA with culturing period [46]. An improved ion release was 
demonstrated in a 7-day solubility test in Hank’s balanced salt solution when 
silicon co-substituted with carbonate substituted HA [43]. Comparable cell 
proliferation and alkaline phosphatase protein secretion on day 7 were 
observed for silicon, carbonate co-substituted HA and carbonated substituted 
HA. The substitution of silicon stimulated the osteoblast differentiation and 
resulted in a higher calcium deposition for silicon, carbonate co-substituted 
HA as compared with carbonated substituted. Similarly, a 5-day solubility test 
in Hanks’ balanced solution showed a higher solubility for strontium, 
carbonate co-substituted HA granules as compared to strontium substituted 
HA and HA [45], aiding the treatment when pathologies were related with 
strontium deficiency. Detailed in-vitro and in-vivo studies of co-substituted 
HA are still in progress.  




2.7  Summary  
This chapter gave a general introduction to the physiology and structure of 
bone, bone grafting, and issues encountered during the use of bone graft by 
providing a general overview of the literature concerning the crystal structure, 
chemical, biological properties, and ionic substitution of HA. Due to the 
antibacterial effect of silver and the relevance of silicon ions in bone, 
particular emphasis was put on the properties of silver- and silicon-substituted 
HA. The key points were:  
 Bone is a complex and dynamic living tissue that undergoes 
continuous remodelling. Bone has several levels of structural 
organisation ranging from the distribution of cancellous and cortical 
bone, to the arrangement of collagen fibres and mineral crystals. The 
mineralised phase(s) of bone consist of calcium phosphate apatites 
with significant quantities of additional ions, which have direct 
influence on the biological responses. 
 Currently, autograft is the most preferred bone grafting material. 
However, limitations in the use of autografts have led to the 
development of synthetic bone graft materials. Due to their favourable 
biological response in-vivo, bioceramics in particularly HA, has 
received significant attention as a bone graft material.     
 However, HA faces the challenges of having a limited ability to form 
an interface with, and to stimulate the development of new bone tissue. 
In addition, hydroxyapatite-based bone graft is a synthetic material that 




tends to represent a site of weakness for the host defence, making it 
susceptible to implant-related infections.  
 The unique crystal structure of hydroxyapatite make it susceptible to a 
variety of cations and anions, permitting the ionic substitutions to take 
place simultaneously as demonstrated in various types co-substitution 
of HA. Although co-substitution of HA is becoming a considerable 
field of research for the future of apatites, there is no reports on co-
substituted HA for functional properties to-date.   
 To overcome issues pertaining to infection in hydroxyapatite-based 
bone graft, substitution of functional ion such as silver has emerged as 
a preventative alternative approach. Furthermore, silicon is found to be 
one of the essential trace elements in biological processes, in eliciting 
specific metabolic role connected to bone growth. The intensive 
research of SiHA has demonstrated that silicon substitution improved 
the bioactivity of HA. Hence, there is potential for the co-substitution 
of silver and silicon into HA for bi-functional properties to facilitate 
bone repair. 





Silver, Silicon Co-Substituted 




Nanostructured apatite has been widely used as bone substitute due to its 
chemically and structurally similarity to the natural bone mineral [259, 260]. 
Despite its similarity with the bone mineral, many studies have investigated on 
substituting elements into hydroxyapatite (HA) to alter its chemical 
composition more closely to the bone mineral so as to influence the interaction 
with biological organisms [45, 46, 257, 258]. Among various substituted 
apatites, silicon-substituted HA (SiHA) was observed in-vitro and in-vivo to 
produce an enhanced rate and quality of bone tissue repair as compared to the 
HA [19, 21, 27, 28]. However, SiHA like any synthetic biomaterial represents 
a site of weakness for the host defence, making it susceptible to implant-
related infections. The use of silver is a good approach to treat implant-related 
infections. Silver and silver-based compounds are a long-lasting antibacterial 
agent, and have been increasingly applied to biomaterials and medical devices 
[189]. The substitution of silver into HA (AgHA) have been demonstrated to 
exhibit excellent antibacterial activity in-vitro against many pathogens 
including S. aureus, E. coli, S. mutans, and C. albicans [36, 40-42, 173, 184, 
199, 205, 212], reducing more than 99 % of the population. Since AgHA and 




SiHA have brought about progressive improvement in the properties of 
stoichiometric HA, the beneficial role of both silver and silicon ions may be 
explored through the development of silver, silicon co-substituted 
hydroxyapatite (Ag,Si-HA). Hence, Ag,Si-HA will be synthesised as a single-
phase compound at various autoclaving durations (0, 2 and 4 h) in this chapter. 
In addition, the morphology, chemical, structural and thermal properties of 
Ag,Si-HA will be investigated to aid the understanding and control of any 
exhibited antibacterial and biological response.  
 
3.2     Materials and Methods  
3.2.1 Synthesis of Ag,Si-HA  
In this study, a stoichiometric HA is defined as a synthetic HA with a Ca/P 
molar ratio that approaches 1.67. Ag,Si-HA was synthesised, assuming that 
silver would substitute the calcium site, and silicon would substitute the 
phosphorus site. Table 3.1 presents the number of moles required for the 
substitution to maintain the stoichiometric HA ratio. Past studies had 
suggested that a silicon level between 0.5 and 1.0 wt.% was sufficient to 
exhibit improved bioactivity [21, 24]. Hence, 0.8 wt.% was chosen to be the 
amount incorporated. Studies had shown that a higher percentage of silver 
would slow down cell growth [40, 184], thus the toxicity of silver was dose 
dependent, a low level of silver (0.3 wt.%) shall be incorporated. Silver nitrate 
(Merck, 100 %) was added to calcium hydroxide (Merck, 95 %), while 
tetraethyl orthosilicate (TEOS) (Sigma Aldrich, 98 %) was added to 




orthophosphoric acid (VWR, 85 %), prior to the precipitation reaction.  
Ag,Si-HA was prepared by a wet precipitation reaction between aqueous 
calcium hydroxide containing silver nitrate and orthophosphoric acid 
containing TEOS. Orthophosphoric acid solution containing TEOS was added 
drop-wise to calcium hydroxide containing silver nitrate suspension under 
continuous stirring at 24 °C whilst the pH was adjusted to above 10.5 by the 
addition of aqueous ammonia (VWR, 25 %) (Figure 3.1). Stirring was 
maintained for a further 16 h after all the reactants have finished adding. 
Precipitate was further aged for 2 weeks before washing with distilled water. 
Ag,Si-HA nanopowder was autoclaved at 127 °C at duration of either 2 or 4 h. 
In addition, Ag,Si-HA nanopowder was also heat-treated at 1150 °C for 2 h in 




Figure 3.1 Schematic drawing of the synthesis set up 
 
 








3.2.2  Characterisation of Ag,Si-HA  
3.2.2.1 X-Ray Fluorescence (XRF) 
The composition of the nanopowder was analyzed by XRF using a Shimadzu 
XRF-1800 sequential X-ray fluorescence spectrometer. 0.4 g of nanopowder 
was compacted to form a disc and inserted into the sample holder to allow the 
X-ray to scan at 40 V and 95 mA. Five samples were measured, and the 
average value was calculated. 
 
3.2.2.2 Transmission Electron Microscope (TEM) 
Particle size and morphology of the nanopowder were examined by TEM 
using JEOL JEM-3010 in a bright mode. 10 mg of nanopowder was suspended 
in 2 ml ethanol and sonicated for 20 min. 2 drops of the suspension were 
added onto the Cu grid and allowed to dry before being viewed under TEM. 
For imaging purpose, the accelerating voltage was 300 kV. The correspondent 
selected area electron diffraction (SAED) pattern was also determined. 

















0.5000 0.3000 0 0 - - 
Ag,Si-HA 0.4985 0.2840 0.0015 0.016 0.3 0.8 




3.2.2.3 X-Ray Diffraction (XRD) 
XRD was used to identify characteristic peaks of the phase purity of the 
Ag,Si-HA. Powder of Ag,Si-HA was prepared and carefully placed on an 
aluminum sample holder. Powders were then characterised using Bruker X-ray 
diffractometer operated at 40 kV and 40 mA with CuKα radiation. Data were 
collected over a 2θ range of 20-40 ° with a step size of 0.03 ° and a count time 
of 20 s on the as-synthesised, autoclaved and heat-treated Ag,Si-HA. 
Identification of the phases was achieved by comparing the diffraction pattern 
of Ag,Si-HA with the ICDD (JCPDS) standards. Match software was used to 
analyse and identify the crystal structure.  
 
Determination of the structural parameters of Ag,Si-HA was made by Rietveld 
refinement of the X-ray diffraction data collected for heat-treated Ag,Si-HA. 
A detailed scan was done over a 2θ range of 20-80 ° with a step size of 0.03 ° 
and a count time of 20 s on the heat-treated Ag,Si-HA. The refinement 
software TOPAS was used and the following parameters were refined: 
background parameters, scale factor, zero point, lattice parameters, atomic 
positions and OH site occupancy.   
 
3.2.2.4 Thermogravimetric Analysis (TGA)    
TGA is a thermal analysis technique used to obtain the mass loss percentage 
of a sample with respect to temperature. 10 mg of powders was heated in a 
platinum pan from 25 °C to 1000 °C at 10 °C/min rate using TA Q-500 in air.   




3.2.2.5 Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectroscopy was used to investigate the types of functional groups 
presented in the sample using BIORAD FTS 3000. Samples were mixed with 
potassium bromide powder, and subsequently compressed into a pellet form. 
Transmission mode was used and the collection of FTIR spectrrum was done 
over a range of 4000-400 cm
-1
. A resolution of 2 cm
-1
 with average of 16 scans 
was employed for each sample to achieve a better signal-to-noise ratio. FTIR 
measurement was then converted to absorbance.  
 
3.3 Results and Discussion  
3.3.1 Composition of Ag,Si-HA  
The chemical analysis of Ag,Si-HA using XRF is listed in Table 3.2. The 
amount of silicon measured in Ag,Si-HA (0.7 wt.%) was very close to the 
expected value (0.8 wt.%). On the contrary, the amount of silver measured in 
the Ag,Si-HA (0.1 wt.%) was lower, compared to the expected value (0.3 
wt.%). Similarly, Oh et al. [38] observed similar silver reduction with only 
0.63 wt.% of silver measured in AgHA when 1 wt.% of silver was introduced 
into HA. The silver ions might not have been fully incorporated during the 
precipitation reaction. This discrepancy demonstrated that the substitution of 
silver into calcium site was not as readily as substitution of silicon into 
phosphorous site. Thus, in order to substitute the desired amount of silver, 
greater amount of silver nitrate would be required in order to account for the 




loss. The silver and silicon co-substitution process can only occur when there 














AgyCa(10-y)(PO4)(6-x)(SiO4)x(OH)(2-x-y) (aq)                                                      
        (Equation 3.1) 
 
Chemical formula (targeted): Ag0.03Ca9.97(PO4)5.68(SiO4)0.32(OH)1.65□0.35 
Chemical formula (measured): Ag0.012Ca9.443(PO4)5.662(SiO4)0.250(OH)0.912□1.008  
where □ is the anionic vacancy 
 
Consistent to the previous studies [24, 25, 240], the substitution of 
phosphorous for silicon in the crystal structure was also found to be feasible 
with the removal of hydroxyl ions to ensure charge balance. However, 
substitution of calcium for silver in the crystal structure was not as 
spontaneous, only ~ 2/5 of the silver ions added has effectively replaced the 
calcium ions. Several intrinsic (e.g. silver size effect, polarizabilty, charge, and 
chemical nature of silver, as well as crystal size of the HA) and extrinsic (e.g. 
washing step and choice of ammonium precursor) factors affected the 
substitution of silver, and resulted in the decline. This showed that the 
consumed silver and silicon accounted for a lower (Ag+Ca)/(P+Si) molar ratio 
of 1.6 (Table 3.2). Also, in order to balance the charges, hydroxyl groups was 
suggested to be reduced. 
 




Table 3.2 Calculated (Ca+Ag)/(P+Si) molar ratio, and measured weight 
percentage of calcium, phosphorus, silver and silicon using  XRF 
 Errors are ± standard errors of the mean 
 
 
3.3.2 Morphology of Ag,Si-HA  
Particle size and morphology of the as-synthesised, autoclaved and heat-
treated Ag,Si-HA are shown in Figure 3.2. All the particles were found to be 
in nanosized range. Particularly, as-synthesised Ag,Si-HA demonstrated 
needle-like morphology, having an average length of ~100 nm and width of  
~8 nm. They were thin and long (aspect ratio of 12.5). On the other hand, after 
autoclaving for 2 and 4 h, both Ag,Si-HA underwent obvious changes in their 
shapes and sizes. Both autoclaved Ag,Si-HA displayed rod-like morphology, 
having an average length of ~50 nm and width of ~15 nm. They became 
shorter and wider (aspect ratio of 3.3), with the edges becoming rounder, 
which were more comparable to the bone apatite (Figure 3.2e) [52, 261]. 
Having to resemble the morphology of bone mineral would lead the cells to 
"identify" the synthetic biomaterial as the bone mineral [262], thus improving 
its affinity towards the synthetic biomaterial. Furthermore, nanorods give rise 
to large surface area, which in turn, result in higher van der waal's interaction 
to enhance the protein adsorbability, consequently leading to desirable 
biocompatibility and bioactivity [263].  
Autoclaved 
duration (h) 
(Ca+Ag)/(P+Si) XRF Analysis (wt.%) 
Ca P Ag Si 
0 1.60 (1) 37.2 (1) 17.3 (3) 0.1 (1) 0.7 (1) 
2 1.60 (1) 37.8 (1) 17.6 (4) 0.1 (1) 0.7 (1) 
4 1.62 (2) 37.8 (4) 17.4 (1) 0.1 (2) 0.7 (1) 




After heat-treatment at 1150 °C, the Ag,Si-HA became rounder and formed 
angular-like morphology (aspect ratio of 1.7), with an average length of ~140 
nm and width of ~81 nm. The dimensions of the Ag,Si-HA are tabulated in 
Table 3.3. Ag,Si-HA particles synthesised by the wet chemistry method were 
all of nanosized scale with a uniform distribution. The correspondent selected 
area electron diffraction (SAED) patterns of the as-synthesised, autoclaved 
and heat-treated Ag,Si-HA are presented in Figure 3.3. The SAED pattern 
exhibited spotted sharp and continuous rings, which were typical pattern of a 
polycrystalline material.   
 
Table 3.3 Dimensions of Ag,Si-HA 
 Errors are ± standard errors of the mean, with the values in parentheses 
 
 
Autoclaving allowed nanosized Ag,Si-HA to become more crystalline, as 
evidenced from the SAED pattern. Crystals grew in the c direction, resulting 
in shrinkage of the length and an expansion of the width. This was observed 
from Figures 3.2 (a-d), as the morphology of the nanoparticles developed from 







As-synthesised 100(20) 8(5) 12.5  
Autoclaved for 2 h 50(13) 15(2) 3.3 
Autoclaved for 4 h 50(18) 15(3) 3.3 
Heat-treated at 1150 °C 140(30) 81(20) 1.7  




However, rod-like morphology with sufficient degree of crystallinity should 
be retained in order to mimic the bone apatite. In addition, with the increase of 
autoclaving duration, no significant changes in the dimensions of the nanorods 
were observed. Therefore, 2 h of autoclaving should be sufficient to achieve 















              
       
 
Figure 3.2 TEM morphology of Ag,Si-HA (a) as-synthesised, (b) autoclaved 
for 2h, (c)  autoclaved for 4h, (d) heat-treated at 1150 °C and (e) bone mineral 
extracted from cortical bone of human tibia [261] 
(c) 
(a)  (b) 
(d) 
(e) 




       
      
Figure 3.3 SAED patterns of Ag,Si-HA (a) as-synthesised, (b) autoclaved for 
2h, (c)  autoclaved for 4h, and (d) heat-treated at 1150 °C 
 
 
3.3.3 Phase Analysis and Crystallinity of Ag,Si-HA 
XRD patterns of the as-synthesised, autoclaved and heat-treated Ag,Si-HA are 
shown in Figure 3.4. The broad diffraction peaks of the as-synthesised and 
autoclaved Ag,Si-HA suggested that the material was made up of small apatite 
crystals. The diffraction patterns of all the Ag,Si-HA were not affected by the 
small amounts of co-substitution since single-phase apatite was produced. 
Similarly, the diffraction pattern for the heat-treated Ag,Si-HA was identical 
 (b) (a) 
(d) (c) 




to the ICDD (JCPDS) standard for apatite (PDF Card No. 9-432), with no 
detection of undesirable secondary phases such as tricalcium phosphate, 
tetracalcium phosphate or calcium oxide. Hence, thermal stability above  
1000 °C was achieved for the Ag,Si-HA. In Figure 3.5, it was observed that 
with autoclaving, the apatite became more crystallised. The diffraction peaks 
of the autoclaved Ag,Si-HA were more distinct and defined, showing the 
characteristic of greater degree of crystallinity. Hence, autoclaved Ag,Si-HA 
consisted of a mixture of amorphous and crystalline HA phase, which would 
favour its solubility property. Similar to the observation in the morphology of 
Ag,Si-HA, no significant change was observed between the two autoclaved 




Figure 3.4 X-ray diffraction patterns of Ag,Si-HA (a) as-synthesised, (b) 
autoclaved for 2h, (c) autoclaved for 4h, and (d) heat-treated at 1150 °C 









The effect of co-substitution was revealed from the changes in the parameters 
of the crystal structure. In particular, the lattice cell parameters and unit cell 
volume. The Rietveld study of Ag,Si-HA suggested an increment in the unit 
cell of HA in the a- and c-axes, and the unit cell volume (Table 3.4). Since 
part of the calcium (0.099 nm) and phosphorous (0.035 nm) sites was replaced 
by silver (0.126 nm) and silicon (0.042 nm) respectively, the packing of the 
larger size atoms distorted the lattice parameters. As a result, it led to an 
expansion of the cell volume, corresponding to the observations made by other 
authors as well [19, 20, 24, 36, 264]. Therefore, from the XRD and Rietveld 
results, it could be implied that silver and silicon were structurally 
incorporated into HA. 




Table 3.4 Structural parameters obtained from lattice refinement 
  Errors are ± standard errors of the mean, with the values in parentheses 
 
3.3.4 Thermal Analysis of Ag,Si-HA 
The thermal stability of Ag,Si-HA was confirmed from TGA results. The 
weight of Ag,Si-HA was recorded when it was heated from 24 °C to 1000 °C 
(Figure 3.6). A sharp drop at 100 °C and a noticeable drop at 850 °C of the 
weight of Ag,Si-HA were observed. The weight loss at 100 °C was due to the 
removal of the moisture on the surface and within Ag,Si-HA. Subsequently, 
the removal of adsorbed water in the sample was completed at around 400 °C 
while the weight loss at 850 °C was due to the burnt-off of the carbonates 
contained in Ag,Si-HA. It is interesting to note that the weight of Ag,Si-HA 
remained almost constant between 400 and 800 °C.  This indicated that there 
was no other impurity contained in Ag,Si-HA. The TGA results further 
corroborated with the detected single-phase apatite in the XRD results (Figure 
3.3). Thus, this indicated that co-substitution of silver and silicon did not 
promote any formation of undesirable secondary phases, and phase-pure 
Ag,Si-HA was able to retain at high temperature.    
Sample a (nm) c (nm) Unit cell volume (nm
3
) 
HA [265] 0.94180 0.68840 0.52880 
Ag,Si-HA      0.94261 (5)      0.68911 (7)      0.53062 (5) 






Figure 3.6 Weight loss of Ag,Si-HA versus temperature (a) as-synthesised, (b) 
autoclaved for 2h and (c) autoclaved for 4h 
 
 
3.3.5 FTIR Analysis of Ag,Si-HA  
Figure 3.7 illustrates the FTIR spectra of as-synthesised, autoclaved and heat-
treated Ag,Si-HA. The IR spectra of all the Ag,Si-HA displayed absorption 
bands, which were characteristics of apatite. Characteristics peaks of apatite 
were prominently located at three regions. Firstly, triplet peaks at 628, 601 and 
564 cm
-1
 were attributed to v4 phosphate bending modes. Secondly, v1 
phosphate stretching modes was observed at 960 cm
-1
, while v3 phosphate 
bending and stretching modes were located between 1020-1090 cm
-1
. Lastly, 
peak at 3569 cm
-1
 was detected for stretching of hydroxyl vibration [266].  
 




Beside detecting phosphate and hydroxyl absorption bands, as-synthesised and 
autoclaved Ag,Si-HA also detected absorption bands at 873, 1300-1650 cm
-1
, 
which was attributed to the carbonate substitution in the HA lattice. Peaks at 
873 cm
-1
 was due to v2 vibrational mode and peaks at 1417, 1454 and 1650 
cm
-1 
were due to v3 vibrational mode of surface carbonate ions. The carbonate 
ions might have come from the reaction between carbon dioxide during the 
synthesis process. Carbon dioxide was produced by TEOS after undergoing 
hydrolysis and autoclaving as represented in Equation 3.1-3.3 [267]. The 
carbonate ions were competing with the hydroxyl ions for v2 site substitution, 
and phosphate and silicate for the v3 site substitutions [266].  
 
 
Si(OCH2CH3) (aq)  + 4H2O (l)  Si(OH)4 (aq)  + 4CH3CH2OH (aq)                                            
        (Equation 3.2) 
nSi(OH)4 (aq)    (SiO2)n (aq)  + 2nH2O (l)                                                                             
        (Equation 3.3) 
CH3CH2OH (aq)  + 4O2 (aq)  2CO2 (g)  + 3H2O (l)                                                                  
         (Equation 3.4) 
 
 
The FTIR spectra of heat-treated Ag,Si-HA revealed some significant 
changes. Hydroxyl stretching band became more distinct at 3569 cm
-1 
in the 
heat-treated Ag,Si-HA. In addition, the broad moisture peak decreased 
drastically, and peaks corresponding to the carbonates disappeared.  Although 
the hydroxyl stretching band at 3569 cm
-1
 became more distinct, the relative 




intensity has been reduced greatly as compared to the hydroxyl band of the 
stoichiometric HA, which was also observed by other authors [21, 26, 219]. 
Based on Equation 3.1, the loss of hydroxyl groups was to compensate the 
excess negative charge that resulted from the incorporation of silicate into the 
HA lattice. This result suggested the presence of silicate tetrahedra in the HA 
structure. Furthermore, additional peaks at 756 and 890 cm
-1
, assigned to 
silicate vibrational modes were observed [14, 24]. During the substitution, 
both carbonates and silicates were competing to substitute into the phosphate 
sites of HA. As carbonates were more readily substituted as compared to 
silicate, silicate vibrational modes at 890 cm
-1
 might have been masked by the 
v2 vibrational mode (873 cm
-1
) of carbonate. As a result, substitution of silicate 
was not clearly observed for the as-synthesised and autoclaved Ag,Si-HA. 
However, with the removal of carbonates at 850 °C as shown in the TGA 
result, the presence of silicate was revealed for the heat-treated Ag,Si-HA. 














































Figure 3.7 FTIR spectra of Ag,Si-HA (a) as-synthesised, (b) autoclaved for 2h, 
(c) autoclaved for 4h and (d) heat-treated at 1150 °C 
 
 
3.4 Conclusions  
In this study, co-substitution of silver and silicon has been investigated so as to 
introduce antibacterial property and enhance the biological response of HA. 
Phase-pure Ag,Si-HA was successfully synthesised via an aqueous 
precipitation technique. The substitution of silver and silicon ions did result in 
small changes in the structure and chemical composition of HA, as determined 
by TEM, XRF, XRD, TGA and FTIR data. A rod-like morphology of 
dimensions ~50 nm in length and ~15 nm in width was observed for 
autoclaved Ag,Si-HA. Furthermore, XRD pattern revealed broad diffraction 
peaks, indicating that Ag,Si-HA particles were nanosized. With the increment 
in temperature, it allowed additional crystallization, but further changed the 
morphology and size of the nanoparticles. Hence, autoclaving was employed 




to achieve sufficient crystallization and at the same time, to maintain the rod-
like morphology and size that were comparable to that of the bone apatite. The 
lattice cell parameters in the a- and c- axes, and the cell volume increased due 
to the incorporation of the larger-size silver and silicon ions. From the 
observation of the reduction in relative intensity of hydroxyl FTIR absorption 
bands, hydroxyl groups have decreased in order to maintain charge balance as 
a result of the co-substitution. All these results showed that the co-substitution 


















Optimisation of Silver Content in  




Like other medical intervention approaches, the insertion of medical 
prostheses such as hydroxyapatite (HA)-based bone graft is a synthetic 
material that tends to represent a site of weakness for the host defences, 
subjecting itself and the surrounding tissues susceptible to both immediate and 
delayed infections. Silver ions have been proposed as an additive for infection 
treatment due to effective bacterial inhibitory effect [39, 178, 179]. The 
incorporation of silver in HA had been limited to below 2 wt.% as the 
increasing silver loading will affect the phase purity of HA. This was observed 
when Kim et al. [41], Rameshbabu et al. [40] and Singh et al. [205] obtained 
undesirable secondary phases with increasing silver content in silver-
substituted hydroxyapatite (AgHA). Generally, the antibacterial effect against 
the suspended bacteria in the medium was suggested to be dependent on the 
release of silver ions [36, 40, 41, 173]. Therefore, the effectiveness of 
antibacterial properties of AgHA would be affected by the homogeneity of the 
dispersion of silver ions incorporated into apatite structure. In circumstances 
when there was an abrupt release of silver ions from AgHA, it would result in 
tissue cytotoxic [216]. Oh et al. [42] reported that AgHA produced by 




incorporating silver ions during the nucleation of HA would give rise to a 
controlled release of silver ions as compared to AgHA produced by 
incorporating silver ions into the apatite structure after HA was synthesised. 
Therefore, it is prudent to incorporate suitable amount of silver homogenously 
in the implant that can adequately reduce bacterial adhesion and at the same 
time, minimise tissue cytotoxicity. In this study, AgHA has been proposed to 
incorporate silver ions within the HA structure during the nucleation of HA. A 
range of compositions of AgHA will be investigated to find the optimum 
antibacterial effect. The in-vitro antibacterial testing will examine the bacteria 
in the test solution as well as the adherent bacteria on the surface of AgHA.  
 
4.2 Materials and Methods  
4.2.1 Synthesis of AgHA 
AgHA was synthesised, assuming that silver would substitute in calcium site. 
A range of silver compositions (0.3, 0.7, 1.6, 3.0, 4.5, 10 wt.%) was 
synthesised to find the optimum antibacterial property. AgHA was prepared 
by a wet precipitation reaction as discussed in Section 3.2.1. Silver nitrate was 
added to calcium hydroxide prior to the precipitation reaction. AgHA was 
either autoclaved at 127 °C for duration of 2 h or heat-treated at 1150 °C for  
2 h in air with a heating rate of 2.5 °C/min. Phase-pure HA of similar 
morphology and crystallinity with AgHA, will be compared in the 
antibacterial study. Similarly, HA was synthesised based on the same 




technique via an aqueous precipitation reaction between calcium hydroxide 
and orthophosphoric acid.  
 
4.2.2  Characterisation of AgHA 
4.2.2.1 XRF 
Elemental content of the autoclaved and heat-treated AgHA with various 
silver contents was determined by XRF. Detailed description of the technique 
was reported in Section 3.2.2.1. 
 
4.2.2.2 TEM 
Microstructure features of the autoclaved and heat-treated AgHA with various 
silver contents was studied using TEM. Detailed description of the technique 
was reported in Section 3.2.2.2. 
 
4.2.2.3 XRD 
Phase composition of the autoclaved and heat-treated AgHA with various 
silver contents was determined using XRD. Detailed description of the 
technique was reported in Section 3.2.2.3. 
 





Type of functional groups presented in AgHA with various silver contents was 
determined using FTIR spectroscopy. Detailed description of the technique 
was reported in Section 3.2.2.5. 
 
4.2.3  Antibacterial Assessment of AgHA  
For antibacterial study, AgHA powders with various compositions were 
compacted uni-axially into 12 mm discs before dry heating at 600 °C for 2 h 
in air. Staphylococcus aureus (S. aureus, ATCC 25923) bacteria was used in 
this study. AgHA discs were sterilised by rinsing three times with phosphate 
buffer saline (PBS) solution, followed by ultraviolet exposure for 30 min. For 
quantitative analysis, AgHA discs were studied by a log reduction assay. 
AgHA discs were immersed in 2 ml of peptone water containing 2 x 10
7
 
cells/ml in a 24-well plate. A negative antibacterial control, which contained  
2 x 10
7
 cells/ml was also prepared for comparison. Silver nitrate was also 
compacted into discs, and used as the positive antibacterial control. The 24-
well plate was incubated at 37 °C for 24 h. After 24 h, 100 μl of the test 
solution was removed from each of the wells in the 24-well plate. The 
concentration of the test solution was reduced to various dilutions. An aliquote 
of 25 µl of the latter at various dilutions was added onto a tryptone soya agar 
in triplicate, and incubated at 37 °C for another 24 h to allow enumeration of 
viable bacterial count. Two replicates were measured, and the mean value was 
calculated. Phase-pure HA discs of similar morphology and crystallinity with 




AgHA, was also compared in the study to determine the antibacterial 
efficiency of silver substitution.   
 
A separate experiment was performed to examine the adherent bacteria on the 
surface of AgHA discs. Each disc was immersed in 2 ml of peptone water 
containing 2 x 10
7
 cells/ml in a 24-well plate, and then incubated at 37 °C for 
6 h. Adherent bacteria on the surface of AgHA discs were fixed with 10 % 
formaldehyde, dehydrated sequentially through a series of ascending ethanol 
concentrations (25, 50, 75, 95, 100 % (v/v) in distilled water) and vacuum 
dried before viewing under a scanning electron microscopy (FESEM, Hitachi 
S-4300). Samples were sputter-coated with a thin layer of gold prior to 
analysis.  
 
4.2.4  Statistical Analysis 
A two-way analysis of variance (ANOVA), followed by post-hoc testing was 
used to determine any significant differences existed between the mean values 
of the experimental groups of log reduction assay. A difference between 
groups was considered to be significant at p < 0.05. 2 replicates were 
measured for log reduction assay, and the mean value was calculated.  
 




4.3 Results and Discussion 
4.3.1 Composition of AgHA 
The actual amount of silver contents that could be incorporated into the HA 
are computed and shown in Tables 4.1 and 4.2. Similar to results reported by 
other authors [38, 40, 208], these values were lower than expected. In addition, 
(Ca+Ag)/P ratio became lower than 1.67 due to the loss of silver content. This 
discrepancy demonstrated that substitution of silver into the calcium site was 
not spontaneous. Inevitable loss during the substitution of silver into HA was 
caused by both extrinsic and intrinsic factors. The extrinsic factor could be due 
to the washing of the material to remove impurities during the process of 
synthesis, which would result in the removal of silver ions. While intrinsically, 
silver ion was found to be difficult in occupying the calcium site as silver
 
ion 
(0.126 nm) had a larger ionic radius than calcium
 
(0.099 nm) ion. Furthermore, 
silver ions could have react readily with ammonium ions presented in the 
solution to form diamminosilver(I) ion [38, 202]. Thus, this resulted in the  
reduction silver content as smaller amounts of free silver ions remained 
available for incorporation into HA. AgHA with various silver contents will be 
referred as 0.2AgHA, 0.3AgHA, 0.5AgHA, 0.9AgHA, 1.0AgHA and 













0.3 0.7 1.6 3.0 4.5 10.0 
Silver (wt.%) 
(Achieved) 
0.2 0.3 0.5 0.9 1.0 1.1 
Sample name 0.2AgHA 0.3AgHA 0.5AgHA 0.9AgHA 1.0AgHA 1.1AgHA 








It was also noted that the amount of silver incorporated in autoclaved and 
heat-treated AgHA were quite comparable despite undergoing heat treatment 
at 1150 °C. Silver nitrate decomposed at 440 °C [268], but presence of silver 
was still detected in heat-treated AgHA samples. Thus, this indicated that 
silver was bonded within the apatite structure. A more detailed study of the 
structural property of AgHA will be discussed in Section 4.3.3.       
 
 
4.3.2 Morphology of AgHA 
TEM micrographs of the autoclaved and heat-treated AgHA are represented in 
Figures 4.1 and 4.2. Autoclaved AgHA displayed a rod-like morphology, 
having an average length of ~50 nm and width of ~15 nm with an aspect ratio 
of ~3, which was comparable to that of the morphology and dimensions of 
Silver (wt.%) 
(Expected) 
0.3 0.7 1.6 3.0 4.5 10.0 
Silver (wt.%) 
(Achieved) 
0.2 0.2 0.5 0.8 0.9 1.1 
(Ca+Ag)/P ratio 1.65 1.64 1.63 1.65 1.63 1.62 




natural bone apatite [52]. The unique properties of nanoscale structure had 
been demonstrated to provide advantageous interaction with the proteins to 
control cell proliferation, differentiation, and mineralisation. [269, 270]. 
Nanosized HA gave rise to greater surface area and higher surface roughness 
compared to their larger particle counterparts. Thus, with a larger surface-to-
volume ratio, nanosized HA allowed greater osteoblast adhesion for 
subsequent cellular processes such as proliferation, synthesis of extracellular 
matrix proteins and formation of mineral deposits [271].  It was also noticed 
that regardless of the silver content, all autoclaved AgHA with various silver 
contents had comparable morphology and dimensions (Figure 4.1). Thus, the 




During the heat-treatment, AgHA crystals grew in the crystallographic c 
direction, causing a shrinkage of the length and an expansion of the width. 
Consequently heat-treated AgHA became rounder and eventually formed an 
angular-like morphology (aspect ratio of 1.9), with an average width of ~85 









     
     
     
Figure 4.1 TEM micrograph of autoclaved (a) 0.2AgHA, (b) 0.3AgHA, (c) 
0.5AgHA, (d) 0.9AgHA, (e) 1.0AgHA, and (f) 1.1AgHA 
(c) 
(a)  (b) 
(d) 
(e) (f) 




      
      
      
Figure 4.2 TEM micrograph of heat-treated (a) 0.2AgHA, (b) 0.3AgHA, (c) 
0.5AgHA, (d) 0.9AgHA, (e) 1.0AgHA, and (f) 1.1AgHA 
(c) 
(a)  (b) 
(d) 
(e) (f) 




4.3.3 Phase Analysis of AgHA 
XRD patterns of the autoclaved AgHA are shown in Figure 4.3. The broad 
diffraction peaks of the autoclaved AgHA suggested that the material was 
made up of small apatite crystals. To assess the effect of chemical changes on 
the phase composition and structure of AgHA, AgHA with various silver 
contents were heat-treated to 1150 °C for 2 h (Figure 4.4). The diffraction 
patterns were identical to the ICDD (JCPDS) standard for apatite (PDF Card 
No. 9-432). AgHA samples of up to 1.1 wt.% of silver were phase-pure, with 
no detection of secondary phases such as tricalcium phosphate (TCP), 
tetracalcium phosphate, calcium oxide, silver or silver oxide. These results 


































Figure 4.3 X-ray diffraction patterns of autoclaved (a) 0.2AgHA, (b) 




Figure 4.4 X-ray diffraction patterns of heat-treated (a) 0.2AgHA, (b) 
0.3AgHA, (c) 0.5AgHA, (d) 0.9AgHA, (e) 1.0AgHA, and (f) 1.1AgHA 




Lattice parameters of HA, 0.2AgHA, 0.5AgHA, 1.1AgHA are determined and 
compared in Table 4.3. Substitution of silver ions into the HA structure 
resulted in a change in the lattice parameters of all AgHA samples. With 
increasing silver content (0.2AgHA, 0.5AgHA, 1.1AgHA), an increase of the 
lattice parameters in a- and c- axes was noticed. The expansion of lattice 
parameters implied the occupancy of the larger silver ion at the calcium site. 
Furthermore, with the increase of lattice parameter, it led to an expansion of 
the unit cell volume. It was also observed that unit cell volume increased with 
increasing silver content. Hence, from the obtained XRD patterns and 
increased lattice cell parameters, it clearly demonstrated that silver was 
structurally incorporated into HA. 
 
Table 4.3 Structural parameters obtained from lattice refinement 
Errors are ± standard errors of the mean, with the values in parentheses 
 
 
Sample a (nm) c (nm) Unit cell volume(nm
3
) 
HA 0.9410 (4) 0.6886 (4) 0.52805 
0.2AgHA 0.9411 (3) 0.6889 (4) 0.52839 
0.5AgHA 0.9413 (3) 0.6895 (4) 0.52907 
1.1AgHA 0.9417 (4) 0.6901 (4) 0.52999 




4.3.4 FTIR Analysis of AgHA 
Figures 4.5 and 4.6 illustrate the FTIR spectra of autoclaved and heat-treated 
AgHA. The IR spectra of all AgHA displayed absorption bands, which were 
characteristics of apatite, consisting of phosphate and hydroxyl vibrations. v4 
phosphate bending was detected at 628, 601, and 564 cm
-1
. Another single 
peak at 960 cm
-1 
was due to v1 phosphate stretching mode. And peaks at 1020-
1090 cm
-1
 were attributed to v3 phosphate bending and stretching modes. On 
the other hand, peak at 3569 cm
-1
 for stretching mode of hydroxyl vibration 
was observed [266]. The absorption bands at 873, 1300-1650 cm
-1
 of all 
autoclaved AgHA were attributed to the carbonate substitution in the HA 
lattice. The carbonate ions might have come from the reaction between carbon 
dioxide and the precursors of HA during the synthesis process, which was 
discussed in Section 3.3.5.  
 
 
By comparing autoclaved and heat-treated AgHA samples, a broad band 
between 3200-3700 cm
-1
 was observed in the autoclaved AgHA, 
corresponding to the water molecules. In addition, hydroxyl stretching band 
became more distinct at 3569 cm
-1 
in the heat-treated AgHA with the 
reduction of the broad moisture peak. Overall, the substitution of silver in HA 
did not affect its characteristics.   
 
 





Figure 4.5 FTIR spectra of autoclaved (a) 0.2AgHA, (b) 0.3AgHA, (c) 




Figure 4.6 FTIR spectra of heat-treated (a) 0.2AgHA, (b) 0.3AgHA, (c) 
0.5AgHA, (d) 0.9AgHA, (e) 1.0AgHA, and (f) 1.1AgHA 




4.3.5 Antibacterial Assessment of AgHA 
Figure 4.7 illustrates the log reduction results of the growth of S. aureus with 
HA and AgHA with various silver contents for 24 h. Growth of S. aureus 




 CFU/ml was 
observed for the bacteria sample (negative control), HA and 0.2AgHA; a 
slight increase in the growth of S. aureus from 2 x 10
7  





for 0.3AgHA. On other hand, a reduction in the growth of S. aureus 




 CFU/ml was observed for 0.5AgHA, 
0.9AgHA, 1.0AgHA, and 1.1AgHA. There was no viable S. aureus that 
survived from the starting population of 10
7
 CFU/ml for silver nitrate. Since 
silver nitrate (positive control) was used as the precursor to synthesise AgHA, 
it was possible that the reduction of viable bacteria observed in AgHA was 










Figure 4.7 Log reduction assays of various AgHA discs incubated in peptone 
water for 24 h, [a] p < 0.05 when comparing bacteria to 0.5AgHA, [b] p < 0.05 
when comparing bacteria to 0.9AgHA, [c] p < 0.05 when comparing bacteria 
to 1.0AgHA, [d] p < 0.05 when comparing bacteria to 1.1AgHA, [e] p < 0.05 
when comparing bacteria to AgNO3; [f] p < 0.05 when comparing HA to 
0.5AgHA, [g] p < 0.05 when comparing HA to 0.9AgHA, [h] p < 0.05 when 
comparing HA to 1.0AgHA, [i] p < 0.05 when comparing HA to 1.1AgHA, [j] 
p < 0.05 when comparing HA to AgNO3  
 
 
Stani´c et al. [36] reported a 3-log reduction in the number of bacteria with 
AgHA in PBS solution. However, only 1-log reduction in the number of viable 
bacteria was observed in this study. This difference in the inhibition of 
bacterial growth rate could be due to the medium used. Bacteria would grow 
rapidly in nutrient-rich peptone water, thus giving rise to a faster bacterial 
growth rate than the bacterial death rate, resulting in an overall slower 
inhibition of bacterial growth rate. Nevertheless, by comparing the growth rate 
between HA and all AgHA samples, inhibition of bacterial growth was clearly 
observed. Thus, this implied the antibacterial efficacy of AgHA. With 




increasing silver content from 0.2 to 0.5 wt.%, the inhibition in the growth of 
bacteria became more effective. However, there was no significant difference 
in the bacterial inhibition rate between AgHA containing more than 0.5 wt.% 
of silver (Figure 4.7). The increase of silver content up to 1.1 wt.% did not 
have a significant impact on the retardation of bacterial growth. As silver ion 
could deplete the intracellular ATP content, which affects the basic metabolic 
cellular functions of the mammalian cells [216], thus it is essential to minimise 
the presence of silver ion in the body. Therefore, substitution of 0.5 wt.% of 
silver into HA should be considered sufficient to retard and inhibit the 
bacterial growth.  
  
 
The optimised silver content (0.5 wt.%) in this study was similar to the 
optimised amount reported by other authors [36, 40, 205]. Rameshbabu et al. 
[40] observed a complete inhibition of the growth of S. aureus with an initial 
bacterial population of 10
8
 CFU/ml after 24 h in AgHA samples containing 
0.5, 1 and 1.5 wt.% of silver. Among the AgHA samples, 0.5 wt.% of silver 
was suggested as the optimum silver content as greater osteoblast spreading 
was demonstrated. Similarly, Stanic et al. [36] also observed pronounced 
reduction of S. aureus in AgHA with 0.4 wt.% after 4 h. Singh et al. [205] 
explored on a much higher silver content (2, 3 and 5 wt.%) of AgHA, which 
contained secondary phases. A comparable reduction of the adherent E. coli 
on the surface of all AgHA in spite of the increasing silver content was 
reported. However, AgHA with silver content greater than 3 wt.% was 
reported to be cytotoxic to mouse fibroblast cells. Thus, this showed that 




having an excess silver content in AgHA could not further enhance the 
antibacterial properties, and most importantly it was not desirable for the 
viability of seeded cells on AgHA. Therefore, the results obtained in the 
antibacterial assessment in this study was in line with those reported in the 
literature [36, 40] and further proved that 0.5 wt.% was the recommended 
silver content to be incorporated in Ag,Si-HA, which will be discussed in 
Chapter 5.       
     
 
Early bacterial adhesion on the surfaces of the AgHA samples at 6 h is 
represented in Figure 4.8. A thick bacterial layer was observed on the surface 
of HA (Figure 4.8a) and 0.2AgHA (Figure 4.8b), whereas a significantly 
lesser amount of adherent bacteria were seen on the surfaces of 0.3AgHA, 
0.5AgHA, 0.9AgHA, 1.0AgHA and 1.1AgHA (Figures 4.8c-g). The SEM 
observation corresponded well with the log reduction assay, suggesting that 
the numbers of viable bacteria were reduced for AgHA. Hence, the presence 
of oligodynamic action of silver could have generated an antibacterial 
adhesion effect on HA, thereby inhibiting the bacteria [272]. Therefore, this 
demonstrated that AgHA was effective in preventing or minimising initial 
bacterial adhesion, which would ultimately circumvent the formation of 
biofilm onto the biomaterial.   
 




Figure 4.8 SEM images of S. aureus adhering on (a) HA, (b) 0.2AgHA, (c) 


























A range of AgHA with silver contents (0.2, 0.3, 0.5, 0.9, 1.0, 1.1 wt.%) was 
synthesised by co-precipitation reaction between calcium hydroxide 
containing silver nitrate and orthophosphoric acid. Despite silver substitution, 
examination by TEM, XRD and FTIR indicated that AgHA nanorods 
mimicked closely to the bone mineral in term of its morphology, dimensions 
and chemical structure. It displayed a rod-like morphology of dimensions ~50 
nm in length and ~15 nm in width. Phase-pure AgHA was achieved for all 
silver contents. The results demonstrated that a- and c-axes lattice parameters, 
and the unit cell volume increased with silver content for AgHA. All these 
results implied that silver ions were structurally incorporated into the apatite 
structure. The FTIR results further revealed the typical characteristic of apatite 
as indicated by the phosphate and hydroxyl vibrations. From the antibacterial 
study, bacterial growth was observed for the bacteria test solution, HA and 
0.2AgHA whilst slight retardation in the bacterial growth was revealed for 
0.3AgHA. Significant inhibition of the bacterial growth were seen for 
0.5AgHA, 0.9AgHA, 1.0AgHA and 1.1AgHA. The early bacterial adhesion 
on the surface of AgHA corresponded well with the log reduction assay, 
which suggested that the numbers of viable adherent bacteria were reduced on 
AgHA. Overall, AgHA containing 0.5 wt.% was the optimum amount that 
could effectively reduce the bacterial growth, and it shall be incorporated in 
Ag,Si-HA, which will be discussed in Chapter 5.    





Mechanism of Antibacterial Action of 





In Chapter 3, Ag,Si-HA was successfully synthesised and characterised, and in 
Chapter 4, silver content giving rise to effective antibacterial property for 
AgHA (0.5 wt.%) was optimised through in-vitro antibacterial study. 
Oligodynamic effect refers to the ability of small amount of heavy metals to 
exert lethal effect on bacterial cells [273]. This effect was observed in the 
silver ions incorporated in AgHA against the adherent S. aureus. Therefore, it 
was hypothesised that the surface silver ions of Ag,Si-HA played a role in the 
antibacterial action. Ag,Si-HA containing 0.5 wt.% of silver and 0.7 wt.% of 
silicon will be synthesised in the present chapter. In addition, the 
physicochemical properties of Ag,Si-HA dry-heated at 600 °C used in in-vitro 
antibacterial and biocompatibility assessment will be examined. Furthermore, 
in-vitro antibacterial assessment will be conducted to examine adherent S. 
aureus and E. coli on HA, AgHA and SiHA with respect to Ag,Si-HA. Lastly, 
mechanism regarding the antibacterial action of Ag,Si-HA will be investigated 
in this chapter.  




5.2 Materials and Methods 
5.2.1 Synthesis of Ag,Si-HA  
The optimised 0.5 wt.% of silver and 0.7 wt.% of silicon content in Ag,Si-HA 
(Chapter 4) was prepared as previously detailed in Section 3.2.1. Ag,Si-HA 
powders were compacted uni-axially into 12 mm discs and then dry heated 
at 600 °C for 2 h in air for the antibacterial assessment. 
 
5.2.2 Characterisation of Ag,Si-HA 
5.2.2.1 TEM 
Microstructural features of the autoclaved and dry-treated Ag,Si-HA was 




Elemental content of the autoclaved and dry-heated Ag,Si-HA was determined 
by XRF. Detailed description of the technique was reported in Section 3.2.2.1. 
 
5.2.2.3 XRD 
Phase composition of the autoclaved and dry-treated Ag,Si-HA was 
determined using XRD. Detailed description of the technique was reported in 
Section 3.2.2.3. 





Type of functional groups presented in autoclaved and dry-treated Ag,Si-HA 
was determined using FTIR spectroscopy. Detailed description of the 
technique was reported in Section 3.2.2.5. 
 
5.2.2.5 X-Ray Photoelectron Spectroscopy (XPS) 
The surface compositions of dry-heated Ag,Si-HA discs that were immersed 
in deionsed water for 1, 3, 5 and 7 days were measured by XPS (Kratos AXIS 
Ultra DLD spectrometer) with an AlKα radiation (1486.71 eV) at a constant 
dwell time of 100 ms and a pass energy of 40 eV. The anode voltage was 15 
kV, and the anode current was 10 mA. The pressure in the analysis chamber 
was maintained at 7.0 x 10
-6
 Pa or lower during each measurement. The 
samples were mounted on standard sample studs by means of double-sided 
adhesive tape. The core-level signals were obtained at a photoelectron takeoff 
angle of 90° (with respect to the sample surface). All binding energies (BEs) 
were referenced to the C 1s hydrocarbon peak at 285 eV. A survey spectrum 
between -5 and 1100 eV was recorded. In the peak synthesis, the line width 
(full width at half-maximum) of the Gaussian peaks was maintained constant 
for all components in a particular spectrum. Surface elemental components 
were determined from peak area ratios corrected with the experimentally 
determined sensitivity factors and were reliable to 10 %.  
 
 




5.2.3 Antibacterial Assessment of Ag,Si-HA 
Dry-heated Ag,Si-HA discs were sterilised by rinsing three times with PBS 
solution, followed by ultraviolet exposure for 30 min. Each disc was immersed 
in 2 ml of peptone water containing 1.5 X 10
7
 cells/ml of S. aureus and E. coli 
in a 24-well plate, and then incubated at 37 °C at various time points for 6, 12, 
18 and 24 h. The study was further extended to 3, 5 and 7 days. Growth of the 
adherent S. aureus and E. coli on Ag,Si-HA was examined using a log 
reduction assay. At the end of each incubation time point, Ag,Si-HA discs 
were removed from the test solution and gently rinsed three times with PBS 
solution. After washing, the samples were put into a new tube containing 5 ml 
peptone water, and vigorously vortexed for 60 s to remove the bacteria 
adhering on the surface of sample to the vortex solution. The vortex solutions 
were diluted in steps. For each time point, 25 µl of each diluted vortex 
solution was added onto a tryptone soya agar in triplicate, and incubated at 
37 °C for another 24 h to allow enumeration of viable bacterial count. Phase-
pure HA, AgHA, and SiHA discs of similar morphology and crystallinity with 




The antibacterial action of the surface silver ions of Ag,Si-HA disc was 
examined in another separate antibacterial assessment. An insert with 
membrane pore size of 0.4 µm was placed in the well (Figure 5.1), to prevent 
samples from coming into contact with 3 x 10
7
 cells/ml of S. aureus. Similar 
set up was used for the control sample. The 24-well plate was incubated at 




37 °C for 24 h. After 24 h, 100 μl of the test solution was removed from each 
of the wells in the 24-well plate. The concentration of the test solution was 
reduced to various dilutions. An aliquote of 25 µl of the latter at various 
dilutions was added onto a tryptone soya agar in triplicate, and incubated at 
37 °C for another 24 h to allow enumeration of viable bacterial count. Two 
replicates were measured, and the mean value was calculated. The growth of S. 
aureus in the test solution of Ag,Si-HA without the insert was also determined 
and compared in the study.     
 
 
Figure 5.1 Schematic drawing of the set-up of the insert in the well plate 
 
 
5.2.4  Statistical Analysis 
A two-way analysis of variance (ANOVA), followed by post-hoc testing was 
used to determine any significant differences existed between the mean values 
of experimental groups for the log reduction assay and ICP results. A 
difference between groups was considered to be significant at p < 0.05. 2 
replicates were measured for log reduction assay and ICP, and the mean value 
was calculated. 




5.2.5 Characterisation on the Effect of S. aureus treated by  
Ag,Si-HA  
5.2.5.1 TEM  
TEM was carried out to inspect the morphological changes of the internal 
structural of S. aureus after interacting with Ag,Si-HA. S. aureus at a 
concentration of 10
7
 CFU/ml (control) was incubated at 37 °C for 6 h. 
Similarly, bacterial concentration containing HA and Ag,Si-HA discs was also 
incubated at 37 °C for 6 h. Bacterial cell pellets were obtained by centrifuging 
at 8000 rpm for 30 min, and washed twice in the PBS solution for 30 min. The 
collected bacteria cell pellets of each sample (control, HA and Ag,Si-HA) 
were fixed by adding 2.5 % glutaraldehyde at 4 °C overnight. The 
glutaraldehyde-fixed samples were then washed twice in PBS solution for 30 
min. The glutaraldehyde-fixed samples were post-fixed in 1 % osmium 
tetroxide for 1 h at 24 °C, and washed twice with deionised water for 5 min. 
The post-fixed samples were first encapsulated in gelatin, and fixed with 
2.5 % glutaraldehyde for 1 h at 4 °C. The gelatin-fixed samples were washed 
with deionised water twice for 5 min, and trimmed into small blocks of 1-2 
mm
3
. The small blocks of gelatin-fixed samples were dehydrated through 
ethanol series (25, 50, 75, 95, 100 % for 10 min each) and 100 % acetone 
twice for 10 min. The small blocks of gelatin-fixed samples were further 
infiltrated with a solution of acetone and araldite resin ratio (1:1 for 1 h and 
1:6 overnight). Finally, the small blocks of gelatin-fixed samples were 
infiltrated in araldite resin (at 24 °C, 40 °C, 45 °C, 50 °C for 1 h each), and 




finally embedded with araldite, and polyemerised at 60 °C for 24 h.  Ultrathin 
sections (approximately 0.1 µm thickness) were cut with a glass knife using a 
ultramicrotome (Lecia ultracut) and then mounted on copper grids. The 
ultrathin sections were then stained with lead citrate for 10 min for TEM 
observation.         
 
 
5.2.5.2 Gram Staining  
Gram staining was carried out to inspect the peptidoglycan layer of the cell 
wall of S. aureus after interacting with HA and Ag,Si-HA. S. aureus at a 
concentration of 10
7
 CFU/ml (control) was incubated at 37 °C for 6 h. 
Similarly, bacterial concentration containing HA and Ag,Si-HA discs was also 
incubated at 37 °C for 6 h. 30 µl of the test solution of each sample (control, 
HA and Ag,Si-HA) was spread onto the glass slide. Bacteria were fixed by 
heating it at 80 °C, and washed with deionised water. Primary stain (crystal 
violet) was added onto the heat-fixed smear of the bacteria culture for 1 min, 
washed with deionised water and dried. Iodine was then added onto the heat-
fixed smear of the bacteria culture for 1 min, washed with deionised water and 
dried. 95 % ethanol was added to decolourise the stain for 10 s, washed with 
deionised water and dried. Lastly, it was counter-stained with carbol fuchsin 
for 1 min, washed with deionised water, and dried for optical microscope 
observation.        
 




5.2.5.3 Inductively Coupled Plasma (ICP) Spectroscopy 
ICP (Perkin Elmer Dual-View Optima 5300 DV ICP-OES system) was used 
to measure the amount of potassium ions leaking from S. aureus (control) and 
S. aureus treated by HA and Ag,Si-HA in test solution for 6 h. HA and Ag,Si-
HA discs were immersed in 2 ml of peptone water containing 2 x 10
7
 cells/ml 
in a 24-well plate, and incubated at 37 °C for 6 h. At 6 h, 1 ml of the test 
solution of each sample (control, HA and Ag,Si-HA) was centrifuged, and the 
supernatant was tested by ICP to measure the potassium ion leakage from the 
inactive bacteria. Supernatant were dissolved in 6.5 % nitric acid and diluted 
by a factor of 10 with deionised water. ICP ionised the sample, and ions were 
separated and quantified by a mass spectrometer. Two replicates were 
measured, and the mean value was calculated. 
 
5.3 Results and Discussion 
5.3.1 Physicochemical Properties of Ag,Si-HA  
Figure 5.2 shows the morphology of Ag,Si-HA containing 0.5 wt.% of silver 
and 0.7 wt.% of silicon. Similar to Ag,Si-HA and AgHA that were reported in 
Section 3.3.2 and 4.3.2 respectively, a rod-like morphology was also 
synthesised for Ag,Si-HA in spite of the increased silver content. Ag,Si-HA 
nanoparticles comprised of an average length of ~60 nm and width of ~10 nm, 
mimicking the dimensions of natural bone mineral.  
 
 




      
Figure 5.2 TEM morphology of (a) autoclaved and (b) dry-heated Ag,Si-HA 
 
 
Despite increasing the silver content of Ag,Si-HA to 0.5 wt.%, the 
(Ag+Ca)/(P+Si) molar ratio of 1.66 remained close to the theoretical value of 
1.67, suggesting that Ag,Si-HA was made up of apatite (Table 5.1). This was 
further confirmed when a phase-pure apatite was identified for Ag,Si-HA in 
the X-ray diffraction pattern (Figure 5.3). The diffraction pattern of Ag,Si-HA 
was identical to the ICDD (JCPDS) standard for apatite (PDF Card No. 9-432) 
[24]. A phase-pure apatite is chemically similar to the bone mineral [63], thus 
obtaining a phase-pure Ag,Si-HA would promote bonding and integration with 













Table 5.1 Calculated (Ca+Ag)/(P+Si) molar ratio, and measured weight 
percentage of calcium, phosphorus, silver and silicon using XRF 
 








Moreover, the IR spectra of Ag,Si-HA exhibited absorption bands of 
phosphate and hydroxyl groups, which were characteristic of an apatite 
(Figure 5.4). Phosphate characteristic peaks were located at 628, 601 and 564 
cm
-1
 for v4  phosphate bending modes, 960 cm
-1 
for v1 phosphate stretching 
 (Ca+Ag)/(P+Si)            
(XRF) 
wt.% Ca wt.% P wt.% Ag wt.% Si 
Autoclaved 1.66 (2) 38.9 (1) 17.4 (1) 0.5 (1) 0.7 (1) 
Dry-heated 1.66 (1) 39.1 (2) 17.5 (1) 0.4 (1) 0.7 (1) 




modes and between 1020-1090 cm
-1
 for v3 phosphate bending and stretching 
modes. In addition, a single peak at 3569 cm
-1
 for stretching mode of hydroxyl 
vibration [266] was detected. The absorption bands at 873 and 1300-1650 cm
-1
 
of Ag,Si-HA were attributed to the carbonate substitution in the HA lattice. 
Peak at 873 cm
-1 
was due to v2 vibrational mode whilst peaks at 1417, 1454 
and 1650 cm
-1 
were due to v3 vibrational mode of surface carbonate ions. As 
discussed in Section 3.3.5, the carbonate ions were formed from the reaction 
between carbon dioxide and precursors during the synthesis process. Lastly, 
peaks at 756 and 890 cm
-1
 were assigned to silicate vibrational modes [14, 24]. 
Thus, FTIR results showed that Ag,Si-HA exhibited the features of apatite, 
and also demonstrated that the incorporated silicon was in the form of silicate 




Figure 5.4 FTIR spectra of (a) autoclaved and (b) dry-treated Ag,Si-HA 




It was noted that the morphology (Figure 5.2b), composition (Table 5.1), 
diffraction pattern (Figure 5.3b), and IR spectra (Figure 5.4b) of Ag,Si-HA 
that was dry-heated at 600 C were similar to the autoclaved Ag,Si-HA 
implying that the physicochemical properties of dry-heated Ag,Si-HA were 
maintained and unchanged.   
 
 
The effect of co-substitution of silver and silicon was revealed from the 
expansion of lattice cell parameters and unit cell volume. The Rietveld study 
of Ag,Si-HA suggested an increment in the unit cell of HA in the a- and c-
axes, and the unit cell volume (Table 5.2). In addition, as compared to 
0.5AgHA with similar silver content (0.5 wt.%), the lattice parameters and 
unit cell volume of Ag,Si-HA were much higher. As silver and silicon possess 
larger ionic radius than calcium and phosphorous, respectively, the co-
substitution resulted in the distortion of the lattice parameters and increment of 
unit cell volume. Therefore, all these results clearly demonstrated that silver 
and silicon were structurally incorporated into HA to form a single-phase 











Table 5.2 Structural parameters obtained from lattice refinement 
Errors are ± standard errors of the mean, with the values in parentheses 
 
5.3.2 Silver Composition on the Surface of Ag,Si-HA  
XPS was engaged to determine the wt.% of silver (with respect to the number 
of elements measured) on the surface of Ag,Si-HA. It was observed that the 
amount of surface silver ions of Ag,Si-HA increased with immersion period 
(Figure 5.5). This trend suggested that the incorporated silver ions diffused 
towards the crystal surface of Ag,Si-HA to interact with the adherent bacteria, 
thus executing antibacterial action. The investigation of the antibacterial 
property of Ag,Si-HA against adherent bacteria will be discussed in Section 
5.3.3, and the mechanism of antibacterial action of surface silver ions of 
Ag,Si-HA will be discussed in Section 5.3.5.       
  
 
Sample a (nm) c (nm) Unit cell volume (nm
3
) 
HA 0.9410 (4) 0.6886 (4) 0.5280  
0.5AgHA 0.9413 (3) 0.6895 (4) 0.52907  
Ag,Si-HA 0.9421 (3) 0.6899 (4) 0.5303  





Figure 5.5 Amount of surface silver ions of Ag,Si-HA with immersion period 
 
 
5.3.3 Antibacterial Assessment of Ag,Si-HA  
The growth of adherent S. aureus on HA and all substituted apatites are 
represented in Figures 5.6 and 5.7. Adherent S. aureus on HA and SiHA grew 
steadily from a starting population of approximately 1 x 10
7 
CFU/ml to a 
population of 2 x 10
7
 CFU/ml and 7 x 10
7 
CFU/ml over a period of 24 h, 
respectively. On the other hand, the number of adherent S. aureus on AgHA 
and Ag,Si-HA were reduced by 2-order to approximately 4 x 10
5 
CFU/ml at 6 
h. The number of adherent S. aureus on AgHA and Ag,Si-HA were further 
reduced to 6 x 10
4 
CFU/ml and 8 x 10
3 
CFU/ml at 12 h, respectively. At 18 h, 
the number of adherent S. aureus on both samples was reduced to zero, and 
this remained till 24 h. The log reduction assay was further extended to a 




period of 7 days (Figure 5.7). Population of adherent S. aureus on HA and 
SiHA remained in the range of 10
7 
CFU/ml, without significant reduction of 
adherent S. aureus at the end of 7 days. However, no viable adherent S. aureus 
were observed on AgHA and Ag,Si-HA. Overall, a 7-log reduction of adherent 
S. aureus was observed for AgHA and Ag,Si-HA as compared to HA and 




Figure 5.6 Log reduction assay of the adherent S. aureus on HA and 
substituted apatites discs cultured over a period of 24 h 
 





Figure 5.7 Log reduction assay of the adherent S. aureus on HA and 
substituted apatites discs cultured over a period of 7 days 
 
 
The growth of gram-negative bacteria, E. coli was also tested on HA and all 
substituted apatites. Consistent with the results of adherent S. aureus, the 
numbers of adherent E. coli on HA and SiHA grew to a population of 10
7 
CFU/ml at 6 h, and maintained to 24 h (Figure 5.8). On the other hand, the 
numbers of adherent E. coli on AgHA and Ag,Si-HA were reduced to 
approximately 4 x 10
4 
CFU/ml at 6 h (Figure 5.8). At 12 h, the number of 
adherent E. coli on AgHA was reduced to zero, and this maintained to 24 h. 
The number of adherent E. coli on Ag,Si-HA was reduced to 2 x 10
3 
CFU/ml 
at 12 h, and further diminished to zero at 18 h. No viable E. coli was observed 
to proliferate on AgHA and Ag,Si-HA on 24 h. Similarly, the log reduction 
assay of E. coli was also extended to 7 days. The number of viable adherent E. 




coli on HA and SiHA remained in the range of 10
7 
CFU/ml whilst no viable E. 
coli was observed on AgHA and Ag,Si-HA (Figure 5.9). Correspondingly, a 
7-log reduction of adherent E. coli was observed for AgHA and Ag,Si-HA as 




Figure 5.8 Log reduction assay of the adherent E. coli on HA and substituted 
apatites discs cultured over a period of 24 h 
 
 





Figure 5.9 Log reduction assay of the adherent E. coli on HA and substituted 
apatites discs cultured over a period of 7 days 
 
 
Compared to S. aureus, no viable E. coli was noticed on AgHA and Ag,Si-HA  
at 12 h. This is because gram-positive bacteria (S. aureus) generally has a 
thicker peptidoglycan layer than gram-negative bacteria (E. coli), thus 
protecting the cell wall from destruction, and consequently, slowing down the 
inhibition rate [189]. On the whole, Ag,Si-HA and AgHA were effective 
against both gram-positive and -negative bacteria and therefore can be applied 
for various antibacterial treatments.   
 
Effective inhibition of bacterial adhesion at post-implantation of 6 h is often 
regarded as the most critical period in preventing implant-related infection 
[274]. Over the period of 6 h, implant is particularly susceptible to surface 




bacterial colonization and beyond 6 h, adherent bacteria can proceed to form 
biofilm at the implant-tissue interface. This was observed in HA and SiHA, 
whereby the growth of S. aureus and E. coli reached a peak population of ~ 
10
8 
CFU/ml whilst obvious inhibition of bacterial growth on AgHA and 
Ag,Si-HA could be observed at 6 h.  
 
In addition to effective inhibition at 6 h, the reduction of adherent S. aureus 
and E. coli were further reduced to zero at 18 h, and proliferation of adherent S. 
aureus and E. coli was not observed up to 7 days. Indeed, the inhibition of the 
adherent bacteria growth on AgHA and Ag,Si-HA was evidenced. Hence, the 
substitution of silver in the apatite was effective in the prevention of bacteria 
adhesion for long-term success of implant. Lastly, it was also interesting to 
note that the inhibition rate of adherent S. aureus and E. coli between Ag,Si-
HA and AgHA were similar. This phenomenon indicated that the substitution 
of silicon into AgHA did not affect its antibacterial property. 
 
5.3.4 Surface Silver Ions of Ag,Si-HA for Antibacterial Action   
Several authors [37, 41, 210] attributed the antibacterial action of AgHA to the 
release of silver
 
ions. These AgHA were formed by incorporating silver ions 
into the apatite structure after HA was synthesised. On the other hand, for 
AgHA produced by incorporating silver ions during the nucleation of apatite, 
it was observed that its antibacterial effect was not dependent on the released 
silver ions, but its antibacterial action was not reported [36]. Based on the 




increasing silver content on the surface of Ag,Si-HA disc, and the significant 
reduction of adherent bacteria on Ag,Si-HA disc reported in the present study, 
it can be hypothesised that surface silver ions of Ag,Si-HA were responsible 
for the antibacterial action. Thus, an insert with a membrane of pore size 0.4 
µm was placed in the well to prevent S. aureus (having a size of 0.5-1.5 µm) 
from getting in contact with Ag,Si-HA, since the insert only allows any 
released silver ions (0.126 nm) to go through to interact with the S. aureus in 
the test solution. 
 
Having cultured for 24 h with the insert, the population of S. aureus (control) 
and S. aureus treated by Ag,Si-HA in the test solution grew from average 
starting population of 3 x 10
7
 to 3 x 10
8
 CFU/ml (Figure 5.10). This 
observation implied that the released silver ions did not provide effective 
antibacterial action. On the other hand, with the absence of insert, the 
population of S. aureus treated by Ag,Si-HA in the test solution decreased 
from 3 x 10
7
 to 2 x 10
5
 CFU/ml. When the Ag,Si-HA disc was placed in the 
well containing S. aureus, S. aureus adhered onto the Ag,Si-HA disc, which 
reduced the population of S. aureus in the test solution while the growth of 
adherent S. aureus on Ag,Si-HA was effectively inhibited to zero as reported 
in Section 5.3.3. Therefore, this simple experiment demonstrated and validated 
the hypothesis that surface silver ions played a role in the antibacterial action, 
which provided an important insight for silver-substituted apatite that was 
synthesised by incorporating silver ions during nucleation of apatite. 





Figure 5.10 Log reduction assays of the test solution in bacteria control with 
insert, Ag,Si-HA with insert and Ag,Si-HA without insert incubated for 24 h 
(* p < 0.05)  
 
 
5.3.5  Effect on S. aureus treated by Ag,Si-HA  
TEM analysis of bacteria shows the morphology of S. aureus and 
morphological changes of S. aureus treated by HA and Ag,Si-HA (Figure 
5.11). S. aureus (control) and S. aureus treated by HA retained their coccal 
morphology (600 nm in diameter) with a homogenous electron density in the 
cytoplasm, which displayed a normal cell characteristic (Figures 5.11a-b). 
Their cell walls and membranes were intact, exhibiting a well-preserved 
peptidoglycan layer and cytoplasmic membrane.  
 
 




In contrast, noticeable morphological changes were observed in S. aureus 
treated by Ag,Si-HA for 6 h (Figure 5.11c). An electron-light region appeared, 
indicating heterogeneity of the electron density in the cytoplasm after treated 
by Ag,Si-HA. The cell wall and the membrane of S. aureus was ruptured, 
displaying an aberrant morphology. In addition, compared with the normal 
cytoplasm membrane shown in Figures 5.11a and 5.11b, detachment of the 
cytoplasm membrane from the cell wall could be discerned. A bacteria with 
disorganised shape exhibits a significant increase in permeability, which 
impairs the bacteria to regulate through cytoplasmic membrane and results in 
cell death [275]. Thus, it was suggested that S. aureus be treated by Ag,Si-HA 
















Figure 5.11 Internal structure of S. aureus observed by TEM. (a) untreated 
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The damage of the peptidoglycan layer of S. aureus treated by Ag,Si-HA was 
further supported by the gram staining. Figure 5.12 illustrates the gram 
staining of S. aureus bacteria (control), S. aureus bacteria treated by HA and 
Ag,Si-HA. Generally, gram-positive bacteria such as S. aureus, which has a 
thick peptidoglycan (50-90 % of cell envelope) layer for the cell wall will be 
stained purple by crystal violet. In contrast, gram-negative bacteria, which has 
a thinner layer (10 % of cell envelope) will be stained pink by the counter 
stain [276]. It was observed that S. aureus (control) and S. aureus treated by 
HA were stained purple due to the thick intact cell wall. On the other hand, it 
was observed that majority of S. aureus that were treated by Ag,Si-HA stained 
pink, with few S. aureus stained purple. The breakage of cell wall and the 
reduction of peptidoglycan layer caused S. aureus treated by Ag,Si-HA to be 
stained pink instead. The impairment of bacterial membrane was due to the 
affinity of silver ions of the electrostatic interaction between thiole of enzymes, 
imidazole, amino and carboxyl groups of cell envelope proteins [185, 186]. 
Consistent with the observation in the morphological changes of TEM results, 
the cell wall of S. aureus treated by Ag,Si-HA was clearly damaged.              
 







Figure 5.12 Gram staining of S. aureus (a) untreated bacteria, (b) bacteria 











The cellular degradation of S. aureus treated by Ag,Si-HA was also 
accompanied by the release of cellular contents in the damaged cells, which 
was evidenced in the electron-light region in the cytoplasm (Figure 5.11c). 
Potassium ion is an important enzyme responsible for protein synthesis. 
However, changes in the bacterial membranous permeability and destruction 
of the cell membrane can cause the potassium ions in the cell to leak [277]. 
Thus, the leakage of intracellular potassium ions is considered as an early 
indication of cellular degradation such as membrane disruption and increased 
permeability [278].  
 
 
Figure 5.13 shows the leakage of potassium ions from S. aureus (control) and 
S. aureus after culturing with HA and Ag,Si-HA for 6 h. Due to the build-up 
of waste, and lack of adequate nutrients and oxygen during bacteria replication 
process, there will be a small number of bacteria dying off [279]. Thus, 
potassium leakage was also detected in the test solution of the control and HA 
samples despite an increasing bacteria growth being observed in Figure 5.7. 
On the other hand, the higher potassium ion leakage observed in Ag,Si-HA 
was attributed to the significant reduction of adherent S. aureus on Ag,Si-HA. 
Consistent with the potassium ion leakage reported by Li et al. [275], there 
was a significant higher amount of potassium ion leakage (p < 0.05) in the 
damaged cell membrane of S. aureus treated by Ag,Si-HA as compared to HA 
(Figure 5.13). This implied that treatment by Ag,Si-HA not only damaged the 
cell wall, it also resulted in an increase in the permeability of cell membrane. 
The cell membrane serves as a permeability barrier to prevent the entry of 




noxious compound. With the increased permeability of the cell membrane, the 
defense system of bacteria was weakened, making it susceptible to the attack 






Figure 5.13 Amount of leakage of potassium ions after treated by HA and 





On the whole, TEM micrographs, gram staining and potassium ion leakage 
results clearly revealed that the surface silver ions of Ag,Si-HA caused an 
impairment at the cell wall, and increased the membrane permeability, which 
in turn, inhibited bacterial growth. From these results, the mechanism of 
antibacterial action of Ag,Si-HA was proposed in the following 2 steps: (1) 
incorporated silver ions in Ag,Si-HA diffused towards the crystal surface 
when immersed in solution, and (2) surface silver ions of Ag,Si-HA 
underwent ion-exchange with the proteins of the adherent bacteria, anchoring 




to the sites that were rich in thiole, imidazole, amino and carboxyl groups, 
exhibiting oligodynamic action. A schematic diagram illustrating the 






















Figure 5.14 Schematic drawing of the proposed mechanism of antibacterial 
action of Ag,Si-HA (a) diffusion of silver ions towards surface of Ag,Si-HA, 
(b) adhesion of bacteria onto Ag,Si-HA, (c) surface silver ions of Ag,Si-HA 
interact and damage the cell wall, and (d) potassium ions leak from the 








Based on the above mechanism, Ag,Si-HA synthesised by incorporating 
silver ions during the nucleation of apatite relied on the oligodynamic effect 
of surface silver ions for its antibacterial action.  Hence, local cytotoxicity at 
the implant site could be minimised as antibacterial action only took place 
when surface silver ions interacted with the adherent bacteria. In addition, the 




Optimised amount of 0.5 wt.% of silver and 0.7 wt.% of silicon were 
successfully co-substituted into HA to form Ag,Si-HA. The (Ag+Ca)/(P+Si) 
molar ratio of 1.66 remained close to the theoretical value of 1.67, retaining 
the apatite structure. A phase-pure apatite was identified for Ag,Si-HA in the 
X-ray diffraction pattern, along with the phosphate, hydroxyl and silicate 
functional groups observed in the FTIR spectra. Despite possessing larger 
ionic radius than calcium and phosphorous ions, silver and silicon ions were 
structurally incorporated in HA as reflected in the distortion of the lattice 
parameters and increment of unit cell volume. The physicochemical properties 
of Ag,Si-HA remained unchanged despite dry-heated at 600 C. The 
increment of silver content on the surface of Ag,Si-HA over a period of 7 days 
suggested that incorporated silver ions diffused towards the crystal surface to 
execute the antibacterial action. Effective antibacterial inhibition of AgHA and 
Ag,Si-HA could be observed at 6 h, and no viable bacteria was detected at  
18 h. Overall, a 7-log reduction of the adherent S. aureus and E. coli bacteria 




was found on the surfaces of AgHA and Ag,Si-HA as compared to HA and 
SiHA, over a period of 7 days. Bacterial reduction of AgHA and Ag,Si-HA 
were similar, implying that the substitution of silicon into AgHA did not affect 
the antibacterial properties. Antibacterial property of Ag,Si-HA was not 
exhibited when an insert was placed to prevent the contact between S. aureus 
and Ag,Si-HA. Thus, this supported the hypothesis that surface silver ions of 
Ag,Si-HA played a role in the antibacterial action. Localised separation of cell 
membrane from the cell wall and the reduction of peptidoglycan layer were 
observed in the TEM micrographs and gram staining, respectively. 
Furthermore, potassium ions leakage from S. aureus cells treated by Ag,Si-HA 
was significantly higher than bacterial control and HA samples. All these 
results indicated that the mechanism of antibacterial action of Ag,Si-HA was 
due to the interaction between surface silver ions of Ag,Si-HA and the 
enzymes and proteins found in the cell wall. Consequently, surface silver ions 
of Ag,Si-HA damaged the cell wall and increased the membrane permeability, 
which disabled the bacterial replication. As opposed to the released silver ions 
reported by several authors, the synthesised Ag,Si-HA in this study is 
dependent on the surface silver ions for its antibacterial action. Therefore, this 
shows that Ag,Si-HA can potentially minimise local cytotoxicity, and 
maintain its antibacterial efficiency for a longer period of time.          









Ag,Si-HA was proposed with the intention of minimising bacteria adhesion 
and allowing improved osseointegration so as to enhance the bone healing 
process, when used as a bone graft. Firstly, co-substitution of silver and silicon 
into HA (Ag,Si-HA) was successfully synthesised and characterised in 
Chapter 3. Subsequently, the silver content of AgHA was optimised to achieve 
effective antibacterial property (Chapter 4). In addition, it was found that the 
oligodynamic action of silver had generated an antibacterial adhesion effect on 
HA, thereby inhibiting the bacteria. Ag,Si-HA with optimised amount of silver 
(0.5 wt.%) and silicon (0.7 wt.%) was demonstrated to display excellent 
antibacterial property in Chapter 5. Furthermore, it was shown that the surface 
silver ions of Ag,Si-HA was responsible for antibacterial action, and the 
mechanism of antibacterial action was proposed. In the present chapter, the 
biological response of Ag,Si-HA will be evaluated by assessing the attachment 
and proliferation of bone cells, both qualitatively and quantitatively 
(alamarblue
TM
, alkaline phosphatase, type I collagen and osteocalcin assays).  
 
 




6.2 Materials and Methods 
6.2.1  Synthesis of Ag,Si-HA 
Ag,Si-HA containing 0.5 wt.% of silver and 0.7 wt.% of silicon was 
synthesised by a wet precipitation reaction. Detailed description of the 
synthesis was reported in Section 3.2.1. Ag,Si-HA powders were compacted 
uni-axially into 12 mm discs and then dry heated at 600 °C for 2 h in air for 
the biocompatibility assessment. 
 
6.2.2 Biocompatibility Assessment of Ag,Si-HA 
Biological response of dry-heated Ag,Si-HA disc was evaluated using human 
adipose-derived mesenchymal stem cells (hMSCs) isolated from human 
lipoaspirate tissue (Invitrogen, Stempro
®
 human adipose-derived stem cell kit, 
passage 2). These cells were thawed before cultured in MesenPRO RS
TM
 
medium for a further passage before they were pooled for use in the 
experiments. Ag,Si-HA discs were sterilised by rinsing three times with PBS 
solution, followed by ultraviolet exposure for 30 min. 2 x 10
4
 cells were then 
seeded on these sterilised Ag,Si-HA discs in 1 ml of dulbecco’s modified 
eagle medium supplemented with 10 % fetal bone serum and 1 % penicillin-
streptomycin, before incubating at 37 C in a humidified atmosphere of 95 % 
air and 5 % carbon dioxide. After 7 days of expansion, the growth media was 
changed to osteogenic inductive media. The osteogenic inductive media was 
supplemented with 10 mM of -glycerolphosphate, 100 M of ascorbic acid 






 M of dexamethasone. The osteogenic inductive media was changed 
every 2 days. Phase-pure HA, AgHA and SiHA discs of similar morphology 
and crystallinity with Ag,Si-HA will be compared in the study.  
 
 
6.2.2.1 Cell Growth 
Cell growth over 1, 3, 5, and 7 days was measured using the alamarBlue
TM
 
medium (Invitrogen). At each time point, samples were cultured in 10 % 
alamarBlue
TM
 medium for 4 h. The absorbance was then monitored at a 
wavelength of 570 nm, with a reference wavelength of 600 nm. 
alamarBlue
TM
 assay detects the level of oxidation during cell respiration. The 
reducing environment of the cells in the alamarBlue
TM
 assay was measured 
through the oxidation of resazurin (blue and non-fluorescent) to resorufin (red 
and fluorescent), which resulted in colorimetric and fluorescence changes. Cell 
number was obtained by cross-referencing to a standard calibration curve of 
hMSCs count against absorbance done at the beginning of the study to obtain 
the live cell count at each time point. 
 
 
6.2.2.2 Cell Morphology  
After 1 and 5 days of culturing, cells were fixed with 4 % formaldehyde in PBS 
solution with 1 % sucrose for 15 min, followed by washing with PBS solution 
and permeabilised at 4 C for 5 min. They were then incubated with 1 % 
bovine serum albumin/PBS solution at 37 C for 5 min to block the non-
specific binding. FITC-conjugated phalloidin (Millipore) (1:1000 in 1 % 




bovine serum albumin/PBS solution) was later added at 37 C for 1 h. After 
washing for three times with 1 x PBS solution for 5 min, DAPI (1:1000 in 1 x 
PBS solution at pH 8.0) was added at 25 C for 5 min. The samples were then 
given a final wash (15 min x 3) before mounting under vectashield antifade 
mountants, and viewed under a confocal laser scanning microscope (CLSM, 
Zeiss LSM 700).  
 
Cell morphology was also examined by SEM. On day 3, 7, 14, and 21, the 
adherent hMSCs on discs were fixed with glutaraldehyde, dehydrated through 
a series of ethanol concentrations (25, 50, 75, 95, 100 % (v/v) in distilled 
water), vacuum-dried and coated with a layer of gold before viewing under 
SEM equipped with energy dispersive X-ray spectroscopy.  
 
 
6.2.2.3 Alkaline Phosphatase (ALP) Activity Quantification  
ALP activity of hMSCs cultured on samples for 14, 21 and 28 days was 
measured using an ALP fluorescent assay. The samples underwent freeze and 
thaw cycles 3 times for cell lysis, and 0.2 % of Nonidet™ P40 substitute were 
added to each sample. 10 μL of TRIS/bovine serum albumin and 100 μL of 4-
methyl-umbelliferyl phosphate (4-MUP) working solution were added to each 
lysated cells and incubated at 37 C for 40 min. 100 μL of 0.6 M sodium 
carbonate was added to each well to stop the reaction, and fluorescence at 
360/450 nm was measured using a 96-well plate microplate reader. ALP 
reacted with 4-MUP to form 4-methyl-umbelliferone (4-MU), and the rate of 




the 4-MU formation was directly proportional to the level of ALP. Thus, ALP 
can be determined by measuring the rate of 4-MU formation. 4-MU value was 
obtained by cross-referencing to a standard calibration curve of 4-MU count 
against fluorescence done at the beginning of the study to obtain the 4-MU 
count over a range of 0-1000 pmol of 4-MU. Finally, ALP activity was 
calculated using Equation 6.1: 
ALP activity = A/ V/ T (mU/ml) 
        Equation 6.1 
A = Amount of 4-MU generated by samples (in nmol) 
V = Volume of sample in assay well (0.05 ml) 
T  = Reaction time (40 min) 
 
ALP results were then normalised to cell number by dividing the ALP activity 




6.2.2.4 Type I Collagen (COL I) Expression 
COL I expression of hMSCs cultured on samples for 14, 21 and 28 days was 
determined by enzyme immunoassay (Metra
TM
 CICP EIA kit, Quidel). For 
analysis, culture medium was first diluted with assay buffer at a ratio of 1:3. 
100 l of sample was then added to each well, and incubated at 25 C for 2 h. 
The wells were washed three times with 300 l wash buffer before adding 100 
l rabbit anti-CICP, and incubated at 25 C for 50 min. The wells were 
washed again three times with the wash buffer. Next, 100 l reconstituted 
enzyme conjugate was added, and incubated at 25 C for 50 min. A final wash 




was performed before 100 l working substrate solution was added, and 
incubated for 30 min. Finally, 50 l of stop solution was added, and 
fluorescence was read at 405 nm. CICP assay is a sandwich enzyme 
immunoassay in a microplate format utilizing a monoclonal anti-CICP 
antibody coated on the plate, a rabbit anti-CICP antiserum, a goat anti-rabbit 
ALP conjugate, and a pNPP substrate to quantify COL I. All the readings were 
first corrected by the mean of the blank group measurements. The standard 
data points were plotted, where y is the corrected optical measurement and x is 
the concentration, and a four parameter logistic fit was made through these 
points to determine A, B, C and D coefficients in Equation 6.2 : 
                      
         Equation 6.2 
 
The COL I results of HA, AgHA, SiHA and Ag,Si-HA were determined from 
the fit. The COL I results of the samples will fall within the range of the 
determined upper and lower asymptotes of the fit (A and D coefficients). COL 
I results were then normalised to cell number by dividing the COL I 




6.2.2.5 Osteocalcin (OCN) Expression 
OCN expression of hMSCs cultured on samples for 14, 21 and 28 days was 
measured by an enzyme immunoassay (Metra

 Osteocalcin ELISA kit, 




Quidel). 25 l of cell medium and 125 l of anti-osteocalcin antibody were 
added to each well before incubating at 25 C for 2 h. The wells were then 
washed three times with 300 l wash buffer. Following that, 150 l 
reconstituted enzyme conjugate was added, and incubated at 25 C for 1 h. 
The wells were again washed three times before 50 l working substrate 
solution was added, and incubated at 25 C for 35 min. Finally, 50 l of stop 
solution was added, and fluorescence was read at 405 nm. OCN assay used 
OCN coated strips, a mouse anti-OCN antibody, an antimouse lgG-ALP 
conjugate and a pNPP substrate to quantify OCN in serum. The OCN results 
were also determined using the four parameter logistic fit, which was reported 
in Section 6.2.2.4. OCN results were then normalised to cell number by 





6.2.3   Statistical Analysis 
A two-way analysis of variance (ANOVA), followed by post-hoc testing was 
used to determine any significant differences existed between the mean values 
of the experimental groups for alamarblue
TM
, ALP, COL I and OCN. A 
difference between groups was considered to be significant at p < 0.05. Five 
replicates were measured for alamarblue
TM
, and the mean value was calculated. 
Four replicates were measured for ALP, COL I and OCN, and the mean value 
was calculated.   
 




6.3 Results and Discussion 
6.3.1 Cell Growth  
Figure 6 shows the cell proliferation of hMSCs on HA and various substituted 
apatites. The alamarBlue
TM  
assay demonstrated a continuous cell growth for 
HA and AgHA from day 1 to 7. A continuous cell growth for Ag,Si-HA and 
SiHA was also observed from day 1 to 3, but cell growth tended to level off 
and reached a plateau for SiHA and Ag,Si-HA from day 3 to 5. The slow cell 
growth on day 5 to 7 indicated that hMSCs on SiHA and Ag,Si-HA might 
have reached the confluent stage.  
 
 
Furthermore, the results obtained demonstrated that the incorporation of silver 
in HA did not affect the overall biocompatibility, and it was clear that 0.5 
wt.% of silver did not induce any noticeable cytotoxicity effect. It was also 
interesting to note that only hMSCs on SiHA and Ag,Si-HA have reached 
confluence, suggesting that hMSCs on SiHA and Ag,Si-HA began to 
differentiate. Generally, cell growth will have to become confluent before they 
can undergo differentiation and, finally mineralise into bone [280]. Similar 
observation was also noticed for Thian et al. [250], where cell growth on 
SiHA coating was slower than HA coating after 5 days of culturing. Thus, the 
comparable cell growth trend of SiHA and Ag,Si-HA indicated that the 
presence of silicon might have promoted the hMSCs to advance into 
differentiation stage. On the whole, results showed that hMSCs were 




proliferating on HA and all substituted apatites, which indicated the 




Figure 6.1  Cell proliferation of hMSCs on HA, AgHA, SiHA, and Ag,Si-HA 
at different time points, [a] p < 0.05 for HA between groups; [b] p < 0.05 for 
AgHA between groups; [c] p < 0.05 for SiHA between groups; [d] p < 0.05 for 
Ag,Si-HA between groups; [e] p < 0.05 when comparing Ag,Si-HA to HA 
within groups, [f] p < 0.05 when comparing Ag,Si-HA to AgHA within groups; 
[g] p < 0.05 when comparing Ag,Si-HA to SiHA within groups   
 
6.3.2   Cell Morphology 
Besides evaluating cell proliferation, biocompatibility of the material can also 
be assessed by observing the morphology and the spreading of attached cells. 
Cell morphology was examined by staining cytoskeletal organisation and 
fixing the adherent cells on the samples. Due to better contrast, cell 




morphology on day 1 was observed by immunofluoresence staining of 
cytoskeletal organisation (Figure 6.2). It could be observed that filopodia 
projecting from the cell edges were more prominent on HA, SiHA and  





Figure 6.2 Images of hMSCs on (a) HA, (b) AgHA, (c) SiHA, and (d)  
Ag,Si-HA on day 1, arrows indicate filopodia, actin cytoskeletons (stained red) 
and cell nuclei (stained blue) of hMSCs 
 
 
On day 5, immunofluoresence staining of cytoskeletal organisation revealed 
that hMSCs remained well-spread on HA, SiHA, and Ag,Si-HA with close 
interaction of actin bundles (Figure 6.3). However, hMSCs were not well-
spread for AgHA. This effect indicated that there was better cell affinity 
towards the surfaces of HA, SiHA and Ag,Si-HA.  
(a) (b) 
(c) (d) 





Figure 6.3 Images of hMSCs on (a) HA, (b) AgHA, (c) SiHA, and (d)  
Ag,Si-HA on day 5, actin cytoskeletons (stained red) and cell nuclei (stained 




Despite having the presence of silver in both AgHA and Ag,Si-HA, hMSCs 
were observed to be more well-spread on Ag,Si-HA. This could be due to the 
influence of the incorporated silicon in Ag,Si-HA. Vandiver et al. [246] 
showed that SiHA had an increased nanoscale attractive van der waals and 
adhesive interactions than HA, which consequently facilitated the attachment 
of cells. Thus, the substitution of silicon into AgHA improved the cell 
attachment. Overall, hMSCs maintained their typical osteoblastic morphology 











SEM micrographs illustrate the cell morphology cultured on HA and all 
substituted apatites for up to 21 days. On day 3, multiple filopodia were seen 
extending from all directions of the cell edges of HA and SiHA (Figures 6.4a 
and c), indicating that the surfaces of HA and SiHA were acting as anchors for 
hMSCs to attach. It was noticed that spherical agglomerates comprising of 
silver and chlorine, as determined by energy dispersive X-ray spectroscopy 
spot analysis (Figure 6.5) were visible on the surface of adherent hMSCs on 
AgHA and Ag,Si-HA (Figures 6.4b and d). Thus, this suggested that the 
presence of chloride ions in the culture medium were attracted to surface silver 
ions of AgHA and Ag,Si-HA, thus forming the spherical agglomerates.  
 
 
In Sections 4.3.5 and 5.3.2, the surface silver ions of AgHA and Ag,Si-HA 
were shown to exert an antibacterial action against any adherent bacteria. 
Instead, the absence of any adherent bacteria on the surface of AgHA and 
Ag,Si-HA resulted in the reaction of surface silver ions with the free chloride 
ions in the medium, forming silver chloride. However, there is no implication 
on the silver chloride agglomerates formed on AgHA and Ag,Si-HA as the 
agglomerates do not affect the attachment of cells during bone regeneration.    
 





Figure 6.4 SEM images of hMSCs cultured on (a) HA, (b) AgHA, (c) SiHA, 






Figure 6.5 Energy dispersive X-ray spectroscopy of silver chloride 











On day 7, hMSCs grew and multiplied, giving rise to more hMSCs attaching 
and spreading across the surfaces of samples (Figure 6.6). hMSCs were 
attached closely with the neighbouring hMSCs, forming cellular bridges. As a 
result, a confluent cell layer was formed, covering the surfaces of HA, SiHA 





Figure 6.6 SEM images of hMSCs cultured on (a) HA, (b) AgHA, (c) SiHA, 




On day 14, cells were seen adhering and spreading on top of each other for all 
samples, forming multilayer of cells with the production of extracellular 
matrix (ECM) on SiHA and Ag,Si-HA (Figure 6.7). In addition, deposition of 
calcium phosphate minerals, as determined by energy dispersive X-ray 
(a) (b) 
(c) (d) 




spectroscopy spot analysis (Figure 6.8) were seen across the ECM surfaces for 




Figure 6.7 SEM images of hMSCs cultured on (a) HA, (b) AgHA, (c) SiHA, 














Figure 6.8 Energy dispersive X-ray spectroscopy of calcium phosphate 
mineral nodules on Ag.Si-HA 
 
 
On day 21, calcium phosphate mineral deposition was subsequently observed 
for HA and AgHA whilst numerous and larger mineral nodules were seen to 
distribute randomly on SiHA and Ag,Si-HA (Figure 6.9). This phenomenon 
was due to the electronegative surface of SiHA and Ag,Si-HA, which 
facilitated the adsorption of calcium ions, thus resulting in an increase in 
surface charge, thereby attracting the phosphate groups, and consequently 
formed calcium phosphate mineral nodules [22, 246]. Therefore, the 
substitution of silicon into AgHA provided a preferential site for the 









Figure 6.9 SEM images of hMSCs cultured on (a) HA, (b) AgHA, (c) SiHA, 
and (d) Ag,Si-HA on day 21 (3500 X magnification) 
 
 
It was interesting to note that silver chloride spherical agglomerates on AgHA 
and Ag,Si-HA seemed to be reduced from day 14 onwards. The agglomerates 
might have dissolved into the medium with increasing culturing period. The 
formation of silver chloride on the surface of Ag,Si-HA occurred at the 
beginning of the in-vitro study (day 3 and 7), illustrating that antibacterial 
effect took place first. Thus, with the reduction of bacteria in the immediate 
vicinity of the bone graft, bacteria will not get to compete with the cells to 
adhere on the surface of implanted bone graft. In addition, impeding bacteria 
adhesion onto the bone graft can prevent the formation of biofilm, which will 
spread to other healthy tissues [274]. Hence, it is beneficial to have 
antibacterial action to take effect first. Subsequently, at the later stage of the 
(a) (b) 
(c) (d) 




in-vitro study (day 14 and 21), enhanced biological activity of SiHA and 
Ag,Si-HA became prominent. The early formation of calcium phosphate 
mineral nodules on day 14 for SiHA and Ag,Si-HA indicated that the 
incorporated silicon in SiHA and Ag,Si-HA aided in promoting the 
differentiation of hMSCs. 
 
 
6.3.3   ALP Activity 
Bones develop in 3 phases: bone proliferation with matrix secretion, matrix 
maturation, and matrix mineralisation. Osteoblasts proliferate and differentiate 
with the formation of ECM (including COL I). Gene expression towards 
osteogenesis lineage would initiate the production of ALP during matrix 
maturation. And finally, ECM would mineralise with the expression of late 
bone gene markers such as OCN during matrix mineralisation. Bone cell 
functionality (differentiation) of HA and various substituted apatites will be 




The level of ALP protein expression by hMSCs cultured on HA and various 
substituted apatites is illustrated in Figure 6.10. ALP is a hydrolyse enzyme 
secreted by osteoblasts, and is responsible for removing phosphate groups 
from nucleotides, proteins, and alkaloids. Therefore, ALP is a useful marker 
for osteoblast activity. A steady increase in the ALP activity at all time points 
was observed for hMSCs cultured on HA, AgHA, SiHA and Ag,Si-HA 




(Figure 6.10). When comparing among the samples, ALP activity produced by 
hMSCs cultured on SiHA was statistically the highest whilst the ALP activity 
produced by hMSCs cultured on AgHA was the lowest on day 14, 21 and 28. 
It was noted that ALP activity produced by hMSCs cultured on Ag,Si-HA was 
much higher (p < 0.05) than hMSCs cultured on HA on day 14, 21 and 28. 
ALP production by hMSCs cultured on Ag,Si-HA was ranked second among 
the substituted apatites. Thus, this demonstrated that the co-substitution of 
silver and silicon did not affect the bone differentiation of hMSCs. In addition, 
bone differentiation of hMSCS cultured on Ag,Si-HA was better than hMSCs 
cultured on HA, indicating the biological benefits of substituting silicon in 










Figure 6.10 Quantitative measurement of ALP protein expressions on HA, 
AgHA, SiHA, and Ag,Si-HA. [a] p < 0.05 for HA between groups;  
[b] p < 0.05 for AgHA between groups; [c] p < 0.05 for SiHA between groups; 
[d] p < 0.05 for Ag,Si-HA between groups; [e] p < 0.05 when comparing 
Ag,Si-HA to HA within groups, [f] p < 0.05 when comparing Ag,Si-HA to 
AgHA within groups; [g] p < 0.05 when comparing Ag,Si-HA to SiHA within 
groups   
 
 
6.3.4   COL I Expression 
COL I is the predominant extracellular protein of bone and is the most 
abundant protein secreted from osteoblasts. Both ALP and COL I indicated the 
initial stage of bone mineralisation, and were considered as markers of early 
osteogenic differentiation, which could appear in-vitro within approximately 2 
weeks of culturing under osteogenic conditions [281]. An increasing 




production of the COL I expressed by hMSCs cultured on SiHA from day 14 
to 28 (Figure 6.11) was noted. COL I produced by hMSCs cultured on Ag,Si-
HA was lower than the COL I expressed by hMSCs cultured on SiHA. 
Nevertheless, hMSCs cultured on Ag,Si-HA expressed greater amount of COL 
I than hMSCs cultured on HA and AgHA on day 14 and 21. Overall, hMSCs 
cultured on Ag,Si-HA produced the second highest amount of COL I 
expression as compared to those cultured on HA and substituted apatites. Once 
again, this demonstrated that substitution of silicon enhanced the 
differentiations of hMSCs on apatite.  
 
 
As COL I is an early differentiation marker of bone formation, its expression 
tends to reduce with time [281], as demonstrated by the decrease in COL I 
expression on all samples on day 28. The COL I production results 
corresponded to the observation of the SEM micrographs of SiHA and  
Ag,Si-HA (Figures 6.7 and 6.9), which indicated a greater differentiation of 
hMSCs occurring on SiHA and Ag,Si-HA. 
 





Figure 6.11 Quantitative measurement of COL I protein expressions on HA, 
AgHA, SiHA, and Ag,Si-HA. [a] p < 0.05 for HA between groups;  
[b] p < 0.05 for AgHA between groups; [c] p < 0.05 for SiHA between groups; 
[d] p < 0.05 for Ag,Si-HA between groups; [e] p < 0.05 when comparing 
Ag,Si-HA to HA within groups, [f] p < 0.05 when comparing Ag,Si-HA to 
AgHA within groups; [g] p < 0.05 when comparing Ag,Si-HA to SiHA within 
groups    
 
6.3.5   OCN Expression 
OCN is a protein produced by bone, and is important in regulating 
mineralisation [282]. OCN revealed the later stage of bone cell differentiation 
and was considered as a late stage marker. OCN expression was detected for 
hMSCs cultured on all samples from day 14 onwards, and increased 
significantly with culturing period (Figure 6.12). A high level of OCN 
expression was detected on day 14 and 21 for hMSCs cultured on SiHA. The 
amount of OCN expressed by hMSCs cultured on Ag,Si-HA were lower than 




the OCN expressed by hMSCs cultured on SiHA, but was significantly greater 
(p < 0.05) than the OCN expressed by hMSCs cultured on HA and AgHA on 
day 14 and 21. Similar to ALP and COL I expressions, it was also observed 
that hMSCs cultured on Ag,Si-HA expressed the second highest amount of 




Figure 6.12 Quantitative measurement of OCN protein expressions on HA, 
AgHA, SiHA and Ag,Si-HA. [a] p < 0.05 for HA between groups; [b] p < 0.05 
for AgHA between groups; [c] p < 0.05 for SiHA between groups; [d] p < 0.05 
for Ag,Si-HA between groups; [e] p < 0.05 when comparing Ag,Si-HA to HA 
within groups, [f] p < 0.05 when comparing Ag,Si-HA to AgHA within groups; 
[g] p < 0.05 when comparing Ag,Si-HA to SiHA within groups    
 
 




On the whole, it could be observed that the production of ALP, COL I and 
OCN from hMSCs cultured on AgHA over 28 days were lower than hMSCs 
cultured on HA. Similarly, the production of ALP, COL I and OCN by 
hMSCs cultured on Ag,Si-HA over 28 days was also lower than hMSCs 
cultured on SiHA. The reduced protein expression could be attributed to the 
presence of silver. Although 0.5 wt.% of silver was considered as the 
optimised amount to be incorporated into the apatite for effective antibacterial 
action (Figure 5.7), and was demonstrated to exhibit an absence of 
cytotoxicity (Figure 6.1), the differentiation and biomineralisation of hMSCs 
were shown to be affected (Figures 6.9-6.11). This was also observed in metal 
ions such as aluminium ion, which suppressed the expression of ALP and 
OCN at non-cytotoxicity level [283].   
 
 
Nevertheless, with the substitution of silicon into AgHA, the production of 
ALP, COL I and OCN from hMSCs cultured on Ag,Si-HA over 28 days 
greatly increased, and even surpassed the amount that were produced by 
hMSCs cultured on AgHA and HA. These results highlighted that the 
substitution of silicon in AgHA promoted the cell differentiation, collagen 
synthesis as well as biomineralisation process. Biomineralisation was shown 
to occur at earlier time points (day 14) and greater in amount for hMSCs 
cultured on Ag,Si-HA than hMSCs cultured on AgHA and HA. It had been 
reported in several studies that silicon facilitated early precipitation of 
carbonated-containing apatite layer, creating and conditioning a surface 
associated with increased adsorption and incorporation of proteins that 




promoted osteoblasts to mineralise [284, 285]. Indeed, all these results clearly 
demonstrated that silicon played an important role in promoting the 
differentiation and maturation of hMSCs. As such, substitution of silicon into 






results showed a continuous cell growth from day 1 to 7 for 
HA, AgHA, SiHA and Ag,Si-HA. However cell growth on SiHA and AgSiHA 
was observed to slow down on day 5, signalling that cell growth has reached 
the confluent stage. Immunofluorescence staining revealed stretched and well-
spread actin cytoskeletons, with filopodia for hMSCs cultured on HA, SiHA 
and Ag,Si-HA. However, hMSCs cultured on AgHA were not well-spread on 
day 5. Flattened hMSCs with signs of early ECM secretion were observed on 
SiHA and Ag,Si-HA on day 14. Biomineralisation seemed to occur on SiHA 
and Ag,Si-HA since several CaP mineral nodules could be observed on day 21. 
The antibacterial effect of Ag,Si-HA tended to take effect first, which was 
evidenced by the formation of silver chloride agglomerates on the adhered 
hMSCs on day 3 and 7. On the other hand, favourable biological response of 
Ag,Si-HA occurred at later time points (day 14 and 21). This was further 
supported by the production of ALP, COL I and OCN expressions by hMSCs 
cultured on Ag,Si-HA, which was significantly higher (p < 0.05) than AgHA 
and HA. All these results showed that substitution of silicon into AgHA drove 
hMSCs towards the maturation stage, without compromising its antibacterial 
property. On the whole, the bi-functional properties of Ag,Si-HA 




complemented each other in minimising post-implant infection, and promoting 
biological response of the bone graft which in turn, facilitated the bone healing 
process.   
 




















In this project, Ag,Si-HA potentiated its use as a bone graft by having  
bi-functional properties of antibacterial and favourable biological response.  
Ag,Si-HA containing optimised amount of 0.5 wt.% of silver and 0.7 wt.% of 
silicon was successfully synthesised via an aqueous precipitation technique. A 
rod-like morphology of dimensions ~50 nm in length and ~15 nm in width 
was observed for Ag,Si-HA. A phase-pure apatite was identified for Ag,Si-HA 
in the X-ray diffraction pattern, along with phosphate, hydroxyl and silicate 
functional groups in the FTIR spectra. Despite possessing larger ionic radius 
than calcium and phosphate ions, silver and phosphorous ions were 
structurally incorporated in the HA structure, as reflected by the distortion of 
the lattice parameters and increment of unit cell volume.  
 
It was found that the oligodynamic action of silver had generated an 
antibacterial adhesion effect on HA, thereby inhibiting bacterial growth. 
Effective antibacterial inhibition of adherent S. aureus and E. coli bacteria on 
AgHA and Ag,Si-HA could be observed at 6 h, and no viable bacteria was 
detected at 18 h. Overall, a 7-log reduction of the adherent S. aureus and E. 
coli bacteria was found on the surfaces of AgHA and Ag,Si-HA as compared 
to HA and SiHA over a period of 7 days. The substitution of silicon into 




AgHA did not affect its antibacterial properties as the bacterial reduction of 
AgHA and Ag,Si-HA were similar. Surface silver ions of Ag,Si-HA was 
shown to play a role in its antibacterial action instead of released silver ions. 
The mechanism of antibacterial action was proposed in 2 steps: (1) silver ions 
diffused towards the crystal surface of Ag,Si-HA as demonstrated in the 
increment of surface silver content, and (2) surface silver ions of Ag,Si-HA 
interacted with the enzymes and protein found in the bacteria wall of the 
adherent bacteria and consequently, damaging the peptidoglycan layer and 
inducing potassium ions leakage as observed in the TEM micrographs and 
gram staining, respectively. Based on the proposed mechanism of antibacterial 
action, Ag,Si-HA can potentially minimise local cytotoxicity and maintain its 
antibacterial efficiency for a longer period of time.  
 
The long-term in-vitro study compared the response of hMSCs cultured on 
HA, AgHA, SiHA and Ag,Si-HA. Results demonstrated typical osteoblastic 
morphology and increasing growth activity of hMSCs cultured on HA, AgHA, 
SiHA, and Ag,Si-HA. However, deposition of ECM and calcium phosphate 
mineral nodules at earlier time point (day 14) were observed to be more 
pronounced for SiHA and Ag,Si-HA than HA and AgHA, as illustrated from 
the SEM micrographs. This was further supported by the greater production of 
ALP, COL I and OCN expressions by hMSCs cultured on SiHA and  
Ag,Si-HA than AgHA and HA. All these results showed that substitution of 
silicon into AgHA drove hMSCs towards the maturation stage without 
compromising its antibacterial property. In summary, the antibacterial effect 




of Ag,Si-HA occurred first (day 3 and 7) whilst enhanced biological response 
of Ag,Si-HA was more prominent at later time points (day 14 and 21). Hence, 
the bi-functional properties of Ag,Si-HA complemented each other in 
minimising post-implant infection and promoting biological response of the 
bone graft. Therefore, Ag,Si-HA serves as an improved alternative for 
biomedical applications.   
 
On the whole, this study highlights that co-substitution of apatite with multiple 
ions is not only confine to influence various metabolic functions of cells. The 
combined approach of preventing bacteria adhesion and influencing the 
metabolic function of cells is feasible, which will potentially promote better 
bone repair. In addition, this study also enhances the understanding of the 
antibacterial role of the silver ions, which are intentionally incorporated into 
apatite for antibacterial properties. The incorporation of silver ions during the 
nucleation of apatite will potentially minimise local cytotoxicity and give rise 
to greater antibacterial efficiency. 
 







8.1     Penetration of the Silver Ions of Ag,Si-HA into Bacteria  
Indeed, the peptidoglycan in the cell wall was shown to be damaged by the 
surface silver ions of Ag,Si-HA, thus affecting its replication. It is also known 
that DNA molecules of the bacteria in the condensed state would affect the 
replication process [189]. Thus, this encourages more researches on the 
exploration of penetration of silver ions into S. aureus to attack the DNA, 
turning it into condensed form. TEM equipped with energy dispersive X-ray 
spectroscopy spot analysis facilities can be engaged to identify the distribution 
of silver ions at the internal morphology of the S. aureus treated by Ag,Si-HA. 
 
8.2    In-Vivo Study of Ag,Si-HA 
In-vivo studies help to elucidate the mechanism of endosseous integration such 
as osteoconduction and bone remodelling, which will take place between the 
implanted Ag,Si-HA and host tissue. Firstly, in-vivo studies can determine 
whether Ag,Si-HA is well-accepted by the host tissue by the observation of 
the presence of inflammatory cells. Through the histology results, various 
observations including the formation of new bone directly on the surface of 
Ag,Si-HA, in the spaces within Ag,Si-HA scaffold, and at the Ag,Si-HA/tissue 




interface would indicate whether bone is in direct contact with the Ag,Si-HA 
surface. Presence of osteoid and osteocytes within the bone deposited directly 
on the surface of Ag,Si-HA, and absence of fibrous tissue between Ag,Si-HA 
and new bone would imply a closed association between regenerated bone and 
Ag,Si-HA surface. In addition, the morphology of the apatite deposits, 
formation of bloods vessels and bone remodelling units can be observed in the 
areas of new bone with Ag,Si-HA. Furthermore, the dissolution of Ag,Si-HA 
in-vivo can also be studied. The percentage of bone growth, rate of bone 
apposition to Ag,Si-HA and bone/implant coverage on Ag,Si-HA can be 
determined through the histomorphometry results obtained in the in-vivo 
studies. Furthermore, bone mineral apposition rate can be calculated to 
characterise the bone formation. Lastly, in-vivo studies should also be 
performed on HA, AgHA and SiHA to compare their bioactivity. Therefore, 
suitable in-vivo studies need to be performed to enhance greater understanding 
of the effect of these ionic substitutions on the properties of Ag,Si-HA. 
 
8.3     Fabrication of Various Forms of Ag,Si-HA  
Bone grafting materials can be fabricated in various forms including powder, 
coating, a bulk component or even a porous scaffold to suit various biomedical 
applications. Various coating methods such as plasma spraying, magnetron 
sputtering, electrophoretic deposition and drop-on-demand dispensing 
technique can be engaged to coat Ag,Si-HA onto the metal surface, to provide 
antibacterial and enhanced biological properties. On the other hand, future 
researches can also look into combining Ag,Si-HA with polymers to form a 




composite, and be fabricated into a three-dimensional scaffold using rapid 
prototyping processes such as printing. Chemical, physical, mechanical and 
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